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Thesis Summary 
Following the European regulation for paediatric formulations, the demand for the 
production of paediatric dosage forms has escalated. Managing the clinical needs of 
children is challenging, especially as this must often be accomplished using adult 
medicine formulations. For this reason, further paediatric dosage forms need to be 
developed to address their clinical needs. There are various formulations which can 
be administered via the oral route including tablets, capsules, liquids and chewable 
tablets. It is essential to mention orally disintegrating tablets (ODTs) which have been 
a popular area of research for scientists in the last decade. 
The overarching aim of this thesis was to develop novel oral dosage forms for children 
and young adults aged 6 to 18 years. The principal theme of this thesis is sub divided 
into two main areas of research: the first area evaluated dosage form preferences in 
children and young adults and assessed the key pragmatic dosage form characteristics 
that would enable formulation of patient centred ODTs; the second area focused on a 
wide range of laboratory-based investigations for development of low dose blends and 
pre-blends of ODT formulations using various blending techniques. 
The results of clinical investigations revealed that ODTs are a preferred dosage form 
among children because they combine the advantages of both solid and liquid dosage 
forms, without incorporating their disadvantages such as difficulty in swallowing and 
lack of stability respectively. Healthcare professionals indicated that taste and 
disintegration time were the most important factors to provide both suitable dose units 
and acceptable medicines for paediatric patients. 
Results from powder blending indicated that the dry particle coater provided a robust 
platform for obtaining content uniformities at 1% and 0.5%w/w API using non-sieved 
carriers. Micro crystalline cellulose as a carrier showed superior flow properties and 
better drug content uniformity for both geometric and ordered blending techniques. 
Furthermore, the co-processed excipients containing 86.5% w/w of milled-mannitol, 
12% w/w pregelatinised starch and 1.5% w/w silica using Aston Particle Technology 
(APT’s) new coating technique can be utilised as a potential multifunctional directly 
compressible ODT pre-blend. An investigation into the role of moisture content on 
micro/macro properties of ODTs illustrated that moisture considerably affects the 
consolidation characteristics of blended powders; and the extent of consolidation and 
the bonding of particles depend, not exclusively on moisture content, but also on the 
powder processing conditions. 
In conclusion this work supports the World Health Organisation (WHO)’s claim for a 
paradigm shift from liquid towards ODT dosage forms for drug administration to young 
children older than 6 years. Data from this study will equip formulators to prioritise 
development of key physical/performance attributes within the delivery system. 
Key words: Paediatric formulations, clinical needs, oral route, blending techniques, 
moisture content.
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1.1. Introduction 
Paediatric medication development has advanced extensively worldwide due to 
legislative encouragements and requirements directed towards the development of 
studies of drugs for use in the paediatric population (FDA, 1994). European Medicines 
Agency (EMA) has reviewed its legislative requirements to drive innovations in 
paediatric formulations (European Commission, 2013). An approved paediatric 
investigation plan is required for all new drugs and all line extensions that are submitted 
for EMA approval after January 2009. Such plans should cover all paediatric age 
groups. Furthermore, the EMA has issued guidelines on pharmaceutical development 
of medicines for paediatric use including route of administration, dosing frequency, 
excipients, patient acceptability, container closure systems and devices and user 
information (CHMP, 2006, Gauthier and Cardot, 2011). The FDA has issued in 2012, 
a law requiring the implementation of the Paediatric Research Equity Act and Best 
Pharmaceuticals for Children Act (Christensen, 2012). Similar to the EMA 
requirements, a paediatric study plan (PSP) is required for submission and approval 
by the FDA (FDA, 2013). There are various routes of drug administration as depicted 
in (Figure 1.1). Oral route of administration is inevitably the most popular route of 
delivery due to ease of ingestion, availability of a wide variety of dosage forms and 
most significantly enhanced compliance and adherence. Different drug formulations 
can be administered orally, including solid and liquid dosage forms (Fasano, 1998, 
Sastry et al., 2000). 
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Figure 1.1: Various routes of administration in the UK market adapted from (Aulton and Taylor, 
2013). 
The provision of safe, as well as effective, pharmacotherapy in paediatrics 
necessitates the availability of medicines alongside information for proper utilisation, 
which is compliant with the patient’s age, physiology and body surface area (Mulberg 
et al., 2013). Therefore, dosage forms formulated specifically for children, are often 
required. Till date, the utilization of unlicensed (medicine with no marketing 
authorisation) as well as off-label medicines in paediatrics is extensive (Mason et al., 
2012). The disadvantages of this being that there are limited studies on their effects 
on the paediatric population; age-appropriate formulations are usually not presented, 
and available formulations are not licensed for paediatric use (Choonara and Conroy, 
2002) .The paediatric population is heterogeneous; ranging from new-borns to young 
people, with large physical as well developmental differences, regarding 
pharmacokinetics and pharmacodynamics. Organ development, metabolic 
competence and skin maturation are some factors that may vary based on age, 
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particularly in early infancy. The paediatric age groups recognized by ICH are shown 
in Table 1.1 (EMA, 2006).  
Table 1.1: Classification of Paediatrics based on age groups. 
• Preterm newborn infants;
• Term newborn infants (0–28 days);
• Infants and toddlers (28 days–23 months);
• Children (2–11 years)
• Adolescents (12 to 16 or 18 years (dependent on region).
1.2. Paediatric Dosage Forms 
Paediatric dosage forms should be versatile so that drugs can be administered to 
neonates, children, and adolescents. The common paediatric dosage forms include 
solid dosage forms (such as tablets); powders, solutions, and syrups (Viner and 
Barker, 2005). Solid dosage forms are drugs, which have been compounded to give a 
definite shape and a standard dose, as is the case with tablets. Powders are a type of 
solid dosage form, which have been ground and are finely divided. They are usually 
administered topically on the skin, sprinkled on food or mixed with liquid diet. On the 
other hand, solutions are dosage forms which are made up of an aqueous base 
(majority) and other pharmaceutical ingredients which give the solution its therapeutic 
effect. Syrups form sugary and have a thicker consistency than solutions, a factor 
which makes them more viscous (Ansel et al., 1995). 
1.2.1. Age Development and Dosage Forms of Choice 
Dealing with children is quite challenging, particularly when it comes to diseases and 
their remedies. For neonates, the challenge is even more pronounced because 
diagnosis alone poses a difficult step. After diagnosis, other challenges include the 
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appropriate choice of formulation and route of administration. Children are remarkably 
sensitive to the effects of drugs; not just on the internal effects that the drugs have but 
also on the outward appearance and the taste. A child may refuse to take a drug 
because the colour is not appealing or because it smells ‘weird’. Even after succeeding 
in making the child swallow the drug in the first instance, this result may not be 
repeated for subsequent doses. This is because children have a unique fine memory 
to conditions, circumstances, and experiences of their past (Sahler et al., 2000). To 
say the least, it will pose a massive challenge trying to convince them to take the drug 
again. For this reason, paediatric dosage forms need to be tailored to address the fears 
and the expectations of the target users. This requests for a higher level of interest 
during manufacturing and even prescribing, since children require lower dose amounts 
to achieve the same effects as seen in adults. In addition, various factors need to be 
taken into consideration, notably taste masking. For drugs that come in the form of 
powders, the dosage form can be changed by tableting the powders and converting 
them into solid dosage forms. Powders can also be granulated to make it easier to 
determine the dose since this becomes a major issue, especially with regard to children 
(van Riet-Nales et al., 2013).  
Table 1.2 shows a matrix developed by the EMA from responses to questionnaires 
sent out to 40 participants (including parents, pharmaceutical scientists and clinical 
paediatricians) in different European countries to develop a relationship between age 
development, dosage form and route of administration (Cram et al., 2009). Moving 
from the left to the right, the emphasis in the columns changes from the applicability to 
preference. 
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Table 1.2: EMA matrix relating oral dosage forms/ route of administration to dosage form and 
age; adapted from references (EMA, 2006, Breitkreutz and Boos, 2007). 
Oral dosage forms Preterm 
new-born 
infants 
Term 
new-
born 
infants 
(0d-28d) 
Infants 
and 
Toddlers 
(1m-2y) 
Children 
(pre-
school) 
(2-5y) 
Children 
(school) 
(6-11y) 
Adolescents 
(12-16/18y) 
Solutions/ drops  2 4 5 5 4 4 
Emulsion/Suspens
ion 
 2 3 4 5 4 4 
Effervescent 
dosage form 
 2 4 5 5 4 4 
Powders/ 
Multiparticulates 
 1 2 2 4 4 5 
Tablets  1 1 1 3 4 5 
Capsules  1 1 1 2 4 5 
Orodispersible 
dosage form 
 1 2 3 4 5 5 
Chewable tablets  1 1 1 3 5 5 
Key:  
Younger ages (preterm-pre-school): 1- not applicable, 2 - applicable with problems, 3 
- probably applicable but not preferred, 4 - good applicability, 5 - best and preferred
applicability.
Older ages (school-adolescents): 1 -not accepted, 2 - accepted under reserve, 3 -
acceptable, 4 -preferred acceptability, 5 - dosage form of choice.  
1.2.2. Definition of Acceptability 
The acceptability of a drug is its ability to meet the patient’s requirements and needs. 
Acceptability also entails the quality of the drug to realize the objectives set out by the 
physician. It involves a number of aspects including the dosage amount and proper 
diagnosis. Of the two, proper diagnosis is of immense importance before embarking 
on managing an ailment, a condition, or a disorder. Proper diagnosis not only gives the 
physician the knowledge of the condition in question, but also provides a head start on 
the best way of managing it. Managing in this case, refers to administration of the right 
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medicine. As mentioned earlier, the administration is determined by a number of 
factors. This calls for a choice on the route of administration to be used. The route of 
administration should be in line with the pharmacokinetic properties of the drug. For 
example, drugs that are absorbed in the stomach are administered orally. Care has to 
be taken regarding some drugs taken orally, as they may undergo breakdown while in 
the stomach. Such drugs (proton pump inhibitors, omeprazole) are usually enteric-
coated to minimize, if not effectively curb, their breakdown as they pass through the 
gastrointestinal tract (Standing and Tuleu, 2005). Enteric coating provides a layer that 
inhibits the action of acids enzymes present in gastric juice and other stomach 
secretions, which contribute to the breakdown of the acid sensitive’s active 
pharmaceutical ingredients (APIs) in the formulation. If such drugs are not enteric-
coated, there is a high likelihood that they will undergo breakdown while still in the 
stomach, and the APIs may fail to reach their intended area of absorption, which could 
be the ileum or even the large intestine (van Riet-Nales et al., 2013). 
1.2.3. Important Factors in the Overall Acceptability of an Oral 
Paediatric Medicine 
For oral paediatric medicines to be acceptable and therefore effective, there are a 
number of factors that need to be considered. One of these is elegance. Elegance 
refers to the outward appearance of the dosage form and its ability to appeal to the 
eye. Among children, this factor becomes crucial because of the sensitivity of children 
to seemingly unimportant matters (EMA, 2006). A child may refuse to take a medicine 
just because it does not look appealing. A factor related to acceptability and which is 
closely related to elegance, is palatability. Children will rarely take drugs that are bitter 
tasting (Hoppu, 2008). For this reason, most drugs which have a bitter taste are coated 
with a sweet tasting substance. If the bad taste is not masked, such drugs may 
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predispose the child to vomiting. If the smell of the drug is putrid, it may also negatively 
influence the acceptability of the drug. The ability of children to differentiate drugs by 
their smell is testimony of their attention to detail. In the same way, a dosage form 
needs to be convenient for it to be acceptable among children. The term convenience 
refers to the method by which it is administered, for instance, as a tablet, a syrup or as 
a powder. Among children of school age, tablets are more popular compared to 
powders because they can easily be administered (Nunn and Williams, 2005). Dosage 
is also accurate and can be easily determined since most tablets are already portioned 
in specific doses. Syrups are also more popular compared to solutions, which in turn 
are preferred over powders (Maheshwari et al., 2013). Excipients added in solutions 
to increase their volume should be neutral and need not have an effect on the ultimate 
intended therapeutic effect of the drug. Lastly, the stability of a drug is of great 
importance with regard to its acceptability. Stability is the ability of a drug to maintain 
its original form in terms of physical appearance, its therapeutic effects, and its 
chemical composition (Allen and Ansel, 2013). A medicine whose chemical structure 
varies after a period, or changes taste, is likely to have low acceptability compared to 
the one whose properties do not vary. In addition, the drug may not produce the 
intended outcome, especially if both chemical and therapeutic variations occur 
(Overgaard et al., 2001). 
1.2.4. A WHO Consultation on Paediatrics and Guidelines 
The World Health Organization (WHO) is the international body that controls products 
and services with regard to human health. As such, it has laid down guidelines and 
procedures for production of paediatric dosage forms. WHO recognizes the need to 
develop drugs and formulations that specifically target children. It admits that even 
though the search for the appropriate dosage formulation with regard to the age, 
physical and physiological conditions of children has been challenging, it is not a lost 
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war (Hill, 2011). However, WHO warns against administering unlicensed drugs to the 
paediatric population, as this is likely to culminate in grave consequences. WHO 
recommends that dosage formulations should be prepared to cover as wide an age 
bracket as possible. This is because the age bracket of children is vaguely defined and 
stretches from preterm infants to term infants, to toddlers and even adolescents. It also 
recommends that manufacturers uphold good manufacturing practices with regard to 
obtaining and processing raw materials, up to preparation of the final pharmaceutical 
product. WHO stipulates that the dosage administered should be in line with the age 
and specific needs of the child. More importantly, the dosage, whether in volume or 
size, needs to be accurate. An overdose or an under dose may result in toxicity or sub 
therapeutic effect respectively. In addition, paediatric formulations should be made in 
ready-to-use preparations, as much as possible. This will minimize, if not eradicate, 
the need to modify the preparation by parents or health care professionals. 
According to WHO, the dosage form should be acceptable and palatable. Furthermore, 
the drug formulation should be palatable without the need to mask the taste or sugar 
coating. Palatability will make it easier for children to accept and swallow the drug. 
Acceptability of the dosage formulation stretches beyond its use among children and 
extends to parents/caregivers and physicians – the dosage formulation should be 
acceptable among parents to increase its chances of being purchased. At the same 
time, acceptability or palatability should not be enhanced by mixing the drug 
formulation with food or drinks. This is because food and drink may affect the 
absorption of the drug or may interact with it, resulting in physical or chemical 
alterations. If there is no alternative, then the food or drink should be in a small amount 
such that it will not have an impact on the effects of the drug (Kozarewicz, 2014). 
Manufacturers also need to indicate whether it is possible to administer a given drug 
with food or beverages, and also incorporate any exceptions. When administering 
drugs to children, it should be ensured that minimum dosing is adhered to. The 
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frequency with which a drug is administered should be made minimal because frequent 
dosing, especially more than twice a day, may have a negative impact on patient 
compliance (Greenberg, 1983).  
WHO recommends that manufacturers should aim at production of quality dosage 
formulations, with the needs of the target population in mind. For instance, the dosage 
formulation should be affordable to most people and the production process should be 
simple. The drug should be able to reach the target population easily by implementing 
viable transport and supply strategies. In addition, instructions for proper storage of the 
drug should be made available. For drugs that need to be dissolved in water before 
being swallowed or those that need water when swallowing, procedures for obtaining 
standard clean water should be outlined. This is because clean water may not be 
locally available in some locations (Hill, 2011). Furthermore, the need to produce 
dosage formulations that are effective among the paediatric population has brought up 
the need to conduct further research in the field of excipient’s toxicity. As a result, 
newer methods, which are still under trial, are being investigated to study the effect of 
commonly used excipients in dosage form development, and their impact on the 
paediatric patient population (Walsh and Mills, 2013). The excipients used in making 
paediatric formulations have witnessed an increasing interest, with the belief that the 
right excipient will be the answer to most of the questions that still remain unanswered. 
To begin with, the excipients to be employed need to have a high safety profile to 
prevent any side effects. They also have to be tolerable because this influences the 
acceptability of the paediatric formulation. Current research projects of excipients used 
in paediatric formulations incorporate all stakeholders, including the target age group 
(children), medical practitioners, and even parents/ care-givers (Fabiano et al., 2011). 
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1.2.5. Standard features of dosage forms for paediatrics 
The goal is to find one formulation suitable for every age group. The primary focus 
should be the safety of the formulation and ideally cover as broad an age range as 
achievable. The guiding standards for choosing paediatric dosage forms should be 
based on the risk/benefit ratio accounting for the precise needs of this susceptible 
population. Desirable characteristics of quality paediatric drugs common to different 
kinds of dosage forms are outlined in (Table 1.3). 
Table 1.3: Standard features for dosage forms of paediatrics are outlined by WHO (2010). 
Convenient, reliable 
administration 
The administered dose should contain an 
amount of API adjusted to the age and needs 
of paediatrics. More than one dosage form of 
API or strength of a dosage form is required to 
cover different age groups. The intended dose 
volume or size should be appropriate. 
Paediatric medicines should be ready to 
administer. Manipulation of dose should be 
minimal. 
Acceptability and palatability Acceptability is the overall acceptance of the 
dosage form regardless of the route of 
administration. Acceptability depends on 
suitability for the particular age group, dosing 
device for a liquid medicine, palatability of an 
oral medicine, dose volume or size to be 
administered, appropriate packaging, clear and 
accurate labelling information and directions for 
use. 
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Palatability is the overall acceptance of the 
taste, flavour, smell, dose volume or size and 
texture of a medicine to be administered in the 
mouth. Compliance can be highly dependent 
on palatability. API palatability may influence 
the choice of dosage form and its design, which 
may include taste-masking ingredients. The 
dosage form should, however, not become too 
attractive to the child (e.g. a sugar-coated tablet 
that is candy-like) in order not to increase risk 
of accidental poisoning. 
Minimum dosing frequency Minimal dosing frequency should be attempted. 
Instructions on the dosing frequency are based 
on the pharmacokinetic as well as 
pharmacodynamics properties of the API, but 
may also be influenced by the design of the 
dosage form. Frequent dosing may conflict with 
the lifestyle of older children. 
End-user needs It is important that dosage forms are convenient 
to produce, as well as affordable. It is also 
important to bear in mind supply chain 
considerations such as ease of transportation 
and storage requirements. Storage in a 
refrigerator by the user is not always possible. 
Depending on age and clinical condition of the 
child, there are restrictions to the applicable 
dose volume or size. Generally, in developing 
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the product, minimum dose volume and size 
should be attempted. Lack of access to clean 
water is an important issue to take into 
consideration in the development of medicines 
to be dissolved, diluted or dispersed prior to 
administration, as it may compromise the 
quality. It may be necessary to educate patients 
on how to obtain water of suitable quality, e.g. 
boiling or filtering instructions. Provision of the 
liquid vehicle as a part of the package may be 
an option to be considered, or the dose may be 
dispersed or dissolved in suitable food or 
beverage prior to administration. Instructions 
on such use should always be labelled. 
Dosage form development for the paediatric population should ensure global 
application including addressing limitations such as lack of appropriate storage 
conditions, cost of production and the lack of access to clean water encountered in 
developing countries. A flexible dosage form platform should also be used to ensure 
delivery of a wide range of APIs. 
1.3. ODTs and Why ODTs for Paediatrics 
 It is essential to mention orally disintegrating tablets (ODTs) which have been a 
popular area of research for scientists in the last decade as new ‘drug delivery systems’ 
have found to be well accepted by many patients, specifically paediatric as well as 
geriatric patients (Parkash et al., 2011). Orally disintegrating tablets (ODTs) are drug 
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formulations, which quickly disintegrate in the mouth and can be absorbed within the 
buccal cavity. The European Pharmacopoeia places the disintegration time at less than 
three minutes (Pharmacopoeia, 1998). The different terminologies for ODTs include 
rapidly disintegrating tablets, orodispersibles, fast dissolving and fast melting tablets. 
They are also designated as fast melting, fast dispersing, rapid dissolve, rapid melt 
and/or quick disintegrating tablets. The European Pharmacopeia (EP) approved the 
term “orodispersible tablet” for those that disintegrate within three minutes or less in 
the mouth before swallowing. Such tablets disperse into smaller granules, melting from 
a hard solid to a gel-like structure in the mouth, permitting patients to swallow with 
ease. The disintegration time (DT) for effective ODTs differs from a few seconds to 
about a minute. 
 ODTs are widely viewed, from dosage administration point of view, as intermediates 
between solid dosage forms and liquid dosage forms. However, they lack the instability 
that is associated with the liquids and the difficulty in swallowing that is common with 
regards the solid dosage forms. Swallowing is a major issue for toddlers and children 
under the age of six. As such, ODTs overcome this disadvantage because they do not 
need to be swallowed, but rather disintegrate upon introduction into the oral cavity 
(Thomson et al., 2009). ODTs are also safer than solid dosage forms because they do 
not have the risk of choking. In addition, they are stable and rarely undergo 
deterioration, be it physical, microbial or even chemical breakdown. Lastly, the 
importance of dosage and dose accuracy has been mentioned before. ODTs have the 
advantage of having dose uniformity because most, if not all come in predetermined 
doses. Figure 1.2 shows the popularity of ODTs in comparison to other dosage forms 
such as tablets and liquids. Even though a good segment of the world’s population still 
prefer tablets and liquids as dosage forms, more people are realizing the benefits of 
ODTs (Brown, 2003). 
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Figure 1.2: Consumer Preferences of ODT to regular tablets or liquids adapted from (Brown, 
2003). 
Since their inception into the market, the demand and preference for ODTs has been 
steadily rising. Consequently, the market base for this dosage formulation is also 
expanding. Analysts project a further increase in the number of consumers who prefer 
and therefore use ODTs at the expense of other dosage forms, in line with the increase 
in oral dosage form use in the past seven years (Figure 1.3). Statistics show that half 
of the population of the patient have a preference for ODTs compared to other dosage 
forms (Deepak, 2004). Furthermore most patients would request their healthcare 
professionals for ODTs (70%), buy ODTs (70%), or choose ODTs to standard tablets 
or liquids (>80%) as shown in (Figure 1.2) (Brown, 2003).  (Sastry et al., 2000) carried 
out a study on dysphagia and stated that “dysphagia is common in about 35% of the 
population, as well as an additional 30–40% of elderly institutionalized patient’s and18–
22% of all persons in long-term care facilities.” Another study revealed that 
approximately 50% of the general public experience dysphagia (Seager, 1998). In 
many developing countries there is lack of supply of pure water and many children die 
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due to drinking of contaminated water. Moreover, pure water might not be available 
while patients are outside, away from their home or any shops. In these unavoidable 
circumstances, the advantages of ODTs are immense and they present a most 
convenient form of taking a drug. Among all the dosage forms available such as oral 
tablets, rectal, parental, and nasal or inhalation products, ODTs are undoubtedly the 
most preferred of dosage form by children (Alyami et al., 2016). Many parents prefer 
ODTs for their children as the tablets give a good mouth feel when they disperse or 
dissolve immediately into small particles by means of dissolution in the saliva. 
According to WHO (Organization, 2010), orally disintegrating dosage forms can be 
divided into orodispersible tablets, oral lyophilisates, and thin flat films (wafers) as seen 
in (Figure 1.4). 
Figure 1.3: Oral Drug delivery Market Forecast (2009-2016) adapted (Konar and 
Mukhopadhyay, 2014). 
Orodispersible as well as orosoluble dosage forms have a wide range of applications. 
They provide the necessary benefits of liquid formulations, making it possible for 
children who cannot consume a complete tablet, to take an ODT. In some situations, 
particularly for younger children, the ODT may need to be dissolved in a little volume 
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of liquid prior to administration. Taste masking may be facilitated by the utilization of 
water-soluble sweeteners in addition to the inclusion of flavours (Fu et al., 2004). 
Figure 1.4: Three forms of orally disintegrating dosage forms adapted from (Organization, 
2010). 
1.3.1. Current status of ODT formulation and future developments 
Advancements in the area of ODT formulation are aimed equally at escalating the 
performance of the dosage form by lessening the disintegration time, and by increasing 
the compliance of patients via masking the unpleasant taste of the API. These 
successes require stable improvement of formulation variables, together with 
Oral lyophilisates 
prepared by freeze-drying of 
aqueous liquids into porous 
units shaped like tablets. 
Excipients are gelatin /alginate as 
structure-forming agents, 
mannitol, which facilitates 
formation of porous structure,  
contributes to a palatable dose. 
Lyophilisates are sensitive to 
moisture and require a vapour-
tight package.
Orodispersible tablets 
possess fast-
disintegrating 
characteristics and are 
formulated by direct 
compression of API, 
mannitol, a super-
disintegrant, as well as a 
flavouring agent. ODTs 
are bendable dosage 
forms suited particularly 
for vastly water-soluble 
APIs.
Thin, flat films (wafers)
to be placed in the oral 
cavity, prepared by 
casting water-soluble 
polymers containing API 
in dissolved /dispersed 
form. Dissolved API 
incorporated is limited. 
Release profile depends 
on polymer, film thickness 
and API solubility. Wafers  
dissolution time is less    
than 30 seconds. 
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technologies concerned in the manufacture of dosage forms. The inclusion of super-
disintegrants to produce efficient ODTs is not new. Conversely, with the development 
design of innovative techniques, it has become promising to formulate ODTs with less 
content of super disintegrants and with improved mouth feel (Pahwa and Gupta, 2011). 
Additionally, the use of dosage forms such as fast dissolving films, chewing gums and 
micro particles, is anticipated to offer an extremely satisfactory means of delivering 
drugs too, particularly among paediatric and geriatric patients. The application of 
techniques such as freeze drying and direct compression is appropriate for formulating 
dosage forms of vitamins, enzymes and thermo-labile drugs, subsequently these 
methods do not generate heat. Likewise, significant research towards constructing 
modified microcrystalline cellulose (MCC) or starch to obtain appropriate forms for 
direct compression has extensively decreased the product development time for 
optimizing ODT formulations. Rational excipient use along with technology can ensure 
the formulation of a satisfactory and efficient ODT, more easily than in the past (Goel 
et al., 2008). 
As ODTs are an excellent dosage form for elderly patients suffering from dysphagia 
and also diabetes, so, an approach was taken by (Mohapatra et al., 2014) to formulate 
metformin hydrochloride which is an anti-hyperglycaemic drug as ODTs (Parkash et 
al., 2011). In their research, key areas of emphasis for ODTs included fast 
disintegration, taste of active ingredients, drug properties, tablet strength and porosity 
as well as moisture sensitivity. For production of ODTs, many aspects need to be taken 
into account such as relevance of powder mixing, mixing powders using dry mixing 
and granulation, sampling of powder mixtures, simple manufacturing processes and a 
systematic selection of excipients. Direct compression is an easy, cheap and 
convenient method to manufacture ODTs. This method requires only two stages in the 
manufacturing process that is, blending and mixing of APIs and excipients, followed by 
compression. Efficient mixing is a very essential and an important step, in order to 
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generate ODTs with high efficacy and fast disintegration in the mouth within few 
seconds. 
1.3.2. Formulation of ODTs 
Desirable characteristics of ODTs include their disintegration in the oral cavity  without 
water, and the conversion of this disintegrated tablet into a soft paste or liquid 
suspension, which gives an excellent mouth feel in addition to ease of swallowing. The 
popularity of ODTs has given rise to various ODT manufacturing technologies, which 
are based on lyophilisation (freeze drying), moulding, sublimation and compaction, 
together with advances to increase the ODT’s characteristics—for example, spray 
drying, moisture treatment and sintering, in addition to use of sugar-based 
disintegrants (Douroumis, 2007, AlHusban et al., 2010). Experimental measurements 
of disintegration times and clinical studies are also carried out to formulate and develop 
an efficient ODT. 
Furthermore, during ODT development, the features of the drug such as, solubility, 
crystal morphology, size of particle, hygroscopicity, compressibility as well as bulk 
density of a drug can significantly affect the tablet’s characteristics, such as tablet 
strength and disintegration time. It is also necessary to optimise tablet porosity to 
ensure quick water absorption, for which elevated wettability of excipients as well as 
high porous tablet network structures are necessary. Tablet strength is directly 
connected with compression pressure, as porosity is inversely associated with 
compression pressure. It is very important to strike a balance between porosity (with 
the intention of fast water absorption) and enhanced mechanical strength. Low 
sensitivity to humidity is also a necessary condition for excipients used in ODTs. This 
requirement is challenging, as water-soluble excipients are often utilized in the 
formulation of ODTs. 
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1.3.3. Methods to formulate ODTs 
Different formulation processes have been used to develop fast-dissolving tablets. 
These processes are summarized in (Table 1.4). 
Table 1.4: Processes employed in the manufacture of ODTs (Bandari et al., 2014). 
Procedures Description 
Freeze drying In the process of freeze drying (lyophilisation), the solvent is 
separated from a frozen drug solution or a suspension 
comprising structure-forming excipients. Tablets generated 
are especially light as well as having highly porous structures 
to permit rapid dissolution/ disintegration. When the dosage 
form is taken, the freeze-dried unit dissolves immediately to 
free the incorporated drug. The freeze-drying procedure might 
result in glassy amorphous structure of excipients as well as 
of the drug substance, which leads to improved dissolution 
rates. Disadvantages are that the process is expensive, and 
at higher temperatures and humidity, the stability of ODTs is 
poor. 
Moulding The core material of moulded tablets is usually water-soluble 
polymers. The powder mixture is moistened with a solvent 
(generally ethanol or water), then moulded into tablets under 
pressures less than those utilized in conventional tablet 
compression. This is recognized as compression moulding. 
The solvent can be separated by air drying. As moulded 
tablets are often compressed at a lesser pressure than other 
compressed tablets, a superior porous structure is formed to 
improve the dissolution. To obtain a better dissolution rate, the 
powder blend typically must be passed through a fine screen. 
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Compaction Granulation methods include wet granulation, dry granulation, 
melts granulation, spray drying. Direct compression 
disintegrants and inorganic excipients used in ODTs. 
Compaction and ensuing treatments: sublimation, humidity 
treatment, sintering. Among these, direct compression is 
featured extensively as the objective of this project is to utilize 
the technique of direct compression to develop and produce 
ODTs. 
However, the easiest and most convenient way to manufacture ODTs is using direct 
compression. 
1.3.4. Direct compression technique 
Direct compression is the cheapest and simplest procedure for manufacturing tablets, 
as conventional machineries and common excipients can be used by pharmaceutical 
companies. Direct compression is the common technique for the production of tablets, 
including tablets containing thermo-labile and moisture-sensitive drugs. This 
procedure can easily be used to produce ODTs by selecting a potential combination 
of ingredients that will allow fast disintegration combined with good physical resistance. 
Generally, sugar-based ingredients are used commonly as bulking agents for various 
reasons, such as extensive aqueous solubility, sweetness, pleasant mouth feeling and 
effective taste masking (Chang et al., 2000). A flow chart outlining the steps of direct 
compression is shown in (Figure 1.5). 
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Figure 1.5: Stages involved in the production of ODTs using direct compression. 
1.3.5. Compression and preparation of orally disintegrating 
particulates (ODPs) 
Multiparticulate dosage forms consisting of pellets and granules are gaining increasing 
attention as an optional oral drug delivery system known as particulate unit dosage 
forms and ranging in size from about 0.05–2.0 mm (Dey et al., 2008). Pellets can be 
generated by utilizing diverse methods in accordance to the appliance as well as 
manufacturer’s choice (Chamsai and Sriamornsak, 2013). The most extensively used 
techniques for pelletization include extrusion/spheronization, solution or suspension 
layering and powder layering. Of the procedures used, extrusion/spheronization is the 
most preferred (Ghebre-Sellassie, 1989). Multiparticulates as a tool provide the 
flexibility to expand dosage form and administration options for paediatric populations 
(Figure 1.6). 
Weighing of active  
ingredients and excipients
Mixing/blending
Direct compression
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Figure 1.6: Versatility of multiparticulates with reference to formulation and method of 
administration, adapted (Stoltenberg et al., 2010). 
1.3.6. Excipients Used in Direct Compression 
In the direct compression method, different excipients are used for different purposes. 
Some of the commonly used excipients are listed in (Table 1.5). 
Table 1.5: List of excipients used in direct compression (Gupta et al., 2012). 
Function of excipients Commonly used examples 
Diluents Lactose monohydrate, anhydrous 
lactose, microcrystalline cellulose, partly 
pregelatinised starch, mannitol, dibasic 
calcium phosphate (anhydrous & 
dihydrate) 
Disintegrant Croscarmellose sodium, sodium starch 
glycolate, crospovidone, partly 
pregelatinised starch, low substituted 
hydroxypropyl cellulose 
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Lubricant Magnesium stearate, calcium stearate, 
sodium stearyl fumarate, stearic acid 
Stabiliser Buffers such as sodium carbonate and 
citric acid. 
Antioxidants such as butylated 
hydroxyanisole and butylated 
hydroxytoluene 
Surfactants Sodium lauryl sulphate, polysorbates 
1.3.7. Inorganic Excipients Used in ODTs 
Tablet disintegration is directly proportional to the quantity of the disintegrant and 
insoluble excipients. Disintegration is furthermore dependent on the relative weight 
ratio amongst the water insoluble and soluble excipients, when water-soluble 
ingredients are utilized (Hirani et al., 2009). Research by Dobetti (2003) produced a 
formulation using insoluble inorganic excipients as the key ingredients of ODTs. It was 
obvious from their formulations that sufficient compression could be exerted to 
generate tablets with hard tensile strength in addition to low friability. Rate of 
disintegration was not significantly influenced by elevated compression force. In the 
formulation, the main excipients used were: 
 Water insoluble components consisting of insoluble excipients, water-insoluble
drugs (coated or uncoated) and water- insoluble lubricant together with a
glidant. The excipients consisted of insoluble inorganic salts (such as di- or tri-
calcium phosphate) or organic fillers (such as microcrystalline cellulose).
 Significantly soluble excipients consisted of compressible sugars, flavouring
agents, sweeteners, binders as well as surfactants.
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 Disintegrants consisted of maize or modified starch, cross-linked PVP
(polyvinylpyrrolidone) or sodium carboxy-methylcellulose.
Disintegration time was enhanced as the amount of insoluble components was 
lessened. If the API was a low dose drug, disintegration time could be elevated by 
including insoluble fillers (such as microcrystalline cellulose and silicon dioxide) or by 
increasing quantity of insoluble inorganic excipients (such as dibasic calcium 
phosphate) (Fu et al., 2004). 
1.4. Significance of powder mixing 
Mixing of dry powders is an important area of research because of its wide application 
in the food, as well as the pharmaceutical industry. This is because unproductive (non-
uniform) mixing procedures can lead to a non-homogenous mixture which gives rise 
to variation in API content within a single dosage form (Bridgwater, 1976). In 
pharmaceutical operations, mixing is an important procedure and it is essential to 
understand the different types of mixing processes and their advantages and 
disadvantages. 
In order to avoid variation in flowability of the powder mixture, segregation needs to be 
monitored by controlling particle size of the API as well as excipients. It is also essential 
to use the correct mixing apparatus and mixing technique. Pilot studies can be carried 
out to investigate whether agglomeration is taking place due to fine particles, volume 
of low meting point solid content and moisture content leading, to softening of particles 
(Portillo, 2008). Table 1.6 summarizes the parameters which need to be considered 
for efficient mixing, these include physical properties of powder, and type of mixing. 
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Table 1.6: Factors to consider efficient powder mixing adapted (Jallo et al., 2012). 
Physical properties of powder 
Components parameters pertinent to particle size 
Shape and size distribution 
Density, hardness and cohesivity 
Nature of the powder 
Particle charge 
Factors of mixing equipment 
Speed, processing time and load 
Type of mixing equipment 
Tumbling mixers 
Agitator mixers 
V-blenders
Double-cone mixers 
1.4.1. Types of powder mixing 
Mixing identifies a procedure where two or more components, which are either 
separated or are in a randomly oriented direction with each other, are treated in a way 
that the particles come close to one another at equal proportion (Çelik, 2016). 
Depending on the flow characteristics of powders, solids are divided into cohesive and 
non-cohesive materials. Due to the operation of the cohesive forces between the 
surfaces of the particles, powders which exhibit high degree of attraction either due to 
small particle size or shape present significant barriers in powder blending leading to 
the formation of aggregates. 
Table 1.7 lists the different types of powder mixing including ordered mixing, geometric 
mixing, shear mixing, dry mixing, convective mixing and macro mixing. 
Chapter 1 
60 
Table 1.7: Different types of mixing process and their description adapted from (Bhatt and 
Agrawal, 2008, Deveswaran et al., 2009). 
Mixing process Description 
Convective or macro mixing Mixing technique in which groups of 
particles are transferred from one region 
of a powder bed into another part. 
Shear mixing Shear forces are generated in the 
materials by utilizing an agitator arm or a 
gust of air. 
Diffusive or micro mixing The material is subjected to gravitational 
forces that cause the upper layers to 
slide, and diffusion of each particle 
occurs above newly developed surfaces. 
Geometric mixing With this method, a homogenous mixture 
is achieved. The smallest amount of 
active ingredient is mixed methodically 
with an equivalent amount of the other 
component. In other words, it is a method 
in which two components of unequal 
quantities are mixed where the 
procedure is started with the smallest 
quantity. 
Ordered mixing When one of the components that is 
added is a fine, micronized powder, the 
combination with the larger components 
(larger particle size) results in adsorption 
of the micronized particles to the surface 
of the active sites where they are 
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attached due to weak forces (Van der 
Waals forces). Ordered mixing is 
generated via mechanical adhesion, 
such that the ordered entity will be the 
smallest model of the mix and will be as 
close in composition to other ordered 
entities in the mix. 
1.4.2. Sampling of powder mixtures 
Information on the particle size distribution (PSD) of powder blends is a prerequisite 
for most industrialised processes, including the manufacture of pharmaceutical and 
biopharmaceutical products. Results of particle size investigations are most 
appropriate when samples taken are representative; more so when suitable dispersion 
methods are utilized. The common variation in particle sizing measurements can be 
traced to incorrect sampling or sample preparation. When determining PSD of 
powdered solids, results will be of minimal value, unless and until the analytical sample 
represents the bulk from which the sample was taken. There are challenges associated 
with sampling of pharmaceutical mixtures. Accurate characterization of granular 
mixtures is sometimes not possible due to the complexity of the system and the lack 
of standard sampling techniques which represent the bulk of the total powder under 
investigation (Muzzio et al., 2003). For most pharmaceuticals, particularly powders, 
various factors should be considered when planning a sampling method. These factors 
consist of: the characteristic of the collection powder from where the sample is taken, 
sampling cost as well as associated assays, expediency and degree of precision. The 
following factors need to be taken into consideration when developing, or adapting a 
sampling process: 
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 Powder quantity from which samples are to be acquired
 Sample amount required
 Characteristics of powder consisting of flow behaviour, shape of particle,
tendency to separate and surface chemistry
 Mechanical strength such as friability
Sampling can be dynamic and static. A summary of sampling techniques and their 
advantages as well as disadvantages are shown in the (Table 1.8). 
Table 1.8: Summary of devices used in sampling and their advantages and limitations (Allen, 
2003). 
Device Advantages Disadvantages 
Cone and Quartering Good for powders with 
poor flow characteristics 
Operator-dependent 
Scoop Sampling Reliable for homogenous 
and non-flowing powders 
Particle segregation in 
non-flowing powders 
Table Sampling Able to separate large 
quantity of material 
Very dependent on initial 
feed 
Chute Splitting Can reduce powder 
sample 
Operator bias by 50% in 
one pass 
Spin Riffling Reliable for free flowing 
powder samples 
Not efficient at handling 
large samples of powder 
As it is not possible to test the complete powder mixture, it is necessary to take 
sufficient quantities and numbers of samples randomly, to make sure that it represents 
the whole powder bulk. This can be carried out by utilizing a powder thief (Muzzio et 
al., 2003). A powder thief is an apparatus particularly designed for taking out definite 
sample amounts from a powder batch. A powder thief has more than one cavity 
engraved in a hollow cylinder which can be opened as well as closed in a controlled 
fashion by an external rotation or else pulled down sleeve (Muzzio et al., 1997) . The 
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powder thief is placed into the powder with closed cavities. When insertion is done, 
cavities are opened and powder runs into the cavities, which can be closed so that 
powder thief is taken out from the powder bed. For arbitrary sampling utilizing a powder 
thief, the idea is that all particles in the powder mixtures should have an equivalent 
possibility of being selected for homogeneity testing. 
1.5. Functionalised particles using dry powder coating 
Dry coating is a pioneering technique in which fine particles are mechanically coated 
onto the surface of larger carrier particles to impart useful properties to the final 
product, which are engineered particles. In dry particle coating, “guest” particles are 
brought in contact with “host” particles by means of mechanical forces (Figure 1.7). 
Due to the high number of clashes between the particles, guest particles are coated 
on the surface of host particles as the Van der Waal’s forces are principal in creating 
a strong adhesive bond between the host and guest particles, which results in the 
formation of value added and engineered composites. Therefore, dry particle coating 
is used to deposit a very small amount of functionalised particles with high degree of 
precision onto drug or excipient particles in order to improve their flow and other 
properties (Honda et al., 1994). 
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Figure 1.7: Schematic overview of coating process technique, the inner part is the coarse 
carrier particle (host) and the outer is particles of the cohesive fine particles (guest) adapted 
(Alonso et al., 1990). 
1.6. Role of Moisture Content 
The levels of moisture associated with solids may significantly affect the physical, 
chemical and mechanical properties of APIs and excipients. Moisture content is an 
important factor during the development of an ideal composition for solid dosage forms 
as well as during the upscaling process (Stubberud et al., 1995). Properties such as 
flow, compaction, disintegration, hardness and porosity are highly sensitive to the 
amount of moisture present. The amount of water present, where it is located and how 
it is distributed within the powder/dosage form, are all crucial factors that should be 
addressed to allow users to control the performance of the powder during processing 
(Faqih et al., 2007). In addition, water interacts with pharmaceutical solids at 
essentially all stages of manufacture. Therefore, water–powder interaction is a key 
factor in the formulation process, and performance of the final solid dosage form.  
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The amount of water associated with a solid at a particular relative humidity (RH) and 
temperature is based on its chemical affinity for the solid, the number of available sites 
for interaction, surface area and nature of the material (Dawoodbhai and Rhodes, 
1989). For example, nonporous talc has low equilibrium moisture content (EMC); on 
the contrary, organic sugars, polymers consisting of hydrogen bonding and crystalline 
hydrates, have high EMCs. In a dry atmosphere, the water will be comparatively tightly 
bound as a non-freely movable layer, which sometimes is represented as a monolayer 
of adsorbed moisture (York, 1981), whereas, at higher RH (>80%), multilayer 
adsorption occurs and the water becomes more moveable and may be present as 
condensed water (Nokhodchi, 2005). 
On this issue, (Nokhodchi et al., 1996) and his team studied the increase in polymer 
chain mobility associated with the presence of internally absorbed water, known as the 
plasticizing effect. This occurrence should adversely affect powder flowability due to 
the increase in particle cohesive and adhesive forces; but on the other hand, should 
have a positive effect on particles consolidation under compression. For externally 
adsorbed water, the effect on the technological parameters is evidently influenced by 
its amount. Thus, lower percentages of water adsorbed on the particles can have a 
very positive effect on powder flowability and compression, due to its lubricating effect 
which improves the particles slippage by removal of micro irregularities on the particle 
surface, and electrostatic charge. Nonetheless, if the adsorbed water content 
increases, the formation of agglomerates due to the presence of liquid bridges could 
clearly worsen flow properties of the solid. As for compression, this increased cohesion 
could promote the formation of interparticulate bonds under pressure, as a result, if the 
presence of water absorbed is excessively high, the hydrodynamic effect must 
significantly limit the compressibility of particles (Bravo-Osuna et al., 2007). 
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1.7. Research aims and objectives 
The overarching aim of this thesis is to design the development of novel oral dosage 
forms for the paediatric patient population. The content in this thesis will cover the 
following main paediatric challenges/gaps in the knowledge:- 
1- To identify children’s experience of taking medicines and the child’s
preferences/opinions for oral dosage forms, in particular ODTs (Chapter 2).
2- To investigate healthcare professionals perceptions or opinions regarding the
use of different dosage forms for paediatric use (Chapter 3).
3- To develop pre-blend for potent model low dose drug using various blending
techniques (Chapter 4).
4- To optimise and characterise ODT pre-blend of excipients for direct
compression (Chapter 5).
5- To study the role of moisture content on micro/macro properties of paediatric
pharmaceutical excipients (Chapter 6).
Further details of the aims and objectives of each chapter are discussed at the 
beginning of each chapter. 
Chapter 2 
Dosage form preference consultation study in 
children and young adults: Paving the way for 
patient-centred and patient-informed dosage form 
development 
Publications relating to chapter 2 
Hamad Alyami, Eman Dahmash, Fahad Alyami, Dania Dahmash, Chi Huynh, David 
Terry and Afzal R Mohammed (2016). Dosage form preference consultation study in 
children and young adults: paving the way for patient-centred and patient-informed 
dosage form development. European Journal of Hospital Pharmacy: ejhpharm-2016-
001023.
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2.1. Introduction 
Paediatric drug administration has gained significant attention over the last 5-7 years. 
Pharmacists and other healthcare professionals in the pharmaceutical industry face a 
myriad of challenges regarding the appropriate choice of the dosage forms for drug 
administration to this important target population (Gauthier and Cardot, 2011). For this 
reason, the common trend has been the manipulation of adult dosage forms into a 
form that can be administered easily to children and young people. However, existing 
knowledge in this field is limited, making it difficult to identify viable solutions. The 
European Regulation on medicinal products (Committee for Medicinal Products for 
Human Use, 2006) stipulates that all formulations produced for young people should 
include safety measures such as assessment of excipient toxicity, appropriate delivery 
system capable of offering dose flexibility and should generally be acceptable to the 
target population.  
The term paediatric dosage forms need to suffice for a wide age range including 
neonates to adolescents (0-16 years). The common oral paediatric dosage forms in 
use are: solid dosage forms (such as tablets), powders, solutions, and syrups (Viner 
and Barker, 2005). For oral paediatric medicines to be acceptable to young patients, 
there are a number of factors that need to be considered, especially elegance and 
palatability. Elegance refers to the outward appearance of the dosage form and its 
appeal to the end user. This may be particularly important for children and their 
adherence to medication regimens (Committee for Medicinal Products for Human Use, 
2006) .Palatability is closely related to elegance and is a factor related to acceptability. 
Children will rarely take drugs that are bitter in taste (Hoppu, 2008) .Therefore, any 
active ingredients with a bitter taste are often coated with a sweet tasting substance. 
If the unacceptable taste is not masked, such drugs may predispose the child to reject 
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the medicine. If the smell of the drug is unpleasant, it may also negatively influence the 
acceptability of the drug. The term convenience refers to the method by which it is 
administered, for instance, as a tablet, syrup or as a powder. Oral liquid drug 
preparations, including solutions, syrups, emulsion and suspension, are considered as 
the most suitable oral formulation for children, since they are developed for younger 
new-borns unable to swallow tablets and accommodate palatability and dose 
adjustment changes required by children (Nahata, 1999, Salunke et al., 2011). 
Nonetheless, liquid formulations present several drawbacks, such as low stability, 
difficulties in taste masking, inappropriate excipients for children (e.g. propylene glycol, 
benzyl alcohol,) and low transportability (Committee for Medicinal Products for Human 
Use, 2006, Hoppu et al., 2012). WHO recognises the need to develop drugs and 
formulations that specifically target children. According to WHO, the dosage form 
should be both acceptable and palatable (Kristensen, 2012). Furthermore, whenever 
possible the drug formulation should be palatable without the need to further mask the 
taste. Dosage form acceptability, which encapsulates a multitude of factors including 
preference, palatability, presentation and ease of use, has a significant influence on 
paediatric patient compliance (Committee for Medicinal Products for Human Use, 
2006). Orally disintegrating tablets (ODTs) may increase bioavailability and faster 
onset of action in adults and children, since dispersion in saliva in oral cavity causes 
pregastric absorption from some water-soluble actives. Taste and flavour together 
primarily determine the acceptability of ODTs (Virley and Yarwood, 1990). Any 
pregastric absorption avoids first-pass metabolism and can be of a great advantage in 
drugs that undergo extensive hepatic metabolism. The study described in this chapter 
was designed with two key objectives: (1) to evaluate dosage form preferences for a 
wide range of formulations (liquids, injections, suppositories, solid dosage forms, and 
patches) among children and young adults who have a history of taking medicines.  
The study was conducted in three regions (the UK, Saudi Arabia and Jordan) at five 
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different centres. These were Birmingham Children’s Hospital (the UK), Nottingham 
Children’s Hospital (the UK), Najran Maternity and Children Hospital (Saudi Arabia), 
General Thar Hospital (Saudi Arabia) and Speciality Hospital (Jordan). Countries were 
chosen based on diverse geographical regions and ethnic mix, ease of access to 
suitable subjects, lack of published data regarding children preferences of dosage 
forms. In addition; (2) the study would provide pragmatic and translatable outcomes to 
support formulating stable and acceptable dosage forms. It is recognised that 
commonly prescribed liquid formulations used in hot and humid Middle Eastern 
countries can present significant stability issues (Spomer et al., 2012). A suitable 
method to collect and understand a stance to a hypothesis is a Questionnaire (Powell 
and Renner, 2013). 
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2.2. Materials and Methods 
2.2.1. Materials 
Microcrystalline cellulose (Avicel PH-102 NF) was purchased from FMC BioPolymer 
(Philadelphia, USA). D-mannitol and magnesium stearate were obtained from Sigma-
Aldrich Company (Pool, UK). Paracetamol 500mg tablets were purchased from a local 
pharmacy. 
2.2.2. Methods 
2.2.2.1. Study Design 
Multi-national, 5 sites, participant-supported questionnaire of children aged (6 to 18 
years) following a demonstration of orally disintegrating tablets. The questionnaire was 
conducted in both English and Arabic languages. 
2.2.2.2. Preparation of direct compression ODTs placebos based on 40% of 
microcrystalline cellulose (MCC) 
Placebo orally disintegrating tablet (ODTs) with various sizes (200, 350 and 500mg) 
were prepared using the direct compression method. Based on a previous study 
carried out in our laboratory, powder blend made of 40% w/w microcrystalline, 59% 
w/w mannitol, and 1%w/w of magnesium stearate was compressed at 2 tonnes using 
a Specac auto tablet press (Slough, UK). ODTs were assessed for in vitro 
disintegration time using USP <701> method (USP-29, 2009) via ERWEKA 2T3 
(ERWEKA GmbH). The prepared tablets were evaluated for disintegration 
characteristics. All the measurements were conducted three times and presented as 
(mean ± standard deviation). 
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2.2.2.3. In vitro disintegration study of the tablets 
Disintegration time is the time necessary for ODTs to disintegrate completely without 
solid residue. In vitro disintegration time for ODTs was assessed with the help of US 
pharmacopoeia monograph (<701> disintegration). In this study, Erweka ZT3, 
Appartebau, GMBH was used as disintegration apparatus as well as distilled water as 
disintegration medium which was maintained at a temperature of 37⁰C by thermostat. 
Time necessary for entire tablet disintegration was calculated using a stopwatch. The 
plastic disk as well as basket rack assembly were washed and dried properly after 
every measurement. All the measurements were conducted three times and presented 
as (mean ± standard deviation) (Table 2.1). 
Table 2.1: The disintegration time of ODTs placebo at different sizes (n=3). 
Size ( mg) Disintegration time ( Seconds) 
200 12± 0.541 
350 17± 0.783 
500 21± 0.642 
2.2.2.4. The Questionnaire 
The questionnaire was developed by an iterative process between the study team and 
paediatric based healthcare professionals. The final questionnaire consisted of four 
sections. These were:  demographic and educational data including gender, age, and 
education; participant experience of taking medicines and their preferences for various 
oral dosage forms (liquids, tablets, capsules and ODTs); preference for colour, shape, 
size, thickness, taste, flavour and disintegration time of tablets; participant feedback 
about the questionnaire. 
2.2.2.5. Ethical approval 
The study was conducted at five centres; in England (2 hospitals), Saudi Arabia (2 
hospitals) and Jordan (1 hospital). Birmingham Children’s Hospital Research and 
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Development provided the necessary research governance approval. The Pharmacy 
Academic Practice Unit at the Birmingham Children’s Hospital oversaw the study. 
Consultation centres in Saudi Arabia and Jordan received a copy of the approved letter 
for the study. 
2.2.2.6. Exclusion criteria and some challenges 
Exclusion criteria included: 
 Under 6 years of age
 Over 18 years of age
 Perceived difficulty in age appropriate communication (e.g. the capacity to
understand and responding to the questionnaire questions)
 No history of taking any medication ( i.e. not for a chronic disease )
2.2.2.7. Statistical analysis 
Participant responses were entered into MS Excel 2007 for analysis. The chi - square 
test was used to examine the independence in the data that was collected. The level 
of significance was chosen to be 0.05. Two-way analysis of variance (ANOVA) was 
used to compare data per age groups and per gender. Statistical analysis was 
performed using Graph Pad Prism software. 
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2.3. Results and discussion 
2.3.1. Results obtained from agenda design 
A total of 104 questionnaires (study cohort n=120, response rate 87%) were completed 
to determine the preference for pharmaceutical dosage forms in the study population. 
A presentation concerning the different dosage forms was delivered to the participants 
in an open-forum style, prior to completion of the questionnaire. This allowed for both 
proactive and interactive contribution from the participants. The participants were 
allowed to ask questions concerning dosage formulations. The questionnaire was 
shown in (appendix 1). The agenda of the study was to determine the opinion of 
children on different aspects of paediatric medication. Seven different events were 
allocated for the time stipulated with each event accorded time, according to its 
relevance and importance. After obtaining the feedback, the participants were engaged 
in an interactive platform in which they were given the chance to voice their opinion on 
areas that could be improved with regard to orally disintegrating tablets and the study 
itself. This session lasted for ten minutes. The last event of the day was to thank the 
participants and to appreciate their input (Appendix 2). 
The slide presentation for orally disintegrating tablets was presented to the participants 
to describe what ODTs are and their use. It was meant to bring out clearly the topic of 
study so that participants do not confuse or mix up the topic of study and other dosage 
formulations. The presentation was prepared prior to the event. This allowed for both 
proactive and interactive contribution by the participants. Every so often, the slides 
were paused and questions posed to find out if the participants were following the 
proceedings. In addition, the participants were allowed to ask questions and for 
clarifications in areas that they felt were vague or simply needed more information. 
They were also allowed to give their opinion about each slide and to contribute by 
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giving any additional information that they thought was not relevant to the presentation 
but was included. Generally, the event was made more of an open forum than an 
interview process. The opportunity presented to the participants to ask questions was 
a commendable idea. Most of the participants had little information on the details of 
composition of drugs and disintegration time. Therefore, the chance to ask questions 
came with numerous benefits with regard to the study. Questions regarding the 
composition of medicines were the most common. With every answer provided, it 
appeared as if a new question would pop up from the answer. For example, when 
explaining that orally disintegrating tablets are made of a combination of excipients 
and active pharmaceutical ingredients, a new question arose on taste. For instance, 
why some drugs tasted sweet, whereas others were bitter. The question of 
disintegration time of orally disintegrating tablets also arose. The difference in flavour 
and taste of tablets was also questioned. To improve their understanding of how drugs 
are produced and how their effects on the target population are measured, the 
participants were given a practical demonstration of the difference between immediate 
release tablets and ODT placebo. They were made to understand that placebos 
provided the basis of understanding the medication needs of the target population and 
that they were important as control measures in drug design and manufacture. They 
were also informed of the importance of placebo in the research for new drugs and 
better treatment methods. The interactive and proactive forum led to the desire of the 
participants to want to witness the actual processes involved in drug making and drug 
testing. The UK participants requested to be permitted to visit the laboratories to get a 
first person account of what drug manufacture involved. Drug design and manufacture 
goes beyond the basic principles of producing drugs with the best therapeutic profile. 
It also involves the manufacture of drugs whose taste is acceptable to the target age 
group, in this case the paediatric population. Drugs, which are not palatable, have 
lower acceptability. For this reason, the taste may be masked or the drug flavoured to 
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‘conceal’ the bad taste. Flavouring involves adding substances that give the drug a 
characteristic taste and smell, different from that of the actual drug (EMA, 2006). Taste 
addiction is a situation in which the patient develops a liking for the taste of the drug 
and feels an urge to take the drug often. Whereas this is beneficial because it gives a 
solution to the question of acceptability, it may result in grave consequences such as 
abuse of the drug. Care should be taken to avert this. The flavouring is important 
because it tailors the taste and smell of the drug to the convenience of the target age 
group. Previous results obtained from research studies on the popular flavours aid in 
developing drugs with specific flavours and which suit the needs of the target age group 
(Noble, 1996, Levitan et al., 2008) 
2.3.2. Questionnaire results 
2.3.2.1. Demographic and educational background of participants 
The current study explores the preference of children not only for the route of 
administration of medicines but also investigates the preferred oral dosage form. This 
study for the first time also incorporates elements of pharmaceutical development 
attributes that should be taken on board when developing medicines for children. Table 
2.2 summarises the demographic characteristics of participants. It gives the 
breakdown of their gender, age and educational level.  
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Table 2.2: Demographic characteristics of participants. 
Characteristics UK 
N=29 
(%) 
Saudi 
Arabia 
N=41 
(%) 
Jordan 
N=34 
(%) 
Total 
N=104 
(%) 
P value 
Gender 
Male 8 (27.6%) 26(63.4%) 18(52.9%) 52(50%) >0.05**
Female 21(72.4%) 15(36.6%) 16(47.0%) 52(50%) 
Age 
in years 
6-8 0 (0%) 7(17.0%) 10(29.4%) 17(16.3%) p>0.05 for 
age group 
p=0.001 for 
regions)* 
9-11 4 (13.8%) 14(34.2%) 14(41.2%) 32(30.8%) 
12-14 8 (27.6%) 12(29.3%) 10(29.4%) 30(28.8%) 
15-18 17(58.6%) 8(19.5%) 0 (0%) 25(24%) 
Educational 
level 
School 20(69%) 40(97.6%) 34(100%) 94(90.4%) 0.0001** 
Higher 
education 
9 (31%) 0 (0%) 0 (0%) 9 (8.7%) 
Working 0 (0%) 0 (0%) 0 (0%) 0 (0%) 
Other 0 (0%) 1(2.4%) 0 (0%) 1(0.9%) 
*Two way- ANOVA  **Chi-Square
Figure 2.1 shows the gender distribution according to age group. Data analysis showed 
that there was no significant difference between the number of male and female 
participants (P> 0.05). 
Figure 2.1: Gender distribution according to age groups for all regions. 
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In Figure 2.2 the educational level of the participants across the three regions is shown. 
Jordan had the highest percentage of participants who had basic education (100%). 
This was followed by Saudi Arabia and the United Kingdom which had 97 percent and 
68 % respectively. Data analysis shows that the difference is significant as the p-value 
is <0.05. 
Figure 2.2: Distribution of participants according to their educational level per region. 
2.3.2.2. Experience of taking medicines and preferred dosage forms 
This section involves the analysis of the responses of the participants on their 
frequency of taking medicines. Females had the highest frequency of taking daily 
medicines (28.6%). On a weekly and monthly basis, the male participants recorded a 
higher frequency of taking medicine than females (27% and 31% respectively) (Figure 
2.3). 
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Figure 2.3: Distribution of the frequency in taking medicines for all regions according to gender. 
Figure 2.4 demonstrates that oral route and in particular tablets were more popular 
across both genders compared to liquids, capsules, powders and other dosage forms. 
Furthermore, male participants (54%) registered their preference for tablets as 
compared to the female participants. In order to explore further their preference for oral 
route, the participants were asked for their preferred oral dosage forms. Alhaddad et 
al (2014) used a cross- sectional study design and validated questionnaires were 
distributed to the people who were above the age of 18 years through face to face 
interviews. They found tablets (69.6%) and capsules (37.6%) represented the highest 
preferred dosage forms. Therefore, it was concluded that prescribers should prescribe 
to patients their preferred dosage forms to improve medication adherence, and hence 
improve outcomes (Alhaddad,et al.,2014). Interestingly, in our study there was no 
significant difference among gender p>0.05(Chi square test) in their preferences. 
However, using two way ANOVA there was a significant difference for  dosage forms 
where suppositories and injections were the least preferred dosage forms (p<0.05). 
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Figure 2.4: Distribution of the patients’ preferences of dosage forms according to gender for all 
regions. 
In our study, results show that ODTs were the most popular oral dosage forms (58%) 
followed by liquids (20%), tablets (12%) and capsules (11%) (Figure 2.5). Regional 
analysis of the data for preferred oral dosage forms indicated that ODTs was the most 
preferred by the majority of respondents (66%, 65%, and 38%) for Saudi Arabia, 
Jordan and UK respectively (Figure 2.6).  
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Figure 2.5: Distribution of the preferred oral dosage forms among paediatrics in all regions. 
The popularity of ODTs in the pediatric population is possibly due to a number of 
factors including ease of administration, stability and convenience of storage (as 
opposed to liquids). However, a study by Ibrahim (2010) showed that the capsules 
were the most prefered oral solid dosage forms when compared to tablets, caplets and 
soft gel. Their  results also showed that ethinicity and age group directly influenced the 
participant preferences for oral dosage forms. For example, capsules were prefered 
by both Malays and Chinese (Ibrahim et al., 2010). 
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Figure 2.6: Distribution of paediatrics who preferred oral dosage form according to regions. 
Analysis of distribution of responses for ODTs as preferred oral dosage form according 
to age group and gender in all regions showed a highest percentage of the children 
were male between 12-14 years of age who preferred ODTs (44.83%) followed by 
females between age group of 11-13 years (38.7%). However, there was no significant 
difference according to age group and gender (p>0.05) (Figure 2.7). The superiority of 
ODTs as a preferred alternative to capsules and conventional tablets is possibly due 
to better patient compliance as it does not require water for administration and the 
tablet disintegrates and dissolves in the oral cavity within seconds (Hirani et al., 2009). 
According to Virley and Yarwood (1990) ODTs may increase bioavailability and result 
in faster onset of action, therefore, dispersion in saliva in oral cavity causes pregastric 
absorption from some formulations. Buccal, pharyngeal and gastric regions are all 
areas of absorption for many drugs. Any pregastric absorption avoids first pass 
metabolism and can be a great advantage in drugs that undergo hepatic metabolism. 
Capsule was the second preferred form by the British respondents; possible 
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explanation for this capsule preference includes the effect of its design, which 
comprises of two different parts, making this dosage form easily distinguishable from 
the other formulations (Reisenwitz and Wimbish Jr, 1996). Another possible 
explanation for the preference of capsules could be attributed to the previous 
experience of the participants in taking capsules over liquid or tablet dosage forms. 
Figure 2.7: Distribution of paediatrics who preferred ODTs as oral dosage form according to 
age group and gender in all regions. 
2.3.2.3. Physical characteristics results for orally disintegrating tablets (ODTs) 
As the first part of the study concluded that the orally disintegrating tablets were the 
preferred dosage forms, the next set of investigations were centred around evaluating 
the preference of different attributes of ODT such as colour, taste, shape, flavour  and 
disintegration time. 
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2.3.2.3.1. Colour Preferences 
The colour of the medicine is of immense importance to most patients and is a great 
determinant of the popularity and acceptability of the medicine (EMA, 2006). Figure 
2.8 showed that pink was the preferred colour for ODTs by more than a quarter of the 
respondents (30.8%) followed by white (26.0%), blue (14.4%), yellow (11.5%), orange 
(7.7%) and finally purple (7.7%). Similarly, (Ibrahim et al., 2010) stated that orange and 
purple were the least preferred while white was the most preferred colour. 
Figure 2.8: Distribution of preferred ODTs colour for all regions. 
Our study exposed an interesting result in which genders and age group have their 
different colour preferences for ODTs.  For example, 27 out of 32 female participants 
preferred pink colour ODTs while male participants tend to prefer white. In European 
and Middle East cultures, white colour represents purity and virtue while pink shows 
femininity and girlishness (Ibrahim et al., 2010). Surprisingly, neither blue nor yellow 
coloured ODTs were preferred by female gender (Figure 2.9). An extremely significant 
difference was detected by Chi- square test in colour preferences (p<0.05). 
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Figure 2.9: Distribution of preferred colour according to gender in all regions. 
Similarly, Figure 2.10 showed that there was a significant level of distribution of the 
preferred colour by age group and gender (p<0.05). The majority of female (6-8 years) 
respondents (85.71 %) preferred pink colour of ODTs while the highest percentage 
(38.89 %) for white colour was recorded for male participants (12-14 years). 
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Figure 2.10: Distribution of the preferred colour by age group and gender. 
With respect to the preferences of colour regionally, although pink colour was the most 
preferred colour, Figure 2.11 shows that Saudi participants preferred white colour 
(32%) than pink (17%), as it was obvious that more than half of the participants were 
male (63%). Similarly, investigations by (Ibrahim et al., 2010) for the preferences of 
colour, shape and taste of oral solid dosage forms among 350 participants in Malaysia 
Chapter 2 
87 
found that white was the most preferred colour by more than half of the respondents 
(55%) followed by blue (20%). 
Figure 2.11: Distribution of paediatrics who preferred colour according to regions. 
2.3.2.3.2. Shape Preferences 
Figure 2.12 shows the user preferences based on the shape of the tablet. Majority of 
the participants preferred ODTs that are round in shape. This accounted for 35.6 % of 
the responses while the heart shape was second with a preference of 22.12%. Least 
preferred shapes were square (94.67 %) and diamond (1.92%). 
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Figure 2.12: Distribution of preference of ODTs shape for all regions. 
With respect to the regional distribution of participants, the results showed that British 
and Jordanian participants did not prefer square shaped tablets (Figure 2.13).
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Figure 2.13: Distribution of Paediatrics who preferred shape According to regions. 
Figure 2.14 showed that more female (36%) respondents preferred heart shape, 
whereas around 44 % of male preferred round shaped ODTs. Statistical analysis test 
displayed no significant difference (p>0.05) for distribution of participants according to 
their gender for shape preferences across all the regions. 
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Figure 2.14: Distribution of participants according to their gender preferred shape in all regions. 
2.3.2.3.3. Size and thickness Preferences 
The size and thickness of a dosage form is vital in its acceptability (Breitkreutz, 2008). 
Small sized (0.15 cm3 ±0.002) ODTs were most preferred (64.42%) compared to the 
medium 33.65% (0.27 cm3±0.006) or large 1.92% (0.33 cm3±0.006) ODTs (Figure 
2.15).In this study, participants felt that small ODTs are easier or comfortable to 
swallow than big ones. Similarly, Overgaard et al (2001) investigated 18 years old 
patient’s acceptance of tablets and capsules based on size, shape and colour. The 
results from the study showed that the difficulty in swallowing increased with the 
increase in tablet size. Correspondingly, size of dosage forms may affect the transit of 
the product through the pharynx and oesophagus and may directly affect a patient’s 
ability to swallow a particular drug product. Larger tablets and capsules have been 
reported to extend oesophageal transit time. This can give rise to disintegration of the 
product in the oesophagus, resulting in pain and localized esophagitis (Channer and 
Virjee, 1986). 
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Figure 2.15: Distribution of preferred ODTs size for all regions. 
Our results demonstrate that the preference for small sized ODTs cuts across all age 
groups (p>0.05) and gender for all study regions (Figure 2.16). 
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Figure 2.16: Distribution of preferred ODTs size according to age group and gender for all 
regions. 
Figure 2.17 showed that analysis of thickness of ODTs also, highlights the preference 
of the participants for thin formulations at the expense of thick ODTs. The majority of 
respondents (66.35%) preferred thinner ODTs (1.14mm ± 0.002); however, 33.65% of 
the participants preferred thicker ODTs (2.47mm ± 0.03). 
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Figure 2.17: Distribution of preferred ODTs thickness for all regions. 
2.3.2.3.4. Taste and flavour Preferences 
The taste of a drug is the result of a perception initiated by afferent sensors in the 
tongue; and may be sweet, neutral, bitter or salty. Flavour is usually a result of the 
addition of excipients. In this present study the majority of the participants (76.9%) 
preferred sweet taste (Figure 2.18).  
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Figure 2.18: Distribution of preferred ODTs taste for all regions. 
Sweet taste preference in our study for paediatric population is contrasted in another 
published study that evaluated the most preferred oral solid dosage forms (OSDF) in 
adult participants. More than half (55.0%) of participants preferred their OSDF to be 
without taste while 40.7% preferred sweet taste (Ibrahim et al., 2010). According to 
other studies, the preference for sweet taste remains high throughout childhood and 
then switches to neutral during late adolescence (Desor and Beauchamp, 1987, 
Mennella et al., 2005). Furthermore, Pepino et al. reported that not only do children 
prefer sweet taste, but sweet tasting solutions in the oral cavity supposedly decrease 
pain in both infants and children, probably via the involvement of the endogenous 
opioid system. Therefore, it is not surprising that many oral formulations for children 
are sweetened (Pepino and Mennella, 2005). 
With regard to flavour, strawberry was the most preferred (30.8%) while orange was 
the least preferred (5.8%) as shown below in (Figure 2.19).  
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Figure 2.19: Distribution of preferred ODTs flavours for all regions. 
Strawberry preference in our study group was confirmed by other studies. For 
example, a study was carried out in 48 healthy schoolchildren in Tanzania and results 
showed that cherry flavour appeared favourable to ensure a high acceptability of anti-
malarial dispersible tablets in small infants and children (Abdulla et al., 2010). A 
possible explanation could be that strawberry is found as a common flavouring in 
various food additives and is effective even at low concentration (Sharma and Lewis, 
2010). According to the EMA, (Committee for Medicinal Products for Human Use, 
2006) cherry and strawberry flavours were most preferred in medication for pain and 
infectious diseases within the European paediatric population; whereas lemon, 
peppermint and orange were recommended for indigestion remedies. 
When considering flavour preference by gender, it was found that strawberry was the 
most preferred flavour by female participants (47.1%). On the other hand, 22.6% of 
male participants preferred lemon followed by mint (17%), then chocolate and 
strawberry with 15.1% each (Figure 2.20). 
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Figure 2.20: Distribution of preferred ODTs flavours for all regions by gender. 
Although, overall strawberry was the most preferred flavour, significant differences 
were found among participant preferences according to the geographical regions. 
Lemon was the second most preferred flavour in Saudi children (24%) while it was the 
least with British (3%) participants (Figure 2.21). 
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Figure 2.21: Distribution of preferred ODTs flavours for all ages by region. 
2.3.2.3.5. Disintegration time preferences for ODTs 
In accordance with the official European Pharmacopoeia Monograph the maximum 
permissible disintegration time for orally disintegrating tablets is three minutes. The 
results showed (Figure 2.22) that that the majority of the participants (87.5%) preferred 
very rapidly (<30sec) disintegrating ODTs followed by rapidly (10.58%) and the least 
preference was for ODTs that would disintegrate between 1.5 and 3 minutes (1.92%) 
respectively. Most participants believed that some tablets have bad taste and that rapid 
disintegration would ensure unpleasant taste can be reduced by quickly swallowing 
the contents of the tablet. Also some participants stated that this is indicative of quick 
onset of action. 
0
5
10
15
20
25
30
35
40
Strawberry Orange Cherry Vanilla Mint Lemon Chocolate Other
(specify)
UK SA JOR
Flavours
P
e
rc
e
n
ta
ge
Chapter 2 
98 
Figure 2.22: Distribution of preferred disintegration time for all regions and all age group. 
2.3.2.3.6. Results obtained from the importance of physical characteristics for 
ODTs 
The results obtained for the analysis of the physical characteristics of ODTs showed 
that 25.0% rated the duration for tablet disintegration in the mouth as the most 
important characteristic, followed by the taste (24.1%), size (15.7%), and flavour 
(13.8%) respectively as shown in (Figure 2.23). Similarly, results were found by 
(Ibrahim et al., 2010) with respect to the importance of the physical characteristics of 
oral solid dosage forms, with slightly more than half (52%) of the respondents ranking 
the size as the most important followed by taste (40%), shape (13.6%), and colour 
(13.4%) respectively.  
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Figure 2.23: Distribution of the most important characters of ODTs for all regions. 
2.3.2.4. Participants’ feedback about the study 
Towards the end of the study, the participants were given the opportunity to give their 
opinions and feedback on how the study was conducted. The participants indicated 
that despite the fact that it was a good questionnaire, there were areas that could be 
improved on. They pointed out that most of them had difficulty making out the 
difference between taste and flavour. Therefore, they suggested that the difference 
between taste and flavour be written on the questionnaire so that the interviewees 
remain informed when making choices. With regard to drug manufacture and design, 
the participants pronounced that the manufacturers should ensure that the taste is not 
terrible. For question three in the questionnaire where the participants were asked to 
indicate their level of education, some of the participants had an issue with the choices. 
In particular, they pointed out that choice two was vague. Therefore, they suggested 
that the term higher education should be specified whether it meant high school, 
college or university level. In contrast, another significant segment of the participants 
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thought that it was a very good questionnaire. The participants also thought that the 
experiment was good and eye opening. The hands-on experience and the practicality 
also earned some credit.  
Overall, in all the regions the participants stated that ODTs are a good idea. Findings 
from this study propose that the formulation of ODTs and their physical characteristics 
are of high importance in encouraging paediatric patients to continue using a particular 
medicine. 
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 2.4. Conclusion 
The general outcome was that solid dosage forms are the preferred dosage forms and 
orally disintegrating tablets are a preferred dosage form for children and young adults. 
The benefits that accrue to ODTs include safety, higher compliance, dose accuracy, 
stability and ease of swallowing. Within the paediatric population, orally disintegrating 
tablets are more convenient because they combine the advantages of both solid and 
liquid dosage forms but without incorporating their disadvantages such as difficulty in 
swallowing and lack of stability. From the results in the current study, it can be 
concluded that the most preferred colours were pink and white, the most preferred size 
is the small sized tablets and the most preferred shape was round . Similarly, physical 
characteristics in order of priority with regard to the acceptability of ODTs included 
disintegration time, taste, size and flavour. This study has identified the favoured 
medication characteristics as expressed by the participants. However, it has not been 
tested whether these desirable characteristics are deliverable due to the physical 
properties of the active ingredients. Similarly the potential benefits in terms of patient 
adherence are implied only, and have not been tested in this present study.
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3.1. Introduction 
The European Medicines Agency (EMA) recognised that there have been limited data 
concerning paediatric population acceptance of oral dosage forms in relation to age 
and developmental status along with the inadequate availability of licensed medicines 
appropriate for administration to children (EMEA, 2006). In addition, there is anecdotal 
evidence that there are increasing concerns amongst healthcare professionals about 
paediatric patients failing to take their prescribed medication (Michaud et al., 2004). 
Many medicines are formulated to enable usage in adults, and these may not be 
suitable for use by children. There may be difficulties in swallowing solid dosage forms 
(e.g. tablets) and there may be issues concerning the availability of the dose strength 
based on current dosage forms available. Many children will require doses smaller 
than adults prompting use of liquids or splitting the dose of solid tablets by cutting them 
into halves and quarters. If suitable dosage forms are not available then patient 
compliance with prescribed medication may be reduced with potential adverse clinical 
consequences (Bauman and Drotar, 2000). 
Reasons that may affect a child’s success in swallowing solid dosage forms include 
developmental stage depending on their age (0 to 18 years), anxiety, fear, intolerance 
to unpleasant flavours and not being able to appreciate the risks associated with 
noncompliance (Patel et al., 2015). 
Treatment failure may result leading to poor clinical control and unnecessary expense 
as a result of unused medication waste. In primary care around £300 million worth of 
medicines are wasted every year of which £150 million is preventable (Barr, 2014). 
Formulation work so far has revealed that liquids seem to be more customary with the 
paediatric population (infant age between 1 month to 2 years and pre-school age 
between 2 to 5 years), whereas oral disintegrating tablets (ODT) may be preferred by 
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those who are older (5 to11 years), and in the adolescent age (12 to16/18 years), 
tablets and capsules may be more appropriate and convenient (Nunn and Williams, 
2005). An ODT is an easy to use dosage form which disintegrates in the mouth upon 
contact with saliva. ODTs can be taken without the need to swallow tablets whole and 
does not require water. 
There is evidence to suggest that ODTs are a potential ideal formulation for children 
since they avoid concerns children may have regarding swallowing tablets (Sumiya et 
al., 2000, Varia et al., 2006). 
Our previous study, which was conducted in three countries including the UK, found 
that approximately 58% of the participants (children age 6-18 years) preferred taking 
ODTs compared to conventional tablets, liquids and capsules (see chapter 2).  
Few studies have been carried out aimed at identifying healthcare professional 
perceptions or opinions regarding the use of different dosage forms for paediatric use. 
However, previous research conducted in similar fields has explored  healthcare 
professional’s perceptions on HIV treatment adherence in children with an 
investigation in to unlicensed/off label medicines use (Mukattash et al., 2011) and 
those exploring paediatric nurses knowledge and practice of mixing medicines with 
foodstuffs (Akram and Mullen, 2012). Most research in this field is targeted at reducing 
prescribing and dispensing errors for children. However, to ensure medication 
adherence in children is supported, when making a decision on medication formulation 
choice for a child, clinicians should take into consideration the acceptability of the item 
to paediatric patients. To the best of our knowledge there are no published studies 
regarding the opinions of healthcare providers concerning paediatric dosage regimens 
including ODTs. Furthermore, limited data is available concerning the effect of ODT 
properties (i.e. taste, texture, flavour, colour, shape, size and disintegration time) of 
individual medicines on child acceptance. It was therefore necessary to conduct a 
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study, exploring the opinions of healthcare professionals regarding paediatric dosage 
forms. 
The primary aim of the present work is to evaluate healthcare professional’s 
perceptions of the paediatric dosage forms to support patient choice and ultimately 
patient adherence to prescribed medication regimens. 
The main objective of the focus group and semi-structured interviews (phase 1 and 2 
respectively) was to design a validated online survey (phase 3) delivered to 
pharmacists, nurses and medical practitioners to evaluate their views and perceptions 
with regards to paediatric dosage forms. This study will provide the opinion of 
healthcare professionals in what dosage forms they believe are preferred by children 
and to also identify healthcare professional’s personal opinions concerning the safety 
and cost effectiveness of formulation types. The secondary aim of this study was to 
compare the findings of this present study concerning healthcare professionals with 
the findings from our previous study concerning children in respect to dosage forms 
(Alyami et al., 2016). 
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3.2. Methodology and Ethical considerations 
Healthcare professionals at BCH were invited via email to participate in the study and 
provided with an information sheet explaining the purpose of the study focus group 
followed by semi-structured interviews. 
Prior to commencing the study, Hamad Alyami (HA) obtained an honorary contract at 
BCH (appendix 3), a variety of focus group and semi-structured interviews were 
performed between June and July 2016 by the researcher (HA). This preliminary 
scoping work was used to develop the experimental design (online survey).  
Focus groups gather a plethora of information in a short period of time and explore 
attitudes, perceptions and approaches. Once piloting a focus group between six and 
eight participants is optimal, the group should have enough participants to get a wide 
perspective without being too large, and thus disordered or disjointed (Eriksson and 
Kovalainen, 2015). 
3.2.1. Overall methodological design of the study 
The study consisted of dual site, cross-sectional, mixed methods study of hospital 
based paediatric doctors, pharmacists and nurses, using an anonymised electronic 
survey (Bristol Online Survey software – BOS); informed by a literature search, focus 
groups and semi-structured interviews.  
This study was carried out at two paediatric hospitals: 
 Birmingham Children’s Hospital BCH (Phases 1,2 and 3)
 Alder Hey Children’s Hospital, Liverpool (Phase 3 only)
Informed by a literature search, this study included a three-phase consensus-building 
process comprising of  
- Phase (1) focus groups with pharmacists and nurses (separately);
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- Phase (2) semi-structure face-to-face interviews with each of the three main
groups of professionals, consent forms were given to focus group phase (1)
and semi-structure interviews phase (2) and
- Phase (3) electronic survey of paediatric hospital healthcare professionals.
Qualitative verbatim transcripts from phases 1 and 2 were subjected to framework 
analysis (Gale et al., 2013). Themes from phase 1 underpinned the basis for phase 2 
interviewees. Themes from phases 1 and 2 generated issues for inclusion within phase 
3. 
The final electronic questionnaire (phase 3) was assembled and managed using 
bespoke software (Bristol Online Survey ™). Results were transferred to SPSS version 
22 and NVivo version 10 software for analysis to facilitate descriptive statistical 
analysis and framework analysis respectively. 
Figure 3.1 presents a flow diagram of the three phases that were carried out. The 
questionnaire was comprised of both closed and open questions to identify 
participants’ perceptions and opinions about dosage forms for children.  
 Focus groups 
Electronic survey 
Phase 1 
Phase 3 
Semi-structure interviews Phase 2 
         Figure 3. 1: Flow chart of research methodology 
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3.2.2. Recruitment and consent 
3.2.2.1. Phase 1 – Focus group 
Two focus groups were undertaken within this study. One focus group consisted of 4 
nurses and one of 7 pharmacists. These focus groups were designed to support the 
development of the healthcare professionals’ questionnaire. All focus groups were 
conducted at the primary study site (BCH). Email invitations to attend the focus groups 
were arranged via the research leads of the two professions at BCH. All potential 
participants received a Participant Information Sheet (appendix 4) and those recruited 
to the study completed and signed the relevant consent form (appendix 5). Private 
rooms were pre-booked within BCH in locations accessible for staff, to create a suitable 
and convenient environment for discussion. The focus groups were facilitated by HA 
(Hamad Alyami) and assisted by CH (Chi Huynh) (research pharmacist/lecturer in 
clinical pharmacy). The groups were digitally audio-recorded using an Olympus digital 
audio-recording device. A question guide (appendix 6) was developed including 
questions to be discussed by the facilitator to ensure coverage of pre-determined 
themes identified by the project support team. 
3.2.2.2. Phase 2 – Semi-Structured Interviews 
Participants from the three professional groups were recruited to undertake semi-
structured interviews. They were recruited by recommendation from the professional 
research leads or via their involvement in the Academic Practice Unit at BCH. A 
minimum of three participants from each of the three professional groups were 
recruited to the study. All potential participants received a Participant Information Sheet 
and those recruited to the study completed and signed the relevant consent form. 
3.2.2.3. Analysis of the focus groups and semi-structured interviews data 
The data collected from Phase 1 and Phase 2 were analysed using framework analysis 
by (Ritchie and Spencer, 2002, Smith, 2015) with the following stages, 1) Data entry 
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and processing; 2) Familiarisation of the focus group and interview data collection and 
identifying an initial framework based on the question guide (for initial framework see 
appendix 6); 3) Coding – all focus groups and interviews were coded and indexed 
using NVIVO 10; 4) Generation of themes (charting) results were charted according to 
the themes; 5) Finalised framework (mapping and interpretation). 
HA transcribed each focus group and semi-structured interview as soon as was 
possible after facilitating the group and interview. Verbatim transcripts were produced 
in Microsoft Office Word 2013 from the digital audio-recordings, hence, the focus 
groups and semi-structured interviews provided 31,895 words of text. Participants 
were anonymously assigned a coded identifier within the text (e.g. speaker 1, speaker 
2 etc.) to ensure the extent to which views were shared could not be identified. The 
verbatim text was copied in to a qualitative data analysis and coding software (QSR 
NVivo 10) and framework content analysis was developed to analyse the verbatim 
files. Qualitative research software (NVivo 10) was used to arrange information and 
combine analysis with linking (Gibbs, 2002). A framework analysis approach was used 
to qualitatively analyse the data (Brooks et al., 2015). The data was coded using coding 
framework based on the question guide for the focus group, interviews and objectives 
of this study (see Table 3.1) .The initial 10 minutes (20%) of the transcript recording, 
was coded independently by two investigators, HA and CH, using the initial framework 
with NVivo Version 10 to assist with indexing the codes. The similarity and differences 
between the two coders was discussed and a final framework developed. The coding 
framework was used to code the rest of the transcript. The interpretation of the results 
from the coding of the focus group and semi-structured interviews were conducted by 
HA and was based on the objectives of the focus group and interviews.  
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Table 3.1: Compiled sample of framework coding for focus groups and semi-structured 
interviews. 
Main code Sub codes ( Nvivo nodes ) 
1. Most common paediatric dosage
forms
1.1 Liquids 
1.2 Tablets 
1.3 Suspensions 
1.4 ODTs 
2. Your preferences for paediatric
oral dosage forms
2.1 Tablets 
2.2 Solutions 
2.3 Capsules 
2.4 ODTs 
2.5 Mini- tablets  
2.6 Depends on age, patient 
3. ODTs as an alternative dosage
forms
3.1 Yes, for young children 
3.2 Yes, it is good alternative 
3.3 Children and parents need 
education regarding ODTs 
3.4 Sometimes not always 
3.5 Should taste good ( sweet ) 
3.6 Not suitable for less than 6 yrs 
4. Enhancement of compliance and
adherence regarding taking
ODTs
4.1 Absolutely, if it  tastes good 
4.2 I think so  
4.3 Taste is going to be important 
4.4 Depends on age/ patient  
4.5 lot of lansoprazole ODTs, it 
helps 
5. ODTs cost effectiveness 5.1 Definitely much cheaper than 
liquids 
5.2 Much more expensive 
5.3 No idea 
6. Any feedback from the patients
or their parents regarding any
issues of ODTs
6.1 Taste not good, talk about taste 
6.2 Too big in size 
6.3 Ease of being able to swallow 
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6.4  Not really 
7. Physical characteristics of ODTs 7.1 Taste 
7.2 Flavour 
7.3 Size 
7.4 Colour 
7.5 Shape 
7.6 Disintegration time 
8. Taste 8.1 Sweet 
8.2 Neutral 
8.3 Not bitter taste 
8.4 Very important 
9. Flavour 9.1 Strawberry most preferred 
9.2 Lemon 
9.3 Orange 
9.4 Fruity 
9.5 Banana 
10. Size 10.1 Small 
10.2 Not big size 
10.3 Size isn’t that important, if it 
disperses in mouth 
11. Colour 11.1 Not important as taste 
11.2 Keep it white 
11.3 May be pink 
12. Shape 12.1 Round 
12.2 Not square  
12.3 Not that important 
13. Disintegration time 13.1 Very fast 
13.2 Not too long 
14. Any comments or any
recommendations
14.1 No, thanks  
14.2 I like the idea 
 14.3 I think it’s a novel idea for 
children 
14.4 The most important things will 
be flavour and the length of time 
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14.5 Talk to the nursing staff as well 
14.6 Taste is the important thing 
14.7 I think it will help a lot of kids 
get away from the liquids 
14.8 More education regarding 
ODTs for patient and their parents 
will be useful  
3.2.2.4. Phase 3 – Electronic survey 
An electronic survey tool was chosen as the instrument for this study. Healthcare 
professionals working at the time of the study for BCH and Alder Hey Children’s 
Hospitals were invited to complete an online survey. Managing of this survey by the 
use of purpose designed electronic survey software was therefore considered to be 
both deliverable and efficient due to suitability of having automated data collection, 
which saves researcher time, effort and offers cost savings advantages (Wright, 2005). 
The questionnaire development was supported by the HCPs focus groups and the 
semi-structured interviews.  
The themes and concerns identified in the phase 1 and 2 were considered for inclusion 
in the survey, including for example factors influencing choice of formulations for 
paediatric patients. A draft survey was created on 11th August 2016 using Bristol 
Online Survey software (BOS).  
The draft questionnaire was piloted with academic supervisors AM and DT (Afzal 
Mohammed and David Terry) and research pharmacist (CH) at BCH. A number of 
comments were received leading to changes in the survey instrument. For example,  
 ‘Why is gender relevant? You need to justify it or remove it’
 Question 2- change word physician to ‘junior medical staff’ and add ‘medical
staff to consultant’
 Question 4- add ‘part years’
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 Question 7,15 and 16- add ‘other’ option and please specify
 Question 8 to 10 add ‘don’t know’ options
The resulting second draft was sent to a small number of HCPs for comments ED 
and JK (Eman Dahmash and Jasdip Koner). Further changes included:  
 Questions 13 - just put ‘which flavour of ODT’
 Questions 19 – comma after paediatric patients
 Question 21 - question re-worded
Email addresses of HCPs were obtained from the site leads at BCH and Alder Hey 
Children’s Hospital (CH and chief pharmacist) respectively and they managed this 
process by reference to staffing lists and responses. The invitation to participate was 
sent from Bristol online survey to the NHS Trust email addresses of the study cohort 
with a link to the survey. First emails were sent out on 1st September 2016, reminder 
emails sent to all respondents 3 and 6 weeks after the initial email was sent. Each site 
was required to return completed surveys from a minimum of five professionals in each 
group.  
Participants were advised that all data were held confidentiality and anonymity was 
assured. 
Responses were exported from Bristol survey into MS Excel 2013 and IBM SPSS 
version 22 for analysis and production of descriptive statistics. 
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3.2.3. Inclusion and exclusion criteria 
Inclusion criteria: 
 Healthcare professionals (HCPs) (doctor, nurse, and pharmacist) at
Birmingham Children’s Hospital (BCH).
 Healthcare professionals (doctor, nurse, and pharmacist) at Alder Hey
Children’s Hospital, Liverpool.
Exclusion criteria: 
 General public.
 Refusal of consent; Unable to give consent; Withdrawal of consent.
3.2.4. Ethical considerations 
An application was submitted online to School of Life & Health Sciences Ethics 
Committee at Aston University and to the Research & Development Departments of 
Birmingham Children’s Hospital (BCH) and Alder Hey Children’s Hospital. No study 
activity commenced until all approvals were granted. Participants were recruited 
following informed consent. The process for obtaining applicant informed consent was 
in accordance with the Research Ethics Committee (REC) guidance and Good Clinical 
Practice (GCP). Participant information sheets and information governance certificate 
were provided. Ethical approval was obtained from School of Life & Health Sciences 
Ethics Committee at Aston University (see appendix 7). Although, Research and 
Development approvals were obtained from BCH and Alder Hey Children’s Hospital, 
the study was confirmed as service evaluation by the head of Research and 
Development of Birmingham Children‘s Hospital (BCH) and Alder Hey Children’s 
Hospital (see appendix 8). 
Responses to the invitation to complete the survey was managed within NHS secure 
systems (including NHS protected servers and NHS email systems). Data was 
accessed by the study team only who all hold contracts with the study sites and 
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possess up to date NHS Information Governance certificates. All responses were fully 
anonymised prior to analysis and all reports accommodated confidentiality 
requirements. Audio files from the focus groups/semi-structured interviews were held 
on-site at BCH, within the secure area of the Academic Practice Unit. Once transcripts 
were approved, original recordings were destroyed. Additionally, paper records (from 
the semi-structured interviews) were also kept within the secure area of the Academic 
Practice Unit at BCH, and were destroyed upon transcription of the interviews. 
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3.3. Results and discussion 
The presentation of the findings is divided into three phases. The first phase reports 
the focus groups of healthcare professionals. The second phase addresses the semi-
structured interviews and the third phase (main phase) presents the online survey for 
healthcare professionals concerning paediatric dosage forms. The healthcare 
professionals that were selected to participate in this study were medical practitioners, 
pharmacists and nurses. The rational for selection of HCPs was to show the 
relationship leading from the prescribing (doctor) through to dispensing medicine 
(pharmacist) and lastly administration by a nurse. 
3.3.1. Phase 1- Focus group 
The focus groups were used to scope the research and inform design of the online 
survey with healthcare professionals (phase 3) and aimed at seeking opinions of 
participants with a different range of backgrounds. One limitation of this method was 
that participants had to obligate their time to take part. Although, it was planned to 
conduct a focus group for doctors, it was not feasible due to the clinical demands of 
the service. However, the information gathered from the BCH focus groups provided 
an understanding in to the opinions of pharmacists and nurses concerning paediatric 
dosage forms, whilst the sample size for doctors was proposed to be increased within 
the semi-structured interviews (phase 2). Table 3.2 shows the number of participants, 
dates conducted and location of the focus groups .The pharmacist and nurse groups 
were conducted at lunchtime, it was intended that each session would last between 30 
and 50 minutes. The exact timings of digital audio-recordings are shown in (Table 3.2) 
below and discussion flowed well between the group members. 
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Table 3.2: Details of the two focus groups for healthcare professionals. 
Focus group Date 
conducted 
Number of 
participants 
Location Time duration 
of group 
(minutes) 
Pharmacists 7th July 2016 7 BCH 43 
Nurses 14th July 2016 4 BCH 32 
Pharmacist 5 mentioned that the most preferred dosage forms for paediatric population 
age (6-18 years) depends upon the patients and what they would prefer so “if they 
were unable to swallow tablets, liquid is obvious default, but if we can't get a liquid then 
we look for alternatives, so do we have to crush a tablet or any ODTs available “ 
In addition, pharmacist 2 reported that texture and taste of ODTs was important for 
children so the ideal taste would be sweet with either citrus or strawberry flavours. 
Across the focus groups, the large sizes of tablets were related to swallowing 
difficulties in paediatric patients especially those less than 6 years of age. 
Several studies exploring children suffering from HIV support these findings and stated 
the negative attitudes of children regarding the size of antiretroviral tablets (Roberts, 
2005, Patel et al., 2015, Ricci et al., 2016).  
3.3.2. Phase 2- Semi-structured Interviews 
A total of 12 healthcare professionals were interviewed at BCH during the study period, 
the HCPs recruited for this phase of the study were predominantly medical staff (2 
consultants and 4 junior doctors) (Table 3.3). All participants answered the questions 
regarding the paediatric dosage forms followed by physical properties of ODTs. Phase 
2 findings suggested that the main issues with the properties of ODT formulations are 
those associated with taste, size and disintegration time. However, colour and shape 
of ODTs were highlighted the least important by 85% of respondents.  
“I think bitter taste they will spill it out, so I think sweet or neutral would be better from 
taste point of view.” (Pharmacist 1) 
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“Size, yes, it should be as small as possible really, just so that they can actually get it 
into their mouths and so they don’t feel uncomfortable with it in their mouth, so they’re 
not going to choke or anything. So if it’s a small tablet and it dissolves that would be 
great.” (Doctor 4) 
“Shape probably not that important.” (Doctor 1)   
“I don’t think colour really matters. I suppose white is a kind of neutral but I don’t think 
it’s really an issue.” (Pharmacist 3) 
“Shape and colour, I don’t think it doesn’t really matter” (Nurse 2) 
Table 3.3: Details of the semi- structured interviews for healthcare professionals. 
Semi-structured 
interviews 
Date conducted Number of participants Location 
Pharmacists 18th -25th July 2016      3 BCH 
Nurses 18th -25th July 2016       3 BCH 
Doctors 18th -25th July 2016  6 BCH 
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Additional informal recommendations from healthcare professionals within phase 2 on 
how to improve ODTs formulations were reported in (Table 3.4) 
Overall, in phase 1 and 2, the majority of respondents (90%) recommended that taste 
and disintegration time were the most important physical properties respectively in 
order to develop and design ODTs formulations. Similarly, various studies stated that 
taste was an important factor in influencing medication adherence and acceptability in 
paediatric population (Matsui, 2007, Squires et al., 2013).  
Table 3.4: Recommendations and improvements to ODTs formulations as reported by focus 
groups and semi-structured interviews healthcare professionals. 
HCPs recommendations to ODTs 
formulations 
Reports of healthcare professionals 
Enhancing the taste of ODT 
formulations using sweet to neutral 
sweeteners 
Pharmacist FG 
Doctor 1, 3, 4 and 5 SI 
Pharmacists SI 
Nurse 1 and 3 SI 
Using strawberry (most preferred), 
orange or banana flavours.  
Nurse FG 
Pharmacist 1,2 and 3 SI 
Using small size of ODTs All participants for FG and SI 
Improving disintegration time ( 
Dissolving very quickly) 
All participants for FG and SI 
Designing shape to be round with 
white colour 
Pharmacist FG 
Doctor 2 SI 
Educating children and may be their 
parents concerning ODTs 
formulations  
Doctor 4 and 5 SI 
Nurse 3 SI  
FG: Focus group; SI: Semi-structured interview 
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3.3.3. Phase 3- Online survey 
A total of 41 online surveys (study cohort n=110, response rate 37.3%) were 
completed. The final online survey consisted of four sections. These were: 
demographic data including details of different healthcare professionals and participant 
years’ experience of working with paediatric patient; healthcare professionals views 
and their preferences for various oral dosage forms (liquids, tablets, capsules and 
ODTs); HCPs recommendations concerning colour, shape, size, thickness, taste, 
flavour and disintegration time of tablets; participant feedback about the survey and 
further recommendations.  
3.3.3.1. Demographic results of 41 healthcare professionals 
The first section of results displayed the names of the Children Hospitals that took part 
and the number of respondents from each Hospital. Participants were from 
multidisciplinary professions. It gives the breakdown of their professions and years’ 
experience working in paediatrics. Pharmacist were the highest percentage of 
participants in this phase (46%) followed by nurse (29%) and medical practitioners 
(24%) respectively. Approximately more than half (54%) of the respondents reported 
their experience ranged from 1 to 5 years. The results showed a significant difference 
among the different healthcare professionals years of experience (p<0.05) (Table 3.5). 
The survey instrument is shown in (appendix 9).  
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Table 3.5: Details of healthcare professional’s respondents at ACH and BCH, including number 
and percentage of each profession and years of experience. 
ACH: Alder Hey Children’s Hospital, Liverpool and BCH: Birmingham Children’s Hospital 
3.3.3.2. Healthcare professionals views regrading paediatric dosage forms 
This section involves the analysis of the responses of the participants according to 
types of dosage forms that have been prescribed, supplied or given to paediatric 
patients. Figure 3.2 illustrated that liquids dosage forms were more popular (58%) 
compared to tablets (33%), ODTs (8%), capsules (1%) and other dosage forms. There 
was a significant difference among distribution of different dosage forms to children 
(p<0.05). In this study liquids were the most prescribed dosage forms among dual 
sites, possibly due to availability as well as shortages for other dosage forms. This was 
supported by evidence from (Adams et al., 2013) who indicated that when healthcare 
professionals were asked to rank the factors that impact their selection of paediatric 
medicines, availability was the most important factor when prescribing oral medications 
to children. 
Characteristics ACH 
N=21 
(%) 
BCH 
N=20 
(%) 
Total 
N=41 
(%) 
P value 
Professions 
Consultant 
(Medical 
staff) 
0 (0%) 0(0%) 0(0%) 
<0.05 
Junior 
medical 
staff 
7(33.3%) 3(15%) 10(24.4%) 
Nurse 3 (14.3%) 9(45%) 12(29.3%) 
Pharmacist 11 (52.4%) 8(40%) 19(46.3%) 
Years of 
experience 
1-5 10 (47.6%) 12(60%) 22(53.7%) <0.05 
6-10 7 (33.33%) 4(20%) 11(26.8%) 
11-15 2 (9.5%) 0(0%) 2(4.9%) 
16-20 0(0%) 3(15%) 3(7.3%) 
>20 2(9.5%) 1(5%) 3(7.3%) 
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Figure 3. 2: Distribution of the types of dosage forms which are prescribed, supplied or given 
by healthcare professionals to paediatric patients indicating a massive preference for liquid oral 
dosage forms, then followed by tablets. 
In our study, when respondents were asked to rank the most preferred oral dosage 
forms, results showed that liquids were the most popular oral dosage form (52%) 
followed by ODTs (30%), tablets (18%) with no preference for capsules (0%) (Figure 
3.3). The rational for healthcare professionals on preference of liquids in the pediatric 
population was possibly due to a number of factors (Figure 3.4), including child age 
weight, parents, cost effectivness and  medicine manipulation. Furthermore, there is a 
regularly thought bias amongst healthcare professionals that liquids are preferred by 
younger children (Bryson, 2014). 
33%
1%
58%
0%
0% 8% 0%
Tablets Capsules Liquids Suppositories Powders ODTs Injections
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Figure 3.3: Distribution of the preferred oral dosage forms among healthcare professionals, 
indicating a preference for liquid dosage forms, which is then followed by ODTs and traditional 
tablets. 
Tablets
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Capsules
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Liquids 
52%
ODTs
30%
Chapter 3 
124 
Figure 3.4: Distribution of factors which influence choice of formulations for paediatric patients 
indicating that patient age is the most influential factor that dictates the preference of dosage 
form. 
3.3.3.3. ODTs formulations 
3.3.3.3.1. Healthcare experience regarding ODTs 
It is essential to mention that ODT have become a popular area of research for 
scientists in the last decade as a new ‘drug delivery system’, with benefits including 
ODTs being a more acceptable dosage form specifically for paediatric patients due to 
ease of use and administration (Parkash et al., 2011). Orally disintegrating dosage 
forms have great promise for paediatric patients as they are easy to administer and 
don’t require water, with a reduction in choking risk due to the rapid disintegration 
(EMEA, 2006). Furthermore, previous studies and surveys stated that ODTs are well 
received by paediatric patients and healthcare professionals (MacGregor et al., 2003, 
Carnaby-Mann and Crary, 2005). The results in this study (Table 3.6) showed that a 
total of 32 (78%) healthcare professionals prescribed/dispensed or administered ODT 
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formulations to children whereas 22% of participants did not prescribe ODTs. 
Additionally, respondents were asked regarding the number of ODT dosage forms that 
had been given to patients; approximately half of the respondents (53.7%) followed by 
only (2.44%) indicated that between 1 to 5 and more than 10 formulations were given 
over the last 12 months respectively. 
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Table 3.6: Details of respondents regarding ODTs prescribing/ dispensing or administering and 
total number of prescribed ODTs over last 12 months. 
Have you ever 
prescribed 
(doctor)/dispensed 
and supplied 
(Pharmacist)/ given or 
administered (nurse) 
ODTs to paediatric 
patients? 
In the last 12 months, do you know how many ODTs 
formulations have you prescribed, dispensed or 
administered? 
Totals 
None 1-5
Formulatio
ns
6-10
Formula
tions
More 
than 10 
Formula
tions 
I don't 
know 
Yes 0.00% 22(53.66%) 5(12.20%) 1(2.44%) 4(9.76%) 32(78.05%) 
No 8(19.51%) 0(0.00%) 0(0.00%) 0(0.00%) 1(2.44%) 9(21.95%) 
Not applicable 0(0.00%) 0(0.00%) 0(0.00%) 0(0.00%) 0(0.00%) 0(0.00%) 
I don't know 0(0.00%) 0(0.00%) 0(0.00%) 0(0.00%) 0(0.00%) 0(0.00%) 
Totals 8(19.51%) 22(53.66%) 5(12.20%) 1(2.44%) 5(12.20%) 41(100.00%) 
Interestingly, when healthcare professionals were asked concerning what extent they 
agree or disagree that liquid formulations could be substituted with ODTs in paediatric 
patients, approximately (63%) of respondents agreed that a suitable alternative to 
liquids was the ODT dosage form as shown in (Figure 3.5). Similarly, Lajoinie et 
al.(2014) identified that approximately 80% of prescribed liquid formulations could be 
substituted with a solid dosage forms in children. 
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Figure 3.5: Distribution of total respondents’ opinions regarding liquid formulations substitution 
with ODTs in paediatric patients, indicating that the participants would strongly agree that liquid 
dosage forms could potentially be replaced with ODTs.  
Considering ODTs could be an alterative to liquid formulations, healthcare 
professionals were asked to give their opinions regarding multiple factors such as 
safety,efficacy, cost effictviness and compliance. Pharmacists indicated more benefits 
regarding safety and suggested that “liquid medications may be more likely to have 
unsuitable excipients for children particularly if they have been formulated for the adult 
population”. Furthermore, regarding dosing error, liquid formulations require 
calculation and measurement of the dose volume, whereas ODT’s are used because 
they are available in the appropriate dose and don't need further manipulation. They 
also mentioned that possible risk of accidental overdose for the patient was higher with 
liquids, for instance, if a young sibling accessed a liquid medicine they may be more 
likely to consume more than if they accessed ODTs. On the contrary, one pharmacist 
stated that “a lot of solid forms come in very poor dosing variances so the tendency is 
to dissolve in liquid and give a proportion, but an accurate dose cannot be guaranteed. 
5%
63%
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7%
0%
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Strongly agree Agree Neither agree nor disagree
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Lastly, there was a number of issues with children who have feeding tubes and the 
tablets blocking them (EMA, 2006). When asked regarding efficacy, the majority of 
participants indicated that they had no idea as there were too few ODT formulations 
available compared to liquids, however, medical staff hypothesised that as ODTs melt 
or dissolve in the mouth then it would go to the blood system quicker than a liquid and 
therefore potentially was more efficacious and faster acting. The vast majority of 
respondents mentioned that, in general, oral solid forms are much less costly than 
liquid formulations, since they are easier to develop, manufacture, transport, store and 
distribute. These findings were in line with previous results by Lajoinie et al.(2014) who 
stated that solid dosage forms were more convenient and less costly compared with 
liquid medications for paediatric patients. With regard to compliance and adherence, 
respondents recommended that ODT formulations may increase compliance but it 
depended on the taste “if it tastes nice, sweet taste, my concern about taste, mostly 
sweet if you compare it with something that children know, like Calpol”.  Similarly, a 
study concluded that tablets for children may be considered as a viable alternative to 
improve adherence and therefore overall acceptability (Ansah et al., 2001). 
Furthermore, research by (Bagenda et al., 2011) confirmed that adherence to tablet 
formulations was significantly superior to liquid formulations. 
3.3.3.3.2. Physical characteristics of ODTs 
Acceptability and adherence of medication in paediatric patients is potentially affected 
by physical characteristics (i.e. taste, flavour, size, shape and colour) of dosage forms 
(Cheng and Ratnapalan, 2007, Squires et al., 2013). Consequently, the next set of 
investigations were focused on assessing the healthcare professionals views and their 
preferences on different attributes of ODTs such as colour, taste, shape, flavour and 
disintegration time. We asked healthcare professionals how medicines for children 
should taste. Their responses–overall and stratified by healthcare profession types are 
shown in (Figure 3.6). The majority of participants (65%) preferred sweet tasting 
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medicines for children followed by neutral/no taste and bitter taste (33% and 2% 
respectively). There was a statistically significant difference (p<0.05) between 
acceptable taste by healthcare care professionals. This is in line with findings from 
Adams et al. (2013) who stated that the majority of participants preferred sweet tasting 
medicines for paediatric populations.  
Figure 3. 6: Distribution of preferred ODTs tastes stratified by different professions indicating 
that sweet taste is preferred by all three sets of healthcare professionals, with neutral taste also 
being popular. 
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The addition of flavours into formulations not only masks the taste of active ingredients 
but also improves medication adherence, for instance flavouring medicine increases 
patient adherence to over 90%, from an average of 50% (Bryson, 2014). In the present 
study nearly the half of the participants (49%) preferred strawberry followed by orange 
and banana (19% and 18% respectively) while no preferences (0%) was recorded for 
mint and lemon (Figure 3.7). Overall strawberry was the most preferred flavour, 
significant differences were found among respondent preferences (p<0.05). Similarly, 
in our previous study which was carried out with the paediatric population confirmed 
that the vast majority of participants preferred sweet taste along with strawberry flavour 
(Alyami et al., 2016). 
Figure 3.7: Distribution of preferred ODTs flavours by all respondents, with strawberry flavour 
being the most popular, followed by orange and banana. 
Due to consideration of size and shape of dosage forms, size and shape may affect 
the transit of the product through the pharynx and oesophagus and may directly affect 
a patient’s capability to swallow a particular drug product (Ranmal et al., 2016). The 
current study reported that vast majority (90%) of respondents’ preferred small size (5 
48.60%
18.90%
4.10%
5.40%
0.00%
0.00%
5.40%
17.60%
Strawberry Orange Cherry Vanilla Mint Lemon Chocolate Banana
Chapter 3 
131 
to 7 mm) compared to the medium 10 % (8 to 12 mm) or big with 0% preference 0% 
(≥13mm), as shown in (Figure 3.8). The size of ODTs was potentially highlighted 
across all groups of healthcare professionals with small size highly recommended. 
Several studies support this findings and have stated the negative attitudes of children 
concerning big sizes of tablets (Reddington et al., 2000, Roberts, 2005, Paranthaman 
et al., 2009). 
 Figure 3.8: Distribution of preferred ODTs sizes by all respondents clearly showing that a small 
dosage form would be preferable. 
Figure 3.9 shows the respondents preferences based on the shape of the ODT 
formulations. The majority of the participants preferred ODTs that are round in shape. 
This accounted for 83 % of the responses while the oval shape was second with a 
preference of 10%, approximately 5% reported that they had no preference for shape 
with the least preferred shapes being triangle and square at 2.4% and 0% respectively. 
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Figure 3.9: Distribution of preferred ODTs shapes by all respondents indicating that a round 
shape is massively preferred compared to any other tablet shapes. 
With respect to colour preferences, (Figure 3.10) demonstrated that white was the 
most preferred colour for ODTs by more than 70% of the respondents followed by pink 
(17%), yellow (5%) and finally blue (2%). A significant difference was identified by Chi-
square test for colour preferences p<0.05. It was worth mentioning that the selection 
of an appropriate colouring agent may positively impact child acceptance and also 
enhance medication adherence (Levitan et al., 2008). The results in (Figure 3.11) 
showed that the healthcare professionals opinions regarding length of time for ODT 
formulations to be dissolved in the mouth, with the vast majority of the participants 
(95%) preferring very rapidly (<30sec) disintegrating ODTs followed by rapidly 
disintegrating ODTs (between 30 to 90 sec) at about 5%. 
82.90%
9.80%
2.40%
0.00%
4.90%
Round Oval Triangle Square Other
Chapter 3 
133 
Figure 3.10: Distribution of preferred ODTs colours by all respondents showing that a white 
tablet is the most preferred colour amongst the healthcare professionals for paediatric 
administration. 
Figure 3.11: Distribution of preferred ODTs disintegration times by all respondents showing 
that a rapidly disintegrating tablet would be seen as the ideal ODT by the healthcare 
professionals. 
Blue Pink White Yellow Other
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Respondents were also asked what the most important physical characteristics of 
ODTs were and the results showed that taste was the most important property 
(approximately 30%), followed by disintegration time, flavour and size (29%, 22% and 
19% respectively) whereas, colour and shape were the least important characteristics 
(Figure 3.12). A significant difference was found between those characters (p<0.05). 
The results indicated that the most important factor was taste with the findings aligning 
with the published literature (Matsui, 2007, Hasamnis et al., 2011, Squires et al., 2013). 
Figure 3.12: Percentages distribution of the most important characteristics of ODTs. Taste, 
disintegration time and flavour appeared as the most important factors by the healthcare 
professionals when considering ODTs.  
3.3.3.4. Further recommendations, feedback and limitations 
In the last section of the study, the healthcare professionals were asked to give their 
opinions, recommendations and feedback on how the study was conducted. The vast 
majority of respondents designated that regardless of the fact that it was a good idea, 
there were areas that could be improved. For instance, they pointed out that most 
questions should be asked to paediatric patients, however this has been covered in 
the previous chapter of this thesis. In addition, pharmacists also indicated that there 
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were very few ODT formulations available to enable them to make an informed answer 
to most of survey questions. With regard to drug manufacture and design, a few 
participants recommended that film formulations may be another form of oral 
dispersible formulations that could offer further advantages. Participants also 
suggested that taste was the most important property reported for ODT administration, 
hence, the manufacturers should ensure that the taste is neutral to sweet, but not bitter. 
The recruitment process in focus groups (phase 1) was carried out through 
pharmacists and nurses but not the medical practitioner group. This may have led to 
under representation of doctors’ perspectives and input. Certainly some healthcare 
professionals participating in focus group from the same institution were known to each 
other, this might have been seen as a potential limitation as respondents may have 
been more disposed to speak in a ‘socially accepted’ style (i.e. less fairly) (Rabiee, 
2004). The study was conducted at two sites in the UK, thus it cannot be generalised 
and viewed as a nationwide perspective, and further exploration in another countries 
is required. 
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3.4. Conclusion 
In summary, this study identified a plethora of recommendations and opinions for 
paediatric dosage forms, particularly how ODTs are perceived by healthcare 
professionals. Secondly, the study identified that HCP perceived suitable organoleptic 
properties of ODTs (e.g. dissolving time) which influenced acceptability in paediatric 
patients. As a result this pragmatic study filled the research gap that existed through 
exploring such healthcare professional’s views and recommendations of the 
acceptability and physical characteristic properties of ODT using a mixed methods 
approach (focus group, semi-structured- interviews and online survey). The overall 
results from dual sites demonstrated that liquid dosage forms are the most 
prescribed/administered dosage form followed by ODTs. Factors found to significantly 
influence choice of formulations for paediatric patients were age, weight, parent/care 
giver and cost effectiveness of dosage forms. Although, the majority of respondents 
agreed that liquid formulations could be substituted with ODTs in paediatric patients, 
the number of available ODTs in the market were insufficient to be prescribed or 
administered. From the physical characteristics results in this study, it can be 
concluded that taste, disintegration time and flavours were the most important 
properties related to ODT administration supporting the results reported from the 
previous study (Alyami et al., 2016). Additionally, the other important characteristics of 
solid dosage forms were white colour, small size, round shape, strawberry flavour and 
rapid disintegration time. Further studies exploring the opinions of parents concerning 
paediatric dosage forms would complement this research. This study also suggests 
that there is a need for further research to develop a wider range of ODTs for use in 
the paediatric population. 
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4.1. Introduction 
Oral drug delivery is the favoured route of drug administration, due to the convenience 
of administration, being non-invasive and therefore more likely to promote patients 
compliance with their treatments (Siddiqui et al., 2011). Efficient and reproducible 
blending process is critical to manufacturing of oral drug delivery systems, as the 
quality of the final product is driven by the quality of the blend (Harnby, 2000). Hence, 
production of non-homogenous blends results in discrepancy in the content of the 
active pharmaceutical ingredient (API) and product failure (Dahmash and Mohammed, 
2015).  
Blending is a process where two ingredients or more are processed in order to achieve 
a homogenous product (Harnby, 2000, Maynard, 2007). To achieve that, three main 
mechanisms of powders blending are involved; convection, diffusion, and shear. 
Convective blending encompasses gross movement of particles within the blend, 
whereas, diffusion is a slow blending process where individual particles are distributed 
upon blending into newly formed interface. Lastly, the shear mechanism of blending 
comprises of blending of material while passing along forced slip planes which could 
aid in breaking agglomerates and hence enable blending (Kaye, 1997, Maynard, 2007, 
Deveswaran et al., 2009). Depending on the flow characteristics of powders, solids are 
broadly divided into cohesive materials and non-cohesive materials. Blending of 
cohesive materials is more complex because of the possibility of developing 
aggregates and lumps (Harnby, 2000, Maynard, 2007). 
Normally, a high drug loading capability is ideal in such formulations; the overall weight 
of tablets is relatively low to allow for rapid disintegration and dissolution (Parkash et 
al., 2011). However, for high potency or low load drugs like vitamins that exist at lower 
loading in formulations, this is a major issue. The problem with manufacturing using 
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such drugs is obtaining a uniform distribution of drug throughout the formulation 
(Zheng, 2009). Uniformity of API is important as it will impact drug dissolution, 
absorption, bioavailability and onset of clinical effect (Hirani et al., 2009). 
Developing formulation for low load drugs where small amount of the API is blended 
with a large amount of excipients/carriers is challenging. Blend homogeneity is 
dependent on multiple factors including: particle size, size distribution and density of 
the individual components, blending process or blending equipment and presence of 
agglomerates within the blend (Kaye, 1997, Portillo et al., 2008). Understanding of 
powder properties particularly particle size, shape, size distribution particle surface 
roughness will enable the selection of appropriate excipients and blending process 
(Flament et al., 2004, Jallo et al., 2012, Dahmash and Mohammed, 2015).   
Various blending techniques to obtain homogenous blends for low API load are 
reported. Apart from the multistep techniques like granulation and spray drying, 
geometric dilution is a commonly used technique when low load API formulation is 
developed. It implies gradual addition of equal portions of the diluent/ excipient to the 
API upon blending. The process increases the chances of equal distribution of the API 
particles within the blend. Ordered mixing or interactive mixing is another promising 
technique where fine API particles are adsorbed to the surface of coarse 
carrier/excipient particles as depicted in (Figure 4.1) (Kukkar et al., 2008, Saharan et 
al., 2008, Dahmash and Mohammed, 2015).  
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Aggregated Fine 
API Particles
Coarse Excipient 
Particles 
Interactive/ Ordered 
Blended Particles 
Application of 
Strong Force
Figure 4.1: Schematic diagram showing the process of interactive/ordered blending. Fine 
aggregated API particles blended with coarse carrier/ excipient particles upon the application 
of strong mechanical force the fine API particles are de-aggregated and get attracted to the 
surface of the excipient particles producing interactive/ ordered blended particles.   
Obtaining optimal concentrations of excipients at the correct particle size and thereby 
enhancing flow is critical in improving manufacturability (Pingali et al., 2011). Particle 
size also has an impact on uniformity of content, with smaller particles allowing for 
more uniform mixes to be achieved (Muselík et al., 2014). This produces a trade-off 
and the need for a balance to be found in order to produce powder blends with ideal 
characteristics for tableting whilst maintaining uniformity of content.  
The work in this chapter aims to evaluate the impact of particle size and dilution 
potential of three model carriers to develop a uniform blend comprising of small dose 
model drug, ergocalciferol using various blending techniques. The objectives of the 
study are: 
- To evaluate the impact of different particle size (non-cohesive, cohesive and
non-sieved) for three model carriers – starch, pregelatinised starch and micro
crystalline cellulose (MCC) on blend homogeneity.
- To study the flowability of cohesive, non-cohesive and non-sieved carriers
using the angle of repose method.
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- Evaluation of morphological properties, surface topography and particle
roughness using surface interferometry and scanning electron microscopy
(SEM).
- To study the effect of increasing carrier ratio from1:5 to 1:50 on drug content
uniformity (geometric dilution).
- To investigate the effect of increasing mixing time from 0 to 32 minutes on drug
content uniformity (ordered mixing, interactive mixing).
- To explore the influence of mixing order of different pharmaceutical excipients
namely D-mannitol, Microcrystalline cellulose, crospovidone and Magnesium
stearate during mixing on blend flow and tablets properties.
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4.2. Materials and Methods 
4.2.1. Materials 
Starch and pregelatinised starch (starch 1500®) were obtained from Colorcon 
(Dartford Kent, UK). Ergocalciferol (Vitamin D2) was purchased from Discovery Fine 
Chemicals (Dorset, UK), whereas two grades of microcrystalline cellulose MCC Avicel 
type (PH-200) and (PH-102) were donated by FMC BioPolymer Europe (Brussels, 
Belgium). D-mannitol, ethanol and magnesium stearate were purchased from Sigma-
Aldrich (Pool, UK), while Crospovidone (CrosPVP, Polyplasdone® XL-10) was 
obtained from Ashland (Wilmington, USA). 
4.2.2. Methods 
4.2.2.1. Micronisation of Vitamin D2 
Vitamin D2 was micronised by manual grinding using mortar and pestle for 30 minutes 
followed by sieving through different sieves for 12 minutes. 4 sieves (with 20cm 
diameter) were selected and weighed with the following mesh size range; 125 µm, 106 
µm, 75 µm, 53 µm arranged as a nest according to size with coarsest on top using the 
vibratory sieve shaker Analysette- Spartan (Fritsch- GmbH) with deep amplitude 
(2.5mm). Then the fraction of particle size< 53 µm was manually passed through sieve 
with mesh size of 20 µm (particles with size ≤20µm were used for the study) in order 
to optimise distribution within powders and ensure better uniformity of content in the 
batches (Zhang and Johnson, 1997). 
4.2.2.2. Sieving process 
The original powders of the carriers (starch, pregelatinised starch and MCC) were 
sieved through different sieves. 8 sieves (with 20 cm diameter) were selected and 
weighed with the following mesh size range; 710 µm, 500 µm, 355 µm, 250 µm, 125 
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µm, 106 µm, 75 µm, 53 µm arranged as a nest according to size with coarsest on top. 
Sieving was carried out for 12 minutes using the vibratory sieve shaker Analysette- 
Spartan (Fritsch- GmbH) at deep amplitude (2.5mm) in order to achieve separation of 
non-cohesive and cohesive parts of the powder. Approximately 40g of each powder 
was collected and labelled for use in the study. The particle size ranging between 125-
180 µm was chosen as a non-cohesive fraction whereas particles with size with less 
than 53 µm were considered cohesive powders. Individual sieves were weighed to 
estimate the powder content. The process was repeated for additional 5 minutes to 
ensure weight difference did not exceed 5%. 
4.2.2.3. Analytical technique 
The amount of ergocalciferol dissolved in the solution samples was quantified using 
UV spectrophotometry (Jenway 6305 from Bibby Scientific Ltd. Staffordshire, UK) set 
at wavelength of 265 nm. Method validation was done based on the International 
conference on Harmonization (ICH) guidelines for validation of analytical procedures 
(ICH, 2005). Calibration curve was prepared from dilution of stock solution of 
ergocalciferol (10 μg/ml), using ethanol as solvent. The absorbance of the dilutions of 
stock solutions were determined by UV spectrophotometer, at wavelength of 265 nm 
(USP, 2003). Six point calibration curve was obtained in a concentration range from 0-
3.6 µg/ml for ergocalciferol. Calibration curve was validated against specificity, 
linearity, accuracy, precision, limit of detection (LOD) and limit of quantification (LOQ). 
4.2.2.4. Powder characterisation 
4.2.2.4.1. Powder flowability (angle of repose method) 
Powder flowability was evaluated using angle of repose method (USP-29, 2009). 5g of 
powders were poured through a funnel onto a flat surface. The funnel was positioned 
10 cm from the horizontal surface, and the powders were allowed to flow freely until 
the formation of a symmetrical cone. Both the base (b) and height (h) of the formed 
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cone were measured and recorded. Equation 4.1 was used to calculate the angle of 
repose (𝛉). Values were expressed as mean ± standard deviation (n=3). 
𝛉 = 𝐭𝐚𝐧−𝟏(𝒉 𝟎. 𝟓𝒃⁄ ) … … … … … … … … … … . . 𝑬𝒒 (𝟒. 𝟏)
Results of the angle of repose correlate to flowability. Angle less than 30° indicates 
excellent flowability, between 31-35° is for good flowability, whereas angles above 45° 
is an indication of poor flowable powder (USP-29, 2009).   
4.2.2.4.2. Particle size analysis (laser diffractometer) 
Powder particle size analysis was performed using laser diffractometer, Sympatec 
HELOS/ RODOS T4.1 (Clausthal-Zellerfeld, Germany). An R3 lens with a working 
range in between 0 and 178 µm was used for this study. The instrument permits the 
powder to circulate continuously through the system during the measurements through 
the sample dispersing system RODOS (dry disperser). Powder sample (0.5 g) was 
spread over the feeding tray of the VIBRI that transfers the sample into the dispenser 
(RODOS). Plots of particle size distribution wereobtained covering the range from 0.5-
175 µm. Parameters such as the volume mean diameter (VMD), X10, X50 (median, 
50% volume percentile) and X90 were obtained. The span of distribution was 
calculated using equation 4.2. All the measurements were conducted in triplicate. 
𝑆𝑝𝑎𝑛 𝑜𝑓 𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛 =
(×90−×10)
×50
 … … … . . 𝐸𝑞 (4.2) 
It should be noted that laser diffraction method produces high velocity for the powder 
which is aided by compressed air set at 3 bars that affects dispersion of the sample 
and hence, it is expected that the agglomerates originating from fine powder are 
dispersed into their primary particles and perfectly distributed (Jallo et al., 2012). 
4.2.2.4.3. Scanning Electron Microscopy (SEM) 
SEM was used to study the morphological structure of particles. Samples were 
distributed by sprinkling on a double adhesive carbon tape placed over an aluminium 
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stub. Then samples were coated twice with gold in a sputter coater Polaron SC500 
(Polaron Equipment, Watford, UK) at 20 mA for three 4 minutes and then examined by 
the SEM before imaging to enable sample conductivity. The sample imaging was 
performed on a field emission scanning electron microscope (Cambridge Stereo Scan 
(S90) Electron Microscope, Cambridge Instrument, Crawley,UK). Different 
magnifications were taken to identify various characteristics and surface features of 
the powders. 
4.2.2.4.4. Surface topography using Interferometer 
Interferometric measurements of particle surface topography were performed using a 
MicroXAM2 interferometer (Omniscan, UK), operating using a white light source. 
Samples were imaged using a 50X objective lens. Scanning Probe Image Processor 
software (Image Metrology, Denmark) was used for the analysis of acquired images. 
Multiple images were stacked together to produce extended fields of average 
roughness in 3-D (Sa), root-mean-square roughness in 3-D (Sq), maximum height of 
the surface (Sy). The software enabled the calculation of adhesion energy and 
flowability parameters.  
4.2.2.5. Blending techniques 
Initial investigations focussed on developing formulations at four different weight ratios; 
1:5, 1:10, 1:20, 1:50. Each of these would contain 10mg of API and 50, 100, 200 and 
500mg of the carrier respectively, weighed out using precise analytical balance then 
blended according to the designed blending technique.  
4.2.2.5.1. Geometric blending technique 
The first blending technique was based on geometric blending. A stepwise geometric 
addition of excipient to the API was carried out to investigate the impact on content 
uniformity. The blending time was set either at one or five minutes and was achieved 
by shaking of the sample containing tube by hand. In this instance, each created batch 
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was made of 600mg that was mixed in a 30ml screw cap tube. Therefore the mass of 
API included and excipient added in order to maintain geometric addition was altered 
to maintain the desired ratio at this increased batch size. Three batches were prepared 
for each ratio and the process was repeated for each of the three carrier powders.  All 
samples were prepared and 5mg of the blend was used for analysis of content 
uniformity using UV spectroscopy.   
4.2.2.5.2. Manual blending technique 
600mg batch size at 1:50 ratio was carried forward for evaluating the impact of manual 
blending on content uniformity. This consisted of addition of the total quantity of carrier 
in one step into the sample tube after the required amount of API had been added. 
5mg was taken from the blended powder over different time points (0, 2, 4, 8, 16, 32 
minutes) for content analysis. The process was repeated for each of the three carrier 
powders. 
4.2.2.5.3. Ordered mixing using dry powder coater  
The ‘dry powder hybrid mixer prototype’ was assembled by the research group at 
Aston University. The machine is designed to supply sufficient mechanical force 
essential to break the agglomerates that are created by the cohesive powder and 
promote ordered and structured blending of powder mixtures. The machine comprises 
of a high speed rotating motor which has a speed ranging between 300-2000 rpm 
which is linked to a rotating container by means of a smooth inner surface in which the 
powder (API as well as carrier/excipient) is enclosed. To assist collision external air 
supply is provided via nitrogen gas which is linked to the mixing container providing 
pressures from 20-40 psi. The aim was to attain a homogenous mixing at 300 rpm, the 
total powder used was 3 g. 2% w/w API was examined for each type of carrier.  
A final investigation was performed using ordered addition of non-sieved carrier which 
comprised of six batches made up to 3 g, containing 1% w/w API and 0.5% API. 
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Blending was done by the same dry powder coater at 300rpm for a total 32 minutes. 
5mg samples were taken from the blended powder over a range of time points (0, 2, 
4, 8, 16 and 32 minutes) to assess blend homogeneity.  
4.2.2.6. Drug content uniformity using UV analysis 
5 mg of the blended powders of ergocalciferol and carriers at 1:5, 1:10, 1:20, and 1:50 
were dissolved in 50, 25, 10, 5ml respectively of ethanol. The solution was filtered 
through a 0.45 μm nylon filter (CHROMACOL LTD, Herts., UK). Ergocalciferol content 
uniformity was assayed using spectrophotometer using UV analysis. 
Spectrophotometer at wavelength 265 nm was used (USP and Volume, 2003, USP-
29, 2009). Values are expressed as mean ± standard deviation (n=9). 
4.2.2.7. Tablet Preparation and Characterization 
Mannitol, MCC, magnesium stearate and crospovidone powders were mixed in 
different order and compacted into 500 mg tablets under compression force at 10 KN. 
The tablet press utilized for preparing the tablets was a bench-top semi-automatic 
hydraulic press from Specacltd. (Slough, UK) which was equipped with flat faced dies 
13 mm in diameter. The tablets were characterized for porosity, hardness, 
disintegration time and friability. All tests were carried out in triplicates (n=3). 
 4.2.2.7.1. Porosity and true density of tablets 
A MultiPycnometer® (Quantachrome Instruments, Syosset, USA) was used to 
determine the true density and porosity of the components in the tablet form using 
helium as the displacement gas set at pressure of 2 bars. Powder sample was placed 
into a tarred sample cell and accurately weighed. The sample true density was 
calculated from the pressure values obtained initially from filling the sample cell with 
helium gas and the pressure of discharged gas from a second empty cell. Calculation 
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of porosity was done using multiPycnometer software. The Samples were repeated in 
triplicate.  
Tablet porosity was calculated by the following equation: 
Porosity = 1-(bulk density/true density)  
4.2.2.7.2. Hardness 
The tablet hardness tester from Schleuniger (Thun, Switzerland) was used to measure 
the hardness of three tablets of each formulation. Hardness is the force required to 
break up the tablet into pieces. All measurements were carried out in triplicate and the 
values reported as mean ± standard deviation. 
4.2.2.7.3. Disintegration Time 
The disintegration time was obtained according to the official USP monograph 701 for 
tablet disintegration testing. Disintegration test apparatus used was ZT3 from Erweka 
(Heusenstamm, Germany). A tablet was placed in the disintegration basket (without 
using a disk) which was raised and lowered at a constant frequency of 30 cycles/min 
in the disintegration medium. Distilled water (800 ml) maintained at 37°C was used as 
the medium of disintegration while disintegration time was recorded for one tablet at a 
time to improve accuracy of recording. Time of disintegration was recorded when all 
the disintegrated fractions of tablet passed through the mesh of disintegration basket. 
Measurements were carried out in triplicate and values were reported as mean ± 
standard deviation. 
4.2.2.7.4. Friability 
The ability of the tablets to withstand mechanical stress, known as friability was 
measured using Roche friabilatorfrom J. Engelsmann AG (Ludwigshafen, Germany). 
Six tablets were utilised at 25 rpm for 100 revolutions. Tablets were sensibly de-dusted 
before and after the test, and friability expressed as the percentage loss in weight. The 
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percentages of loss in tablets (% Friability) weights were calculated using the following 
equation. 
     % Friability = (initial weight- final weight) / initial weight x 100  
4.2.2.8. Statistical Analysis  
Statistical analysis were done using Graph Pad Prism software (Version 3.01, CA, 
USA). One way analysis of variance (ANOVA) and pair-wise multiple comparisons 
method (Tukey’s test) were used to compare data groups by using mean values and 
standard deviation (SD). The significant difference was determined using the 
probability value of 95% (P < 0.05). 
4.3. Results and Discussion 
4.3.1. Analytical technique 
Absorption spectrum of ergocalciferol showed maximum absorbance at 261nm 
(appendix 10.a). According to specification from the manufacturer, ergocalciferol 
absorbs UV at 265nm, and the result obtained in this study is similar to the specification 
supplied by the manufacturer. It was also found out that analysis by UV spectrometry, 
MCC starch and pre gelatinised starch had no interference (See appendix 10).  
The response of the drug was linear in the concentration range investigated and the 
linear regression equation was y = 0.0443x with correlation coefficient R² = 0.999 
(appendix 11). 
The accuracy of the method is the closeness of the measured value to the true value 
for the sample (Zhang and Johnson, 1997). Accuracy of the method was studied by 
recovery experiments. The recovery was performed by preparing three different 
concentrations of 2, 5 and 10 μg/ml of ergocalciferol standard solution. Three samples 
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were prepared for each recovery level. The solutions were then analysed, and the 
percentage recoveries were calculated from the calibration curve (Table 4.1). 
Table 4.1: Evaluation data for accuracy study of ergocalciferol. 
Sample Theoretical 
amount(μg/ml) 
Actual 
amount(μg/ml) 
% recovery 
1 2 2.023±0.04 101.1±2.01 
2 5 4.933±0.05 98.667±1.01 
3 10 9.918±0.38 99.177±3.802 
In addition, precision of the analytical method was ascertained by carrying out the 
analysis for two different concentrations (2 and 10 μg/ml) for ergocalciferol and the 
analysis was repeated six times. Assay of method precision including intra-day and 
inter-day precision were evaluated and samples were kept in the refrigerator. The % 
assay, mean assay, standard deviation and % relative standard deviation (RSD) were 
calculated (Table 4.2 and 4.3). 
Table 4.2: Precision study for 2 μg/ml ergocalciferol. 
Sample % Assay Intra-day % Assay Inter-day 
1 98.93 98.21 
2 102 99.24 
3 101.10 99.30 
4 103 96.24 
101.3 95.54 
5 100.78 99.64 
6 101.17 98.03 
Mean 98.93 98.21 
SD 1.271 1.59 
%RSD 1.25 1.62 
The developed process was precise as the %RSD values for the repeatability and 
intermediate precision studies were <1.26% and <1.62%, respectively (Table 4.2) for 
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2 μg/ml ergocalciferol. The percentage recovery for three samples was found to be 
near to 100% which shows that the procedure was accurate and hence validated. 
Table 4.3: Precision study for 10 μg/ml ergocalciferol. 
Sample % Assay Intra-day % Assay Inter-day 
1 101.10 97.68 
2 101.50 97.46 
3 100.70 95.15 
4 99.50 96.46 
5 101.25 94.21 
6 100.97 99.64 
Mean 100.83 96.77 
SD 0.71 1.77 
%RSD 0.70 1.82 
The Limit of detection (LOD) and limit of quantification (LOQ) of ergocalciferol were 
determined by using standard deviation of the response and slope approach as defined 
in International Conference on Harmonization (ICH) guidelines. LOD and LOQ values 
were calculated (Table 4.4) using below equations 
 LOD=3.3δ /S 
     LOQ=10 δ /S 
 Where, δ= standard deviation of residuals from the curve; S=slope of the curve  
Chapter 4 
152 
Table 4.4: Regression and validation parameters of ergocalciferol. 
Parameter Results 
1 Slope 0.0443 
2 Intercept 0.000 
3 Standard 
regression equation 
y=0.0443x 
4 Correlation Coefficient 
(R2 ) 
0.999 
5 Residual standard 
deviation 
0.0021 
6 LOD (μg/ml) 0.16 
7 LQD (μg/ml) 0.48 
The limit of detection (LOD) for lowest amount of analyte which can be detected  and 
is analysed by means of a statistical approach that is based on determining replicate 
blank (negative) samples or  by means of an empirical approach, comprising of 
measuring gradually more dilute analyte concentrations. The limit of quantitation (LOQ) 
is the concentration at which quantitative data can be recorded with an elevated degree 
of confidence (Armbruster et al., 1994). Our method showed that the LOD was 
0.16μg/ml and LOQ was 0.48μg/ml (Behera et al., 2012). 
4.3.2. Powder characterisation 
In-depth analysis of powder properties enables understanding or even predicting their 
performance upon blending with API. The primary aim of this study was to investigate 
the impact of particle characteristics on blending small quantities of candidate API. The 
classification of the powders into cohesive and non-cohesive was done to identify the 
impact of particle size during the process of blending on dose uniformity. The study 
commenced with the evaluation of particle size measurements and was followed up 
with powder flow, scanning electron microscopy and interferometry studies. 
Understanding powder flow is a critical attribute during pharmaceutical manufacturing 
processes like, mixing, packaging, transportation, tabletting and capsule filling. 
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Therefore, it becomes vital to determine the flow properties of powders prior to 
commencing the manufacturing process. 
There are two classes of material properties that need to be considered in blending 
powders. The first is the cohesive materials that tend to aggregate leading to flowability 
issues while the second class is the non-cohesive free flowing materials that could 
demonstrate excellent flowability but can lead to occasional segregation (Ottino and 
Khakhar, 2000, Aulton, 2002, Builders et al., 2010, Bridgwater, 2012).  
Particle size analysis results as depicted in (Table 4.5) showed that the average 
particle size of starch is around 11.9±0.51 µm which is expected from a cohesive fine 
powder. Optimising drying conditions to produce gelatinisation of starch can cause the 
particles to adhere together to form aggregates (Newman et al., 1996) and hence the 
average particle size of pregelatinised starch exhibited an increase of VMD to 
79.75±1.49 µm. With regard to MCC, using the laser diffraction particle size analyser 
results produced an incomplete distribution curve as the powder contains particles with 
size exceeding 175 μm. Similar results were obtained for ergocalciferol (VMD: 
73.66±5.18 µm). According to a publication by Zhang et al (1997) which analysed if 
drug particle size or mixing impacts on poor content uniformity, it was noted that 
decreasing particle size enhances content uniformity provided drug aggregation is 
controlled .Therefore, ergocalciferol was micronised to enhance content uniformity in 
this study.  
Table 4.5: Flow properties of starch, pregelatinised starch (P.starch), MCC and ergocalciferol 
(Erg.) showing the particle size analysis parameters (X10, X50, X90, Span and volume mean 
diameter (VMD)), angle of repose (°) and the corresponding flow property.   
Produc
t 
X10 X50 X90 Span VMD 
(µm) 
θ 
(°) 
Flow 
property 
Starch 7.72±0.62 11.75±0.43 16.65±0.33 0.761±0.0
5 
11.9±0.51 42.46±2.5 Passable 
P. 
Starch 
27.72±2.4
6 
77.24±2.52 134.27±3.3
9 
1.38±2.48 79.75±1.4
9 
34.90±2.2 Good 
MCC 18.65±0.2
9 
62.75±2.07 141.26±0.6
6 
1.96±0.05 73.05±0.8
9 
28.0±1.44 Excellent 
Erg. 9.22±1.31 67.52±13.1
5 
142.10±3.7
6 
2.07±0.33 73.66±5.1
8 
34.98±1.9
8 
Good 
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The results of flowability based on angle of repose showed that (apart from starch) 
flowability was good to excellent for the non-sieved materials. Owing to its small 
particle size, starch demonstrated low flowability profile which was further evident from 
the SEM images that showed individual particles as well as cluster of granules. Starch 
particles were small in size and had typical angular, spherical shape or rounded shape 
with smooth surface (Figure 4.2 a).  Pregelatinised starch SEM images (Figure 4.2 b) 
showed larger clusters of particles and hence have enhanced flowability when 
compared to starch. The excellent flowability of MCC could also be attributed to the 
granular particle shape and larger particle size (Figure 4.2 c). The general shape for 
ergocalciferol can be described as longitudinal and irregularly shaped with some 
roughness on the surface (Figure 4.2 d) but as the particle size was large, flowability 
was good.   
Figure 4.2: Scanning electron microscopy micrographs at 1000 times magnification of (a) 
starch (b) pregelatinised starch (c) MCC and (d) ergocalciferol.  
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As the aim of the work was to further investigate powder behaviour upon mixing and 
the performance of blend, the three excipients (pregelatinised starch, starch and MCC) 
were sieved and the cohesive part of the powder (particle size less than 53 μm) as well 
as non-cohesive part where the size of the particles was between 125-180 μm were 
collected and further investigated except for starch where only non-sieved and 
cohesive portions were used as the particle size of starch was low. Flow properties of 
non-cohesive pregelatinised starch was found to be excellent as depicted in Table 4.6. 
Similarly as expected, cohesive fractions of both starch and pregelatinised starch 
materials showed poor flowability due to their smaller particle size. The non-sieved and 
non-cohesive MCC fell into the excellent flow properties category whereas the 
cohesive MCC portion had fair flow. The results obtained were statistically significant 
(p<0.05) as larger particles have better flow properties whereas smaller particles due 
to increased Van der Waals interactions exhibit poor flowability (Zhang and Johnson, 
1997). The non-cohesive MCC and non-sieved had similar flow properties as the 
particles around 200µm generally have excellent flow properties (Liu et al., 2008). 
Table 4.6: Flow properties of cohesive starch, cohesive and non-cohesive pregelatinised starch 
and cohesive and non-cohesive MCC showing the particle size range (obtained upon sieving), 
angle of repose (°) and the corresponding flow property.   
Carrier (particle size) Particle size range 
(μm) 
Angle of repose 
(°) 
Flow property 
Cohesive starch <53 49.30 ± 0.59 Poor 
Non-cohesive pregelatinised 
starch  
125-180 30.14 ± 2.3 Excellent 
Cohesive pregelatinised 
starch 
<53 48.44 ± 4.2 Poor 
Non-cohesive MCC 125-180 25.0 ± 0.86 Excellent 
Cohesive MCC < 53 39.46 ±1.29 Fair 
An attempt to further understand the material enhanced functionality and performance 
upon processing with various APIs was studied using interferometry. The technique 
provides an in-depth analysis of the surface properties and topography parameters as 
summarised in (Table 4.7). The first parameter is the average surface roughness (Sa) 
and the results showed high surface roughness for MCC followed by pregelatinised 
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starch and then starch. Sieving to obtain the fine fraction of material resulted in a 
significant increase in surface roughness for pregelatinised starch (ANOVA, p<0.05) 
whereas the starch showed slight reduction in roughness. The increase in roughness 
upon sieving could be attributed to the increase in surface area with lower particle size 
as the average size of pregelatinised starch dropped from 40 to 25µm. The change in 
particle size upon sieving for starch was minimal and the particles were <10 µm. 
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Table 4.7: Surface topography parameters and flow properties of the main excipients showing 
average roughness (Sa), mean square value of average roughness (Sq), maximum roughness 
height (Sy) particle radius (R), adhesion energy (AE), angle of repose (𝜽) and flow property 
(FP) (mean ± SD, n=5). 
Material Sa 
(nm) 
Sq 
(nm) 
Sy 
(nm) 
R 
(μm) 
AE 
(aJ) 
(𝜽) FP 
Cohesive MCC 875±60 1230±115 9604±105 26.5 28.5 39.46±1.29 Fair 
Non-sieved starch 126±38 168±60 1700±103 6.0 114.5 42.46±2.5 Passable 
Cohesive starch 81±34 109±46 703±156 3.5 108.5 49.3±0.59 Poor 
Non-sieved 
pregelatinised starch 
174±53 233±80 2934±160 40.0 251.5 34.9±2.2 Good 
Cohesive 
pregelatinised starch 
264±109 390±212 5216±173 25.0 153.6 48.44±4.2 Poor 
In this study the high surface roughness of MCC was anticipated to enhance content 
uniformity compared to starch and pregelatinised starch. It was expected that fine API 
particles will be easily lodged into and between the rough surface apertures of MCC 
and hence enhance uniformity. It was reported that the higher the degree of roughness 
results in better content uniformity of the blend (Leach et al., 2008). Therefore, based 
on particle size and surface roughness, MCC showed best uniformity followed by 
pregelatinised starch and starch. Further the poor content uniformity of starch could 
also be attributed to the small particle size (3.5-6µm) and cohesive nature of starch 
that showed high cohesive energy (~110aJ). The second parameter from table3 is the 
Sq. It is the root mean square value of the surface roughness within the sample area. 
It is considered as a more statistically significant parameter than Sa (Leach et al., 
2008). Similar to the results obtained from Sa values, MCC particles showed higher 
Sq values than that of pregelatinised starch or starch.  
The third parameter Sy is the maximum height of surface. It is the sum of the height of 
the largest peak height value and the largest valley depth within the sample. Examining 
both the Sq value and the Sy value, an indication of whether the apparent roughness 
is due to isolated features or the overall surface roughness can be derived (Leach et 
al., 2008). 
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Figure 4.3: Interferometer topographical images of (a) cohesive MCC, (b) non-sieved starch, 
(c) cohesive starch, (d) non-sieved pregelatinised starch and e) cohesive pregelatinised starch.
Results for all the samples indicated that the Sy value were different compared to that 
of Sq value which indicates that the topography is irregular as evident from the 3D 
images in (Figure 4.3). On the other hand, the change in Sy value for MCC particles 
was of a greater magnitude and provides a stronger evidence of the degree of 
roughness compared to the other excipients. Surface energy parameters as depicted 
in (Table 4.7) showed the change in adhesion energy for different materials. The lowest 
was noted for cohesive MCC with particle size of around 26μm and adhesion energy 
of 28.5aJ. Such low energy for MCC possibly explains fair flowability despite the small 
particle size (39.46±1.29). It was reported that particles of less than 50μm are highly 
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cohesive (Dahmash and Mohammed, 2015). This also could be further correlated to 
surface roughness (Sa) where high roughness values will result in less surface contact 
between particles and hence less cohesiveness, better flowability to produce 
homogeneous blend (Leach et al., 2008). The cohesive energy for pregelatinised 
starch and starch were related to the change in surface roughness of material and 
hence could justify that higher roughness is related to lower cohesive energy however, 
that could not clearly relate to flowability as the particle size of pregelatinised starch 
and starch were very low.  
4.3.3. Investigation of various blending techniques and their impact 
on drug content uniformity 
Ergocalciferol is a suitable model as the maximum dose is generally around 750-800 
micrograms per tablet. The different ratios of drug to carrier were selected to simulate 
dilution of drug during tablet development when mixed with different excipients. Starch, 
pregelatinised starch and MCC are routinely used in tablet manufacturing and 
represent a pragmatic choice to investigate the above hypothesis. 
Having investigated material properties for the model drug as well as the different 
particle fractions for the three carriers, the next objective was to study the impact of 
different blending techniques primarily on the content uniformity of the drug. Geometric 
blending including the impact of total powder content as well as duration of blending 
was investigated. In addition ordered mixing using two different approaches including 
manual blending and high speed blending were investigated.  
4.3.3.1. Geometric mixing technique 
Geometric blending is a standard technique to mix small amounts of drug and 
according to British Pharmacopeia (BP, 2012), drug content for ergocalciferol should 
range between 90 to 120% of the claimed label. Four formulations were prepared for 
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geometric blends (drug: carrier ratios: 1:2, 1:10, 1:20 and 1:50). All mixtures were 
prepared with a total batch size of 600mg.  
4.3.3.1.1. One minute geometric mixing 
The first set of studies focussed on the impact of particle size characteristics of pre 
gelatinised starch on content uniformity. The results presented in (Figure 4.4) showed 
that blending for one minute using different particle size fractions of pregelatinised 
starch in various ratios resulted in poor drug recovery. Although the deviation 
increased with the increase in dilution, all the different batches that were tested failed 
the content uniformity test.  Similar trends were observed for non-sieved as well as 
cohesive blends. Despite the failure to meet the required pharmacopeia standards for 
drug recovery, the results showed some interesting trends. It would be expected that 
cohesive powders would potentially result in non-uniformity due to particle aggregation 
whereas non-sieved powders would generate a more uniform drug mix. From the 
current study, it can be clearly seen that the recovery was the least from non-cohesive 
blends followed by non-sieved and cohesive powders. Although the cohesive blends 
provide greater surface area for particle interaction, the short blending duration (1 
minute in this case) ensures that particle aggregation is controlled thereby resulting in 
a slightly better distribution and recovery of the drug. On the other hand, despite the 
good flow properties of the other two mixtures, uneven particle distribution possibly 
resulted in segregation and low drug recovery. One-way Analysis of Variance 
(ANOVA) for the data set demonstrates that p value was <0.05. 
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Figure 4.4: Influence of drug: carrier ratio and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and pregelatinised starch (non-sieved, 
cohesive and non-cohesive) mixed at various ratios (1:5, 1:10, 1:20 and 1:50) using geometric 
mixing for 1minute (mean± SD, n=9). 
Studies investigating dilution and blending using starch showed similar results as 
shown in (Figure 4.5). The different grades of starch (with different particle sizes) in 
the various ratios tested resulted in low drug recovery. All the batches that were tested 
failed the regulatory requirement. The results showed that the percentage drug 
recovery decreased with an increase in dilution of the drug with the carrier. The 
cohesive blend of starch resulted in lower drug uniformity with the increase in dilution 
compared to non-sieved this could be attributed to the high cohesive nature of the 
starch. 
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Figure 4.5: Influence of drug: carrier ratio and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and starch (non-sieved and cohesive) mixed 
at various ratios (1:5, 1:10, 1:20 and 1:50) using geometric mixing for 1minute (mean± SD, 
n=9). 
There was a significant difference between the different ratios for MCC (p<0.05, two 
way-ANOVA) (Figure 4.6). Further, the non-sieved grade was superior to the other 
grades in term of content uniformity. Overall, geometric mixing for one minute for all 
carriers including pregelatinised starch, starch as well as MCC did not meet the 
required uniformity range. Nevertheless, non-cohesive pregelatinised starch together 
with ergocalciferol in various ratios was shown to be produce statistically insignificant 
drug uniformity.  
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Figure 4.6: Influence of drug: carrier ratio and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and MCC (non-sieved, cohesive and non-
cohesive) mixed at various ratios (1:5, 1:10, 1:20 and 1:50) using geometric mixing for 1minute 
(mean± SD, n=9). 
4.3.3.2. Effect of increasing blending time on drug content uniformity  
Based on the results achieved from the earlier experiment, the time of mixing was 
elevated up to five minutes from one minute. The rationale was to determine if longer 
blending time would promote uniform distribution and aid diffusion of the API particles 
within the carrier particles. The longer the time for mixing, greater is the time of contact 
between all the particles and this may induce better homogeneity due to more chances 
of collision and particle distribution (Muselík et al., 2014).  
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Figure 4.7: Influence of drug: carrier ratio and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and pregelatinised starch (non-sieved, 
cohesive and non-cohesive) mixed at various ratios (1:5, 1:10, 1:20 and 1:50) using geometric 
mixing for 5 minute (mean± SD, n=9). 
The results obtained in (Figure 4.7) showed that drug recovery was complete and all 
the ratios tested showed that prolonged blending time resulted in complete drug 
recovery. The results showed no significant difference (one-way ANOVA, p>0.05) 
between the different ratios of pregelatinised starch. Similar trends were obtained 
when pregelatinsed starch was replaced with starch (Figure 4.8). It can be 
hypothesised that the increase in blending time promotes better distribution of the drug 
irrespective of the particle characteristics and the type of the carrier. The process of 
powder blending is influenced by different forces including diffusional, shear and 
convective forces. In the method employed for geometric blending, it can assumed that 
the impact of shear forces would be minimal as the powder particles are not subjected 
to higher magnitude forces as that would be obtained in fluidised bed or high speed 
blenders. It is likely that the resultant uniform mix of the powder blend for both the 
carriers with different particle size fractions could be due to the combination of diffusion 
and convective blending. In the case of non-sieved and free flowing powder blends, 
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convective mixing ensures the transport of powder bed from one location to the other. 
This allows for the movement of large particles from one area of the mixing vessel to 
the other generating a random blend. The results from the investigation above where 
the duration of blending was one minute possibly initiated the transfer of the bulk 
powder without the generation of a consistent random mix (Muselík et al., 2014). 
Following the increase of the duration of blending, it is likely that the movement of 
powder beds through convection increases the distribution of the particles of the drug 
between the carrier particles resulting in the generation of a random mix.  The longer 
duration of blending also ensures that diffusional mixing promotes movement of 
particles at the micro-level thereby enhancing content uniformity. The longer duration 
of powder blending results in prevention of de-mixing which can take place before an 
ultimate random state is obtained. Cohesive blends on the other hand present a 
different set of challenges. Although the increase in blending time resulted in a uniform 
mix for both the carriers containing cohesive powders, the outcomes can be explained 
based on the processes that occur during dry cohesive blending. 
Figure 4.8: Influence of drug: carrier ratio and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and starch (non-sieved and cohesive) mixed 
at various ratios (1:5, 1:10, 1:20 and 1:50) using geometric mixing for 5 minute (mean± SD, 
n=9). 
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Previous research has shown that cohesive blends segregate due to multiple factors 
including particle shape, size and the intensity of cohesion (Tang and Puri, 2004). The 
process of blending for cohesive powders relies on not only the properties of the 
cohesive particles but also on the adhesive interactions in a binary mixture. Simulation 
studies for dry blending of cohesive mixtures by (Chaudhuri et al., 2006) confirmed 
that the extent and intensity of the cohesive forces between similar particle sizes 
controls the degree of segregation which ultimately impacts on the homogeneity of the 
powder blend. The studies showed that the presence of low intensity cohesive forces 
promotes mixing possibly due to the larger surface area available for the particles 
within the binary mixture to achieve a random state of distribution. In our study, it can 
be concluded that the intensity of the cohesive forces between the particles for both 
carriers is relatively weak thereby ensuring that aggregation between similar particles 
is reduced and therefore promotes a more uniform distribution of the particles of the 
drug (i.e. mixing drug-carrier). Interestingly, the non-sieved MCC formulation displayed 
ideal uniformity whereas the non-cohesive and cohesive formulations became slightly 
less uniform as shown in (Figure 4.9). The difference between these formulations was 
significant (p<0.05), indicating that the increasing mixing time still showed benefit for 
obtaining uniformity with the largest particle size. 
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Figure 4.9: Influence of drug: carrier ratio and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and MCC (non-sieved, cohesive and non-
cohesive) mixed at various ratios (1:5, 1:10, 1:20 and 1:50) using geometric mixing for 5 minute 
(mean± SD, n=9). 
Although the results for the 5 minute mixing were promising, the true focus for this part 
of the investigation was the API dilution ratio (1:50 formulations) for which 8 batches 
were created for each carrier type. Therefore, it becomes evident that geometric 
addition with 5 minute mixing serves to improve uniformity for highly dilute blends 
(1:50) compared to 1 minute mixing. A similar need for increasing blending time for 
dilute blends was found by (Kornchankul et al., 2002) for the drug Buspirone between 
two blends of differing concentrations.  
4.3.3.2. Ordered blending technique 
Following investigations of geometric blending, ordered mixing using bulk powder 
quantities was investigated to study the impact on drug content uniformity. Ordered 
bulk mixing represents a more convenient method from an industrial perspective due 
to the availability of a wide range of equipment and relatively shorter processing time. 
0
20
40
60
80
100
120
140
01:05 01:10 01:20 01:50
%
 E
rg
o
ca
lc
if
e
ro
l
Ergocalciferol: MCC Ratio (w/w)
Non-sived MCC Non-Cohesive MCC Cohesive MCC
Chapter 4 
168 
4.3.3.2.1. Ordered blending using manual blending 
The objective of this study was to determine the time dependent effect on content 
uniformity during bulk mixing using a manual blending technique. The 1:50 ratio was 
chosen for this technique as it represents the maximum dilution potential for the drug 
that was used in our previous studies. This technique was carried out to find the 
relationship between percentage drug recoveries with respect to time. Blending was 
performed until a constant relative standard deviation for drug content was obtained. 
Similar to the above investigations, the three different particle size ranges for the three 
carriers were investigated. 
Figure 4.10: Influence of processing time and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and pregelatinised starch (non-sieved, 
cohesive and non-cohesive) mixed at drug: carrier ratio of 1:50 using vigorous hand blending 
technique (mean± SD, n=9). 
The results in (Figure 4.10) demonstrate that content uniformity increased with 
blending time with all forms of pregelatinised starch and the highest percentage drug 
content uniformity was achieved after 32 minutes in all three forms of pregelatinised 
starch. Cohesive pregelatinised starch showed the highest percentage of drug 
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recovery at various time points when compared to the non-cohesive blends. For 
example, after half an hour of physical mixing, cohesive powder of pregelatinised 
starch showed highest content uniformity of about 75% while non cohesive was lowest 
around 55% (ANOVA, p<0.05). Interestingly these results are similar to that obtained 
using geometric blending where the cohesive blends of pregelatnised starch 
outperformed the non-cohesive mixtures despite all the three grades not achieving the 
pharmacopeia standards.  
Figure 4.11: Influence of processing time and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and starch (non-sieved and cohesive) mixed 
at drug: carrier ratio of 1:50 using vigorous hand blending technique (mean± SD, n=9). 
In the case of starch with ergocalciferol as shown in (Figure 4.11)  it was observed that 
the increase in percentage of drug recovery was exhibited by non-sieved starch (one 
way ANOVA, p>0.05). The non-sieved MCC reached the lowest acceptable level of 
uniformity at 32 minutes of mixing as shown in (Figure 4.12). However, smaller 
particles allowed for faster achievement of uniformity within a powder blend (Rohrs et 
al., 2006). It is evident from the graph that the relative standard deviation for all the 
samples as shown in (Figure 4.13) followed a similar pattern. The results showed that 
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the standard deviation began to plateau just after five minutes and there was no 
difference until the conclusion of the study. 
Figure 4.12: Influence of processing time and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and MCC (non-sieved, cohesive and non-
cohesive) mixed at drug: carrier ratio of 1:50 using vigorous hand blending technique (mean± 
SD, n=9). 
Using this type of mixing, all batches for the three carriers (except non-sieved MCC) 
did not achieve the requirements of BP for drug content uniformity of ergocalciferol 
(90-120%). Figure 4.13 shows relative standard deviation (RSD) for ergocalciferol 
based on 1:50 pregelatinised starch, starch and MCC after physical mixing over 
different time points. It was observed that RSD for ergocalciferol was the lowest for 
non-sieved MCC which showed an initial value of 15% at 0 minute which decreased to 
approximately 1% after 32 minutes. Hence, non-sieved MCC had the lowest standard 
deviation compared to all carrier formulations. The graph demonstrates that the drug 
distribution for the different types of blends requires longer duration to obtain more 
homogenous blend. The higher deviation at the start indicates that the drug is 
concentrated in various pockets comprising of “drug-concentrated” areas which need 
to be relocated within the bulk of the diluent. Continuous blending ensures that 
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convective mixing predominates and the drug has the opportunity to distribute itself 
between the carrier particles. The standard deviation begins to plateau after about five 
minutes which possibly suggests that the drug rich domains have been redistributed 
randomly within the bulk of the carrier. It is possible that after the first five minutes, the 
diffusional mixing predominates and therefore micro mixing of the drug between the 
particles is the key factor. Despite the expected cohesive forces between the smaller 
particles fractions which can promote aggregation, it is possible that weak/lower 
intensity forces operate which ensure that diffusional micro mixing predominates over 
the cohesive interactions. 
Figure 4.13: Influence of processing time, carrier type and carrier particle size on blend 
homogeneity as expressed in RSD. Blends are made of ergocalciferol and carrier mixed at 
drug: carrier ratio of 1:50 using vigorous hand blending technique (n=3). 
The likely variation when mixing by hand poses problems as it cannot be standardised 
enough to eliminate any experimental error, particularly with rate and force of mixing 
applied to the mixing vessel. Furthermore, hand mixing is not a viable mixing process 
for scaling-up and therefore machine mixing was investigated. 
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4.3.3.2.2. Ordered mixing using dry powder mixing device 
The last method of blending included investigation of a dry powder blender/coater as 
a technique to generate homogenous powder blends. Hersey (1975) and Ishizaka 
(1989) ((Hersey, 1975, Ishizaka et al., 1989) described “ordered mixing” as cohesive 
powder mixing process where fine particles are dispersed/attached to the surface of 
coarse particles to generate an ˝interactive mixture˝. 
The blending device used in this study was built at Aston University. The device 
consists of a rotating chamber fitted on to a central fixed shaft. The fixed shaft is 
perforated allowing for fluidisation of powder. In the current study the speed of the 
device was fixed at 300rpm with no air injection. The speed was chosen after 
optimisation studies in another project within our group showed that higher speeds 
lead to the formation of dry coated particles whereas lower speed promotes 
homogenous blending and formation of interactive/ordered blend. The total amount of 
powder blends was 3 g. Three samples were taken out for each batch: first sample 
was 5 mg taken from the right side, second sample from the middle and the third 
sample from left side. In interactive mixing using dry powder mixing device, the mixing 
process of the mixture depends on two forces. The adhesion forces of the API to the 
carrier particles and the cohesion forces between the drug particles. Proper mixing will 
be achieved and no agglomerates will be left only if the adhesion force between 
materials is greater than the cohesive forces between similar particles (Lohrmann et 
al., 2007). Based on the results obtained from ordered mixing using manual blending, 
the dry powder mixing device at speed 300 rpm was investigated in order to promote 
uniform distribution of the drug between the carrier particles.  
The results obtained in (Figure 4.14, 4.15 and 4.16) showed that drug recovery was 
achieved after 4, 32 and 2 minutes of mixing for all blends of pregelatinised starch, 
starch and MCC respectively. The possible reason behind the enhancement of drug 
uniformity is a result of sufficient mixing process that included different forces such as 
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convective, shear and diffusional forces. Two-way analysis of variance (ANOVA) test 
and Tukey’s test demonstrated a statistically significant difference between batches 
and between each batch with different times (p<0.05). It can be hypothesised that the 
impact of shear forces was achieved after 16 minutes of mixing, so that the deviation 
sharply decreased with all forms of carriers at 32 minutes of mixing.  
Figure 4.14: Influence of processing time and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and pregelatinised starch (non-sieved, 
cohesive and non-cohesive) mixed at drug: carrier ratio of 1:50 using interactive blending 
technique (mean± SD, n=9). 
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Figure 4.15: Influence of processing time and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and starch (non-sieved and cohesive) mixed 
at drug: carrier ratio of 1:50 using interactive blending technique (mean± SD, n=9). 
Figure 4.16: Influence of processing time and carrier particle size on content uniformity of 
ergocalciferol. Blends are made of ergocalciferol and MCC (non-sieved, cohesive and non-
cohesive) mixed at drug: carrier ratio of 1:50 using interactive blending technique (mean± SD, 
n=9). 
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From (Figure 4.17), it was seen that the RSD for ergocalciferol was the highest for non- 
sieved and cohesive starch which showed an initial RSD of 85% and 80% at 0 minute 
and decreased to approximately 5% in 32 minutes.  
Figure 4.17: Influence of processing time, carrier type and carrier particle size on blend 
homogeneity as expressed in RSD. Blends are made of ergocalciferol and carrier mixed at 
drug: carrier ratio of 1:50 using interactive blending technique (n=3). 
4.3.3.2.3. Mixing of 0.5% and 1 % of API: non-sieved carrier using dry powder 
blending device 
The blending process was then carried forward to investigate two further diluted 
batches of API (Figure 4.18 and 4.19). These blends were closer to low dose levels 
seen in manufactured formulations (Zheng, 2009). Although the 1% formulation was 
at an acceptable uniformity only for MCC after 8 minutes of mixing (99%), 
pregelatinised starch and starch formulations achieved uniformity after 16 and the full 
32 minute mixing period respectively. Therefore, it is clear from (Figure 4.18) that less 
time was required to get good content uniformity (8 minutes) with MCC compared to 
pregelatinised starch and starch that required longer mixing durations with less 
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homogeneous blend. On the other hand, more time was required for starch as 
significantly more blend was present in the non-mixing zone which was observed after 
mixing was ceased. Thus, Any API held in this zone would have a greater impact on 
sample uniformities obtained, and this problem is well documented with low dose 
blends (Zheng, 2009). Furthermore, a smaller API concentration would be more likely 
to experience segregation of API due to the comparatively reduced interactions with 
the larger MCC particles, as well as the tendency for API to form agglomerates in 
blends at concentrations below 3% (Muzzio et al., 2002, Alchikh-Sulaiman et al., 2016). 
Figure 4.18: Influence of processing time and carrier type on content uniformity of 
ergocalciferol. Blends are made of 1% ergocalciferol and non-sieved carrier (pregelatinised 
starch, starch and MCC) mixed using interactive blending technique using the novel dry powder 
coater at 300rpm (mean± SD, n=9). 
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Figure 4.19: Influence of processing time and carrier type on content uniformity of 
ergocalciferol. Blends are made of 0.5% ergocalciferol and non-sieved carrier (pregelatinised 
starch, starch and MCC) mixed using interactive blending technique using the novel dry powder 
coater at 300rpm (mean± SD, n=9). 
However, in this study, it is expected that homogeneity with MCC and pregelatinised 
starch was achieved earlier due to the formation of ordered mixing between fine API 
particles and the surface of the excipient. These two excipient surfaces showed high 
degree of roughness that will promote the interactive blend formation. The energy 
produced within the device throughout the processing time will enable the break of API 
agglomerates and aid collision between particles through both convective and 
diffusional currents resulting in interactive blends. 
4.3.4. Effect of different order of mixing on powder flow 
The secondary aim of this study was to provide a systematic investigation of the effect 
of mixing order of excipients mannitol, MCC, crospovidone and magnesium stearate 
on powder flow and tablet characterisation in the formulation of compressed ODTs. 
These excipients were selected based on their role as binder, filler, or dual functional 
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binder/disintegrant systems. The formulation and the processing parameters are listed 
in (Table 4.8). 
Table 4.8: Formulation content, order of blending mannitol, MCC, crospovidone (Cros) and 
magnesium stearate(Mg. Stearate) and processing parameters for pharmaceutical excipients 
using dry mixing device. 
Formulatio
n 
Mannitol 
(64.5%) 
MCC 
 30% 
Cros 
(5%) 
Mg. 
stearate 
(0.5 %) 
Mixing 
technique 
Duration 
per blend 
(min) 
Speed 
(rpm) 
Batch 
size 
(gm) 
F1   1 2        3 4 Interactive 
Interactive 
Interactive 
   5 
   5 
   5 
300   20 
  20 
  20 
F2   1 3        2 4 300 
F3   3 1        2 4 300 
Prior to studying the compaction properties of quaternary mixtures, powder 
characterisation of the individual powders and mixtures were investigated to 
understand the compaction mechanism of materials and determine the impact of order 
of each excipient in quaternary blends (Table 4.9). 
Table 4.9: Flow properties of starch, magnesium stearate (Mg.stearate), Mannitol, 
crospovidone, F1,F2 and F3 showing the particle size analysis parameters (X10, X50, X90, 
Span and volume mean diameter (VMD)), angle of repose (°) and the corresponding flow 
property. (F1: mannitol and MCC mixed at first stage, crospovidone was added at stage 2, F2: 
mannitol and crospovidone mixed at first stage, MCC was added at stage 2 and F3: MCC and 
crospovidone mixed at first stage, mannitol was added at stage 2. Magnesium stearate added 
at the end and mixed for 2 minutes. 
Product X10 X50 X90 VMD 
(µm) 
Span θ 
(°) 
Flow 
property 
Mg 
stearate 
1.35±0.01 5.49±0.0
7 
25.16±1.2
1 
10.4±1.3
9 
4.33±0.
19 
47.38±2.
75 
Poor 
Mannitol 4.51±0.17
4 
28.06±0.
61 
75.02±6.8
5 
34.99±2.
37 
2.52±0.
18 
46.56±
4.92 
Poor 
Crospovid
one 
8.66±0.14 22.74±0.
49 
55.66±5.0
1 
29.37±2.
73 
2.09±0.
19 
31.22±
4.25 
Good 
F1 8.71±0.09 36.32±0.
36 
108.31±2.
55 
47.7±0.7
4 
2.74±0.
05 
42.8±4.
56 
Passable 
F2 8.51±0.09 36.27±0.
59 
110.91±2.
26 
47.98±1.
00 
2.82±0.
02 
43.74±
1.36 
Passable 
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F3 8.64±0.14 36.08±0.
51 
105.87±1.
27 
47.06±0.
54 
2.71±0.
01 
36.67±
1.11 
Fair 
Mannitol showed a high angle of repose 46.56±4.92 whereas crospovidone 
demonstrated a slightly lower value of 31.22±4.25. Based on the classification (Table 
4.9), mannitol has poor flowability and crospovidone has good flowability. The 
flowability for all formulations, prepared at various order of blending was passable (F1 
and F2) and fair (F3), however no significant difference (P>0.05) was observed for the 
measured angle of repose for all the different mixtures studied. An enhanced flow was 
showed in powders F3 and, where the largest amount of agglomeration was formed. 
It was hypothesised that the larger agglomerated particles lost the needle shaped 
feature of mannitol and had reduced cohesive forces and levels of segregation which 
resulted in slightly improved powder flow (Koner et al., 2015). 
 Kaerger, et al. examined the influence of particle size and shape on the flowability and 
compactibility of paracetamol and MCC mixture. It was identified that blend prepared 
from small particles exhibited increased angle of repose and densification of the 
blends; these findings support the observations of this study (Kaerger et al., 2004). 
Mean volume distribution (VMD) for mannitol was 34.99 µm and median (X50) was 
28.06μm. Mannitol shows a particle size distribution pattern with a span of distribution 
of 2.52 and 90% of mannitol particles were below 75.02μm indicating that the largest 
proportion of the powder mix is made of fine powder. 
4.3.5. Effect of different order of mixing on tablet properties 
In this section tablet properties containing the different order of mixing of excipients 
were investigated. Nearly all ODT products contain mannitol as formulation diluent as 
it has low hygroscopicity profile as well as the sweetness and creamy mouth feel. 
However, the main disadvantage of powdered mannitol is the poor compaction 
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property usually resulting in low tablet hardness and subsequent unacceptable friability 
levels (Al-Khattawi et al., 2012). 
4.3.5.1. Mechanical properties of ODTs 
Commonly, tablet dosage forms are exposed to various mechanical stresses during 
the manufacturing steps, transportation and handling by patients. Thus a successful 
tablet formulation must have a sufficient mechanical strength. The results for hardness 
of tablets made from quaternary mixtures of fixed concentrations of 30% w/w MCC, 
64.5% (w/w) of D-mannitol, 5% w/w crospovidone and 0.5% w/w magnesium stearate 
showed similar results of hardness for all formulations (p>0.05) (Figure 4.20). The high 
crushing strength for all ODTs formulations (> 70 N) possibly due to the addition of 
MCC which could be explained by the microfibrillar structure of the MCC which has 
been exhibited to show mechanical interlocking, thus , preventing extensive stress 
relaxation (Bolhuis et al., 1996). 
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Figure 4.20: The hardness and friability profile of different order of blending of ODTs, 30% w/w 
MCC, 5% w/w crospovidone , 64.5% w/w mannitol and 0.5% magnesium stearate. (F1: 
Mannitol and MCC mixed first, crospovidone second, F2: mannitol and crospovidone mixed 
first, MCC second and F3: MCC and crospovidone mixed first, mannitol second. Magnesium 
stearate added at the end and mixed for 2 minutes then compressed at 10 KN. Values for 
hardness are represented as mean ± standard deviation (n=3). 
Similarly, the results for friability for all batches did not achieve the pharmacopeial limit 
of <1% (Figure 4.20). Based on previous study a further increase of MCC concentration 
might yield lower friability due to the binding property of MCC. Furthermore, 
enhancement in friability of MCC based tablets is attributed to the high plasticity of 
MCC and mechanical interlocking ability which overcome the poor binding capacity 
leading to tablets with acceptable physico-mechanical properties. (Al-Khattawi et al., 
2014a). 
4.3.5.2. Disintegration time and porosity studies 
The assessment of disintegration time is considered an essential issue in optimising 
and developing orally disintegrating tablets. According to the U.S. FDA specification, 
the disintegration time of such tablets should not exceed 30 seconds (FDA, 2008). 
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Although, all formulations showed no significant difference in disintegration time 
(ANOVA, P>0.05), lower tablet disintegration time was observed with F2 which was 
approximately 22 seconds (Figure 4.21). It is possible that as MCC was added and 
mixed in the second stage (mannitol and crospovidone mixed first, then MCC) the 
surface access of MCC to water entering into the tablet promotes faster disintegration 
of the tablets. (Reier and Shangraw, 1966).  
Figure 4.21: The disintegration time and porosity profile of different order of blending of ODTs, 
30% w/w MCC, 5% w/w crospovidone, 64.5% w/w mannitol and 0.5% magnesium stearate. 
(F1: Mannitol and MCC mixed first, crospovidone second, F2: mannitol and crospovidone mixed 
first, MCC second and F3: MCC and crospovidone mixed first,mannitol second. Magnesium 
stearate added at the end and mixed for 2 minutes then compressed at 10 KN. Values are 
represented as mean ± standard deviation (n=3). 
The porosity of the ODTs at various order of blending is summarised in (Figure 4.21). 
The results showed that produced tablets for all formulations with insignificant 
differences in their total porosity (p>0.05). However, as all tablets in this study were 
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produced using the same procedure and the same materials, any differences in their 
porosity would have been attributed to the change in the order of mixing. 
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4.4. Conclusion 
The development of formulation with low API content is challenging and requires a 
proper understanding of API and excipients properties. In this study, it was found that 
flow properties improved as particle size increased, with the non-sieved, non-cohesive 
MCC and non-cohesive pregelatinised starch having excellent flow whereas the 
cohesive pregelatinised starch and starch had an angle of repose just outside the 
threshold of being considered to have poor flow properties. In case of geometric mixing 
technique for 1 minute all formulations failed to meet the required pharmacopeial 
standards for drug content uniformity. Therefore, an increase in mixing time to 5 
minutes with geometric addition showed considerable uniformity improvements for all 
carrier types. Ordered mixing with the dry powder coater allowed for uniformity to be 
reached faster than hand order mixing, and was able to keep the blend containing 
cohesive powder within the acceptable uniformity range throughout the mixing period. 
The powder coater was also useful in obtaining good uniformities at 0.5% and 1% API 
using non-sieved carrier. All blends showed acceptable uniformity after the 32 minute 
mixing period, with the 1% API also achieving this only for MCC after 8 minutes of 
mixing, whereas the 0.5% API with MCC blend reached ideal uniformity at the end of 
16 minutes mixing period. This study also highlighted the importance of excipient 
mixing order for (Mannitol, MCC, crospovidone and magnesium stearate) on tablet and 
powder properties. Although all formulations (F1-F3) demonstrated similar results for 
powder and tablets characterisations (no significance difference), powders flows were 
fair to passable for all batches whilst MCC alone showed excellent flow property. The 
inclusion of excipients with high plastic deformation proficiency (MCC) improved tablet 
hardness and reduced friability. The resultant mixture tablets exhibited good hardness 
and friability profile. Overall, it is critical to realize that mixing order has significant 
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impact on blend and tablet properties. The study concluded that MCC showed better 
% drug content uniformity in both the mixing techniques. 
Chapter 5 
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5.1. Introduction 
Tablets are extensively used as drug delivery system due to their suitability with 
respect to self-administration and ease of manufacture (Jivraj et al., 2000). 
(Bhattacharyya et al., 2006). Nonetheless, paediatric and geriatric patients experience 
difficulties in swallowing conventional tablets, which leads to poor patient compliance. 
To overcome this limitation, ODT formulations have been developed which provide the 
advantages of both a solid dosage form as well as a liquid preparation (Jonwal et al., 
2010). Regardless of the growing popularity and success of ODTs over the last 
decade, many challenges still face the development of these tablets. For example, the 
number of fillers/binders/glidants which can be selected for ODT formulations is limited 
because these bulk excipients have to fulfil special requirements, such as being 
soluble in water, pleasant taste, mouth feel, sweetness, hardness and rapid 
disintegration in the mouth (Gohel and Jogani, 2005). Consequently, novel co-
processed excipients blends have been developed which satisfy the need of more than 
one excipient (summarized in Table 5.1). 
Furthermore, the inclusion of these co- processed excipients alongside API in ODTs 
may provide a solution for the poor mechanical strength/high friability profile 
investigated for individual excipients such as mannitol (Al-Khattawi et al., 2012). 
Hence, the incorporation of adjuvant excipients combined with mannitol, such as 
binders, disintegrants or combined systems of both is essential. For this reason, dry 
powder coating technique was developed in order to enhance the quality of material 
which resulted in introducing a strong adhesion of the fine particles on the surface of 
carrier particles, providing homogenous free flowing mixture (Alderborn et al., 1988, 
Honda et al., 1994, Pfeffer and Dave, 2001). 
The work in this chapter aims to develop a novel co- processed blend including starch 
1500, D-mannitol and silica for use in ODTs, that has the ability to disintegrate in a 
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matter of seconds (< 30 sec) with suitable tablet mechanical strength ( Hardness > 50 
N). It was hypothesised that starch 1500 powder coated with milled- mannitol and silica 
will overcome the significant challenge of very poor flow of milled mannitol.  
- The objectives in this study were:
- To optimise the process parameters and mixing types using dry powder composite
coating device. 
- Investigate the effect of inclusion of API (Ibuprofen) and silica concentrations on the
powder flow and ODT properties. 
- Understanding the dry powder coating process using a range of quantitative and
microscopic techniques. 
Table 5.1: Overview examples of marketed co- processed excipients blend. Adapted from 
(Chaudhary et al., 2010) (Kathpalia and Jogi, 2014). 
Co-Processed 
Excipients  
Manufacturer Composition      Advantages 
   Ludiflash® BASF 
(Germany) 
Mannitol-90 
Kollidon® CL-SF-
5 
Kollicoat® 
Rapidly disintegration time 
Good mechanical strength 
Good flowability 
    ProSolv® JRS (USA) MCC- 98
Silicon Dioxide
Better flow 
Less sensitivity to wet 
granulation,  
better tablet hardness 
StarCap1500® 
Colorcon (UK) Maize Starch, 
Pregelatinized 
Starch 
Good flowability 
Excellent disintegration time 
Pharmaburst ™ 
500 
SPI Pharma 
(USA) 
Mannitol, Starch, 
Crosspovidone, 
Cross  
Carmellose 
Sodium,  and 
Collidal Silica 
Rapid disintegration for ODT 
tablets 
Good palatability 
F-MELT Fuji (Japan) mannitol, xylitol, 
MCC, 
crospovidone 
fast disintegration time 
good flow 
Less capping 
pleasant mouth-feel 
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5.2. Materials and Methods 
5.2.1. Materials 
D-Mannitol and Rhodamine B were obtained from Sigma-Aldrich (Dorset, UK).
Magnesium stearate was purchased from Fischer Scientific (Loughborough, UK), while 
pregelatinised starch (starch 1500®) was obtained from Colorcon (Dartford Kent,UK). 
Ibuprofen was purchased from Discovery Fine Chemicals (Dorset, UK), whereas 
microcrystalline cellulose (PH-200) was donated by FMC BioPolymer Europe 
(Brussels, Belgium). Colloidal silicon dioxide (SiO2) (AEROSIL® 200 Pharma) was 
used as received from Degussa AG (Düsseldorf, Germany).  
5.2.2. Methods 
5.2.2.1. Preparation of Ball Milled Mannitol 
Milled mannitol samples were prepared using a Fritsch Pulverisette 7 planetary ball 
mill (Idar-Oberstein, Germany) according to parameters ( speed 200 rpm, time 30 
minutes and weight of powder 3.614 g) optimised by our team in a previous study 
(Koner et al., 2015). Powders were accurately weighed, the weighed samples were 
transferred into agate vials (45 cm3 volume) along with 13 agate balls (diameter 10 
mm). The vials were sealed with a plastic ring to avoid atmospheric contamination.  
5.2.2.2. Preparation and optimisation process of ODTs pre-blends using 
interactive and composite powder coating technique 
The three key excipients studied included pregelatinised starch (starch 1500), mannitol 
and silica. Both D-mannitol (milled and un-milled) with starch1500 were composite 
mixed for 30 min followed by addition of various ratios of silica ranging from 0.5 to 2% 
w/w and continuous blending for 5 minute. The composite mixing process was carried 
out considering several critical operating parameters; speed of the mixer, mixing time 
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and the use of air flow. As for the materials used, the parameters considered were 
pertinent to the guest loading percentage, measured in weight per weight, and the type 
of carrier material in terms of particle size and shape. Samples were tested alongside 
interactive mixtures with the same content, but mixed at low speeds (200rpm) using 
cube mixer. The schematic in (Figure 5.1) illustrates the different mixing techniques 
used to optimise pre-blends.  
Figure 5. 1: A schematic representing an example of mixing process using 12% w/w starch 
1500, 87.5% milled mannitol and 0.5% w/w silica. 
5.2.2.3. Characterising pre-blend powder 
5.2.2.3.1. Powder flow properties (angle of repose method) 
The angle of repose measurement was performed using the recommended British 
Pharmacopeia procedure (Pharmacopoeia, 2012).  Approximately 10 g of powder was 
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poured through a funnel into a base free from vibration to form a pile. The funnel was 
positioned 2 - 5 cm from the top of the powder pile as it was forming. Angle of repose 
was determined by measuring the height of the pile (h) and diameter of the base (d); 
then angle of repose (α) was calculated from the equation: 
tanα = h ÷ (0.5 × d) 
5.2.2.3.2. Particle size analysis 
Particle size of the powders was measured by the laser diffraction technique using 
HELOS/BR particles size analyser equipped with a RODOS dry disperser with VIBRI/L 
vibrating feeder, from Sympatec (Clausthal-Zellerfeld, Germany). The measuring 
range of the lens was 0 - 175µm. About 1 g of each powder was placed in the feeder 
tray and the run started at trigger condition of 2% Copt (optical concentration) for 10 
sec with a powder dispensing pressure of 2bar. Volume mean diameter (VMD) was 
recorded for the powders and all the measurements were examined in triplicate. 
5.2.2.3.3. Scanning electron microscopy (SEM) 
The morphology of starch 1500, milled and un- milled D-mannitol, the mixture and the 
coated powder particles were examined using a Carl Zeiss EVO LS 15 from Cambridge 
Instruments (Crawley, UK) scanning electron microscope (SEM). Approximately 1-2 
mg of each material was placed onto a double-sided adhesive strip on an aluminium 
stub. The specimen stub was coated with a 15nm of gold using a Quorum QR105S 
sputter coater from Polaron Equipment ltd. (Watford, UK) at 20 mA for 3 min followed 
by sample examination using SEM. The acceleration voltage (kV) and the 
magnification can be seen on each micrograph. Various magnifications were applied 
to identify characteristics of the powders. 
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5.2.2.3.4. Confocal laser scanning microscopy (CLSM) 
This technique was used to confirm coating, 15% rhodamine B (a known fluorescent 
probe) was used as a guest material with 85% microcrystalline cellulose (MCC) as 
carrier material. MCC (mean particle size was sieved to be similar to starch 1500, 60 
µm) was chosen due to auto- fluorescence of starch 1500 (discussed in results 
section). Dry coating process was run for 60 minutes in two stages at 2000 rpm and 
nitrogen gas pressure set at 3 bars. Rhodamine B was micronized using mortar and 
pestle and passed through sieve with mesh size of 38μm and the sample retained at 
sieves with pores size of 20μm was used. Confocal microscopy was carried out 
according to the method reported in (Korlach et al., 1999), the samples (control, first 
coated sample and second coated) were then observed on a Leica Microsystem 
confocal microscope (TCS SP5 II) using a 10 X dry objective. Fluorescence 
micrographs of the labelled MCC particles were obtained using confocal microscope 
equipped with a Tunable Multiphoton Laser z-stacking and detector. The samples were 
measured at wavelength 543 nm and placed on a slide without any further treatment.  
5.2.2.3.5. Quantitative analysis of fluorescence intensity particles using ImageJ 
To quantify coated material (rhodamine B) levels in particles, a single in-focus smooth 
was acquired. Using ImageJ (v1.48, NIH), an outline was drawn around each particle 
and regions of interest included circularity, area, integrated density, mean fluorescence 
measured, along with several adjacent background readings (appendix 12). The total 
corrected fluorescence was calculated using equation below (McCloy et al., 2014). For 
first and second coated samples, 0.3 μm z-sections were taken, de-convoluted, and 
shown as Interactive 3D Surface Plot maximum projections using ImageJ.  
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CTF =  Int Den − (Area of selected particle × Mean  fluorescence of background readings) 
     Where CTF is corrected total fluorescence and Int Den is integrated density.  
5.2.2.3.6. Calculation of surface coverage 
Surface coverage was calculated using the equation and method described in(Yang et 
al., 2005). The amount of guest material in weight percentage required to achieve 
100% coverage within the given parameters was as follows: 
Gwt% =
Nd3 Pd
(D3 PD) + (Nd3 Pd) 
× 100 
Here: 
N =
4(D + d)2
d2
Where d is the diameter of guest particle, D is the diameter of the host particle, Pd is 
the density of the guest particle and pD is the density of the host particle. 
5.2.2.4. Tablet preparation 
Ternary mixture pre-blend were prepared using cube mixer or dry powder coater 
comprising of the excipients using different concentration of silica (0.5, 1, 1.5 and 2 % 
w/w), varying D-mannitol or milled mannitol concentration and fixed concentration 
(12% w/w) of pregelatinised starch. Ibuprofen was incorporated at concentration 
ranging from 10 to 50% w/w. Blending of the drug and excipients pre–blend was carried 
out by cube or composite mixer for 10 min followed by adding 1% w/w magnesium and 
continues blend for 2 min. The tablets (500 mg) were prepared using a bench-top 
hydraulic press from Specac ltd. (Slough, UK) equipped with flat faced dies of 13 mm 
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diameter at fixed compression force 20 KN for 6 sec. 15 tablets were prepared at each 
drug concentration; three were used for porosity, three for hardness, three for 
disintegration time and six for friability test.    
5.2.2.4.1. Helium pycnometry for true density and porosity measurement 
True density and porosity were measured for all the powders/tablets using a helium 
multipycnometer from Quantachrome Instruments (Syosset, USA). Each powder 
(1000 mg) or tablet (500 mg) was placed into a micro sample cell and assessed for 
true volume and in turn true density. True volume Vt was obtained using the equation: 
𝑉𝑡 =  𝑉𝐶 −  𝑉𝑅  (
𝑃1
𝑃2 − 1
) 
Where Vt is true volume of the sample, VC is volume of the sample cell, VR is the known 
reference volume, P1 is atmospheric pressure and P2 is pressure change during 
determination. Vt  was used to calculate the true density of the tablet by weighing the 
tablet and substituting the values into: 
𝑇𝑟𝑢𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝑇𝑎𝑏𝑙𝑒𝑡 𝑊𝑒𝑖𝑔ℎ𝑡
𝑇𝑟𝑢𝑒 𝑉𝑜𝑙𝑢𝑚𝑒
Porosity (ε) was calculated using the equation: 
𝜀 = 1 −  (
𝐵𝑢𝑙𝑘 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
𝑇𝑟𝑢𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
) 
Bulk density was calculated from: 
𝐵𝑢𝑙𝑘 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝑇𝑎𝑏𝑙𝑒𝑡 𝑊𝑒𝑖𝑔ℎ𝑡
𝐵𝑢𝑙𝑘 𝑉𝑜𝑙𝑢𝑚𝑒
Bulk volume was acquired by measuring the radius (r) and thickness (h) of the tablet 
using a digital calliper and substituting in the equation for volume of a flat-faced tablet: 
𝑉 =  𝜋 ×  𝑟2 × ℎ 
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5.2.2.4.2. Tablet hardness 
A tablet hardness tester from Schleuniger (Thun, Switzerland) was used to investigate 
the hardness of three tablets of each formulation. Hardness is the force required to 
break up the tablet from its original structure and was measured in Newton (N) for this 
study. All measurements were carried out in triplicate and the values reported as mean 
± standard deviation. 
5.2.2.4.3. Tablet friability 
The friability test of the tablets was performed according to the USP <1216> method 
(2009) using tablet friability apparatus Sotax F2 Friabilator USP from Sotax AG (Basel, 
Switzerland). Six tablets were accurately weighed after careful de-dusting using soft 
brush, placed into the rotating drum and rotated for 100 revolutions with an average of 
25 rounds per minute. The tablets were removed and de-dusted again and accurately 
weighed. The percentages loss in weight (% Friability) was calculated using the 
following equation. 
% Friability =  
Initial Weight − Final weight
Initial weight
 × 100 
5.2.2.4.4. Disintegration time of the tablets 
The disintegration time of the tablets was investigated using a USP disintegration 
tester (Erweka, ZT3). Distilled water (800 ml) kept at 37 ºC was used as a medium and 
the basket was raised and lowered at a fixed frequency of 30 cycles/min. One tablet 
was tested at a time. All the formulations were evaluated in triplicate and standard 
deviation was calculated. 
5.2.2.5. Statistical analysis 
One way (ANOVA) followed by Tukey post-hoc test or student t-test were performed 
using GraphPad Prism 7 software (California, USA). Statistical significance was 
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considered at a p value <0.05. Where applicable, all results are presented as mean ± 
SD for triplicate measurements to account for the noise encountered within the 
experiments.   
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5.3. Results and Discussion 
The work presented in this chapter provides a new formulation preblend for ODTs 
which consists of milled-mannitol, pregelatinised starch and silica. Pre-blend products 
were obtained by composite mixing using dry powder coater. Optimisation of process 
parameters, e.g. speed, time of mixing, inclusion of air were essential on product 
quality. Similarly, optimising the concentration of excipients was crucial to produce a 
fast disintegrating tablet with good mechanical properties. The study commenced with 
the evaluation of powder flow and was followed up with particle size analysis. 
Furthermore, co-processed excipients alongside different concentration 10-50%w/w of 
API (ibuprofen) and 1% magnesium stearate as the lubricant were assessed for their 
tableting functionality. 
5.3.1. Flowability, particle size and morphological studies 
Powders prepared by blending or processing for direct compression of ODTs usually 
have poor flowability due to their smaller particle size, cohesivity and possibly non-
uniform shape (Castellanos, 2005). Initial attempts to examine dry powder coating 
technique were carried out by studying the flow properties of fine and cohesive API 
powder (ibuprofen) (Han et al., 2013), as a model drug. Ibuprofen has low solubility 
and is available as a very cohesive powder with small particle size, volume mean 
diameter (VMD) was 38±0.89 microns. The study compared interactive powder mixes 
obtained from cube mixing to dry coated powders using composite blender.  
The results showed extremely poor flowability (>50%) of non-processed and 
processed using cube mixer (i.e. interactive mixing of ibuprofen for 30 min), whilst 
composite ibuprofen showed a fair flowability (40.14 ±1.98) (Table 5.2). Analysis of 
particle size measurements for the processed ibuprofen (composite only) when 
compared to non-processed showed a significant increase in size (ANOVA, p<0.05).  
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Table 5.2: Processing technique, flow properties and particle size analysis of bulk/processed 
ibuprofen. Results reported as mean ± standard deviation (n=3). 
Formulati
ons Code 
Ingredients & 
Process  
Silica 
Conc. 
(% 
w/w) 
Time of 
Adding 
Silica 
Angle of 
Repose 
        (°) 
Flow 
property 
VMD (μm) 
F0a Ibuprofen (bulk 
powder , un-
processed ) 
N/A N/A 56.73±1.97 Very 
poor 
 37.98±0.89 
F0b Processed 
Ibuprofen  
(interactive 
mixed for 30 
minutes using 
cube mixer ) 
N/A N/A 56.70±0.89 Very 
poor 
37.66±1.08 
F0c Processed 
Ibuprofen 
(composite 
mixed for 30 
minutes using 
dry powder 
coater) 
N/A N/A 40.14±1.98 Fair 40.18±0.89 
To further support composite mixing, high speed air was introduced into the processing 
chamber which provided enhanced flow possibly due to de-agglomeration of fine and 
cohesive ibuprofen powder (Figure 5.2 iii). 
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Table 5.3: Formulation content (F1-F5), processing technique, flow properties and particle size 
analysis of pre-blend composed of un-milled mannitol or milled–mannitol  87.5% w/w, 12%w/w 
strach1500 and 0.5% w/w silica. Results reported as mean ± standard deviation (n=3). 
Formulat
ions 
Code 
Ingredients & 
Process  
Silica 
Conc. 
(% 
w/w) 
Time of 
Adding 
Silica 
Angle of 
Repose 
        (°) 
Flow 
property 
VMD (μm) 
F1 Cube 
Unmilled/Starch 
   0.5 
Added 
at the 
start 
and mix 
for 30 
min 
24.11±2.49 Very 
excellent 
45.54±2.31 
F2 Composite 
Unmilled/Starch 
22.94±2.03 Very 
excellent 
43.05±0.51 
F3 Cube 
Milled/Starch 
50.62±3.04 Poor 16.72±0.83 
F4 Composite 
Milled/Starch 
38.90±1.27 Fair 16.32±0.75 
F5 Composite 
Milled/Starch 
  0.5 Added 
at the 
end and 
mix for 
5 min 
43.64±0.82 Passable 17.49±1.20 
Figure 5.2: Visual evaluation of bulk ibuprofen (i), processed using cube mixer (ii) and 
composite (iii) using dry powder coater, after processing for 30 min. 
Based on the results obtained from the preliminary experiment, the next stage was to 
develop a pre-blend where mannitol was selected as guest material (un-milled or milled 
mannitol 41.3±0.19, 12.08±0.38 microns respectively) whereas starch1500 was used 
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as a carrier (60±0.98 microns). Additionally, a model glidant (silica) was chosen to 
provide a synergistic effect with composite mixing in order to enhance flowability. The 
processing parameters for obtaining the pre-blend were selected from a previous 
optimisation study carried out in our laboratory (Alyami et al., 2016).  
Irrespective of the processing technique (i.e. cube or composite), it is important to note 
that, pre-blend formulations containing un-milled mannitol (F1 and F2) showed 
excellent flowability (24.11±2.49 and 22.94±2.03 respectively) which was attributed to 
particle size. However, milled mannitol demonstrated poor to fair (50.62±3.04 and 
38.90±1.27) flowability (F3 and F4) respectively (Table 5.3). It is possible that milled 
mannitol has a high degree of adhesion between particles due to increase in surface 
area which in turn results in poor flow. Although milled pre-blend showed very poor 
flowability, it was taken forward to the next stage as it improved tablet properties (Koner 
et al., 2015). 
Formulation and process strategies were investigated in order to enhance flowability 
and the first approach was to study the effect of increasing glidant concentration (0.5-
2% w/w). Results as illustrated in (Table 5.4) (F6-F8) showed that increasing silica 
concentration resulted in significant improvement in flowability (ANOVA, p<0.05), for 
example, the flowability of composite/milled containing only 0.5% silica (F5) shifted 
from passable to good and excellent when 1 and 1.5% silica were added respectively. 
It was hypothesized that the fine glidant particles (19.37µm) adhere to the surface of 
the powders and increase the distance between particles, which in turn leads to a 
reduction of the forces of attraction between them. Additionally, it can be explained 
that composite mixing provides a ball bearing type effect whereby silica forms a mono 
layer on the powder particles causing them to roll over one another which reduces 
frictional and adhesive forces between the surfaces (Sheth et al., 1980, Jonat et al., 
2004). SEM analysis was carried out to confirm the degree of silica particle coverage 
and distribution on the pre-blend powder as was evidenced in (Figure 5.5 e and f). 
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Table 5.4: Effect of increasing glidant concentration (silica) of formulation content (F6-F8), on 
flow properties of pre-blend composed of milled–mannitol 86-87.5% w/w, 12% w/w strach1500 
and 1-2% w/w silica. F9 and F10 showed a strategy to enhance flow of formulation which 
contain 0.5 % silica by increasing composite mixing time to 15 and 30 min respectively. Results 
reported as mean ± standard deviation (n=3). 
Formulations 
Code 
Ingredients 
&Process 
Silica 
Conc. 
(% 
w/w) 
Time 
of 
Adding 
Silica 
Angle of 
Repose 
        (°) 
Flow 
property 
VMD (μm) 
F6 Composite 
Milled/Starch 
   1 Added 
at the 
end 
and 
mix for 
5 min 
33.15±2.13 Good 17.08±0.16 
F7 Composite 
Milled/Starch 
  1.5 26.17±1.46 Excellent 16.89±0.21 
F8 Composite 
Milled/Starch 
    2 25.97±1.19 Excellent 17.01±0.13 
F9 Composite 
Milled/Starch 
  0.5 Added 
at the 
end 
and 
mix for 
15 min 
37.31±1.66 Fair 18.99±0.86 
F10 Composite 
Milled/Starch 
  0.5 Added 
at the 
end 
and 
mix for 
30 min 
37.18±2.11 Fair 19.76±1.52 
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The second approach was based on increasing composite mixing time of pre-blend 
containing 0.5% w/w silica from 5 min to 15 min. The results showed that processing 
the blend for 15 min improved the powder flow from passable to fair , similar trend was 
obtained with processing for 30 min (F5, F9 and F10) respectively (Table 5.3 and 5.4). 
It is worth mentioning that the guest particles were more de-agglomerated and better 
distributed, with the longer processing time. 
Table 5.5: Formulation content (F11-F15), processing technique and flow properties of pre-
blend composed of un-milled mannitol or milled–mannitol  87.5% w/w, 12%w/w strach1500 
,0.5% w/w silica and inclusion of ibuprofen 10-50% w/w . Results reported as mean ± standard 
deviation (n=3). 
Formulations 
Code 
Ingredients 
&Process 
Ibuprofen 
Conc. 
(% w/w) 
Silica 
Conc. 
(% 
w/w) 
Adding 
Silica 
Angle of 
Repose 
 (°) 
Flow 
property 
F11a Cube 
Unmilled/Starch 
10 
0.5 
Added 
at the 
start 
22.16±1.65  Excellent 
F11b Cube 
Unmilled/Starch 
30 21.78±0.53 Excellent 
F11c Cube 
Unmilled/Starch 
50 17.24±0.24 Excellent 
F12a Composite 
Unmilled/Starch 
10 18.12±1.42 Excellent 
F12b Composite 
Unmilled/Starch 
30 18.41±1.18 Excellent 
F12c Composite 
Unmilled/Starch 
50 17.11±0.41 Excellent 
F13a Cube 
Milled/Starch 
10 41.87±0.81 Passable 
F13b Cube 
Milled/Starch 
30 42.75±1.97 Passable 
F13c Cube 
Milled/Starch 
50 43.93±0.49 Passable 
F14a Composite 
Milled/Starch 
10 35.68±2.63 Fair 
F14b Composite 
Milled/Starch 
30 37.48±1.13 Fair 
F14c Composite 
Milled/Starch 
50 38.41±0.91 Fair 
F15a Composite 
Milled/Starch 
10 
0.5 
Added 
at the 
end 
and 
mix for 
5 min 
43.72±1.18 Passable 
F15b Composite 
Milled/Starch 
30 45.14±0.75 Passable 
F15c Composite 
Milled/Starch 
50 47.33±0.45 Poor 
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On the other hand, the flowablity results of the composite and interactive mixtures at 
various concentrations of ibuprofen ranging from 10% to 50% are depicted in (Table 
5.5). The powder blend containing un-milled exhibited excellent flow when compared 
with milled powder batches which have poor to passable flow. Interestingly, a clear 
trend can be seen whereby increasing ibuprofen concentration decreased flowablity of 
the powders. It is possible that ibuprofen has high cohesivity and adhesivity (Liu et al., 
2008), and further support was obtained from SEM images of ibuprofen as it has a 
distinct needle shape with rough surface (Figure 5.4 i and j). However, the flowability 
of pre-blend powders were improved substantially by increasing glidant concentration 
(p value <0.05) (Table 5.6). 
Table 5.6: Formulation content (F16-F20), processing technique and flow properties of pre-
blend composed of milled–mannitol 86-87.5% w/w,12% w/w strach1500 , 0.5-2% w/w silica and 
inclusion of ibuprofen 10-50% w/w . Results reported as mean ± standard deviation (n=3). 
Formulations 
Code 
Ingredients 
&Process 
Ibuprofe
n 
Conc. 
(% w/w) 
Silica 
Conc. 
(% 
w/w) 
Adding 
Silica 
Angle of 
Repose 
    (°) 
Flow 
property 
F16a Composite 
Milled/Starch 
10       1 
Added at 
the end 
and mix 
for 5 min 
33.98±2.1
1 
Good 
F16b Composite 
Milled/Starch 
30 37.25±1.6
4 
Fair 
F16c Composite 
Milled/Starch 
50 39.19±2.7
5 
Fair 
F17a Composite 
Milled/Starch 
10     1.5 27.76±0.9
4 
Excellent 
F17b Composite 
Milled/Starch 
30 30.19±2.0
6 
Excellent 
F17c Composite 
Milled/Starch 
50 33.26±1.4
4 
Good 
F18a Composite 
Milled/Starch 
10        2 27.34±1.5
8 
Excellent 
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F18b Composite 
Milled/Starch 
30 29.21±2.1
9 
Excellent 
F18c Composite 
Milled/Starch 
50 32.98±1.6
4 
Good 
F19a Composite 
Milled/Starch 
10 
0.5 
Added at 
the end 
and mix 
for 15 min 
37.66±0.8
8 
Fair 
F19b Composite 
Milled/Starch 
30 39.21±1.5
8 
Fair 
F19c Composite 
Milled/Starch 
50 41.08±0.6
4 
Passable 
F20a Composite 
Milled/Starch 
(IBU+ pre-
blend 
composite) 
10 
0.5 
 Added at 
the end 
and mix 
for 5 min 
(IBU+ 
Pre-blend 
were 
composit
e mixed 
for 10 
minutes) 
33.75±2.3
1 
Good 
F20b Composite 
Milled/Starch 
30 36.21±1.0
6 
Fair 
F20c Composite 
Milled/Starch* 
(IBU was 
added on one 
stage ) 
50 39.32±0.9
8 
Fair 
F20d Composite 
Milled/Starch*
* 
(IBU was 
added on two 
stages) 
50 38.11±1.2
7 
Fair 
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Table 5.7: Particle size distribution parameters for Un-milled/milled mannitol, strach1500, silica 
and ibuprofen, using laser diffraction technique, (mean ±SD, n=3). 
Ingredient X10 (μm) X50 (μm) X90 (μm) VMD (μm) 
Un-Milled 
Mannitol 
6.93±0.16 34.66±0.14 84.97±0.51 41.31±0.19 
Milled Mannitol 0.84±0.01 5.16±0.21 31.95±0.87 12.08±0.38 
Starch 1500 12.09±0.37 47.66±1.12 129.22±1.42 60.00±0.98 
Colloidal silicon 
dioxide 
5.98±0.57 14.88±0.89 37.13±0.22 19.37±0.34 
Ibuprofen 7.09±055 33.08±2.38 78.40±2.38 37.98±0.89 
Figure 5.3: Particle size distribution of (a) Un-milled mannitol and (b) ibuprofen established by 
laser diffraction showing similar distribution between mannitol and ibuprofen. 
(a)
(a)
(a)
(a)
(b)
(b)
(b)
(b)
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Interestingly, when scanning electron microscopy (SEM) tests were carried out, it was 
recognized that the shape of the mannitol particles was similar compared to ibuprofen 
as well as particle size distribution (Figure 5.3).  
Figure 5.4: SEM images powder of (a and b) un-milled mannitol, (c and d) milled mannitol, (e 
and f) starch1500, (g and h) silica and (i and j) ibuprofen.   
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 Figure 5.5: SEM images of (a) control 1 cube un-milled pre-blend, (b) control 2 cube milled 
pre-blend, (c) first coat of composite/milled ,(d) second coat of composite/milled alongside 0.5% 
w/w silica, (e) second coat of composite/milled alongside 2% w/w silica and (f) Zoomed area 
showing small particles of silica coating the surface of pre-blend powder. 
5.3.2. Particle coating formation using confocal microscopy 
Qualitative evidence aimed at examining the influence of dry particle coating and the 
extent of guest particle deposition as well as uniformity of coat over the carrier particles 
was analysed using confocal microscopy followed by quantitative investigation using 
ImageJ software. 15% w/w rhodamine B was selected as guest and micronized to be 
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similar to milled- mannitol particle size (mean diameter 10 µm) and used as a 
fluorescent probe. Starch 1500 was selected as a control, however it was fluorescent 
under confocal microscopy. Thus, 85% MCC was used as control and carrier (Figure 
5.6 a). Furthermore, surface complete coverage was calculated using true density and 
particle size according to the equation mentioned in the methods section. MCC has a 
true density of 1.86 g/cm3 whereas rhodamine B was 0.81 g/cm3. .14.33% w/w from 
guest amount (15% w/w) was required to produce complete coverage (first coat) 
however, in order to achieve second coat, remaining amount of guest was added and 
composite mixed for an additional 30 min.  
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Figure 5.6: Confocal microscopy images of control, first coat and second coat samples with Z-
stack slices A (i-vii), B (i-vii)-one coating and C (i-vii)-two coats respectively using a 10x 
objective (bars= 150 µm). The dry coated particles are shown by the red colour whereas carrier 
material (MCC) representing by the black internal region (non- florescent colour).  
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The results clearly demonstrated that rhodamine was deposited uniformly around the 
surface of MCC particles forming less bright and thinner layer for first coat whereas 
brighter continuous layer can be seen for second coat (Figure 5.6 b and c respectively). 
Further confirmation on the coating quality was performed using ImageJ software 
through 3D images of maximum projection for control, first coat and second coat 
samples (Figure 5.7). The results showed that less rhodamine (fluorescent) was 
presented in the first coat, as was shown by the dark areas (control) not fully coated 
by guest, however, second coat (Figure 5.7 iv and v) showed a fully coated particle 
surface.     
Figure 5.7: 3D images of group of particles (i) control, (ii-iii) first coat and (iv-v) second coat 
using plugins interactive 3D surface plot of ImageJ software. Black colour indicates control in i 
and non-coated area (ii-v) whereas different colours indicates coating layer. 
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Furthermore, ImageJ was used as another confirmative technique where first coat and 
second coat samples were taken forward in order to quantify fluorescence intensity. 
The results showed that a significant increase in average corrected total fluorescence 
was obtained for second coat sample when compared to single coat (increased by two 
fold compared to first coat) (ANOVA, p<0.05). Additionally, there was a similar trend 
for integrated density for both samples (Figure 5.8). 
 
 
 
Figure 5.8: Quantitative total fluorescence (CTF) analysis was performed on MCC particles 
coated with Rhodamine B; (a) indicating first coated sample and (b) indicating second coated 
sample. Integrated density (IntDen) was applied using ImageJ software, analysis was carried 
out to the maximum projection images of samples. Average bar is the mean of A, B, C, D and 
E bars samples.    
 
5.3.3. Tablet characterisation studies 
In this section tablet properties of the different pre-blend of powders containing the 
different ibuprofen concentrations were investigated. Disintegration time and  hardness 
were both affected by the increase in ibuprofen concentration  possibly as a result of 
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the different densification mechanisms of the powder bed due to increase of cohesive 
bonding between ibuprofen particles (Al-Khattawi et al., 2014a).  
5.3.3.1. Mechanical properties results of ODTs  
Generally, tablet dosage forms are exposed to various mechanical stresses during the 
manufacturing steps (e.g. packaging process), distribution and handling by patients. 
Consequently a successful tablet formulation must have an acceptable mechanical 
strength. 
The results of the hardness and friability are shown in (Figure 5.9 and 5.10) 
respectively.   
 
 
Figure 5.9: Comparison of hardness of ternary mixture pre-blend containing (12% w/w 
starch1500, 87.5% w/w milled or un-milled mannitol and 0.5% silica) tablets of ibuprofen. 
Tablets were compressed at 20 kN compression force. Data marked with a single asterisk (*) 
indicates results that are silica added at start & composite mixed for 30 min. (**) indicates the 
silica added at the end & composite mixed for 5 min, (***) indicates silica added at the end & 
composite mixed for 15 min and (****) indicates ibuprofen+ pre-blend (silica added at the end 
& composite mixed for 5 min) were composite mixed for 10 min. Results reported as mean ± 
SD (n=3). 
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The hardness of the tablets (Figure 5.9) increased significantly by increasing ibuprofen 
concentration (ANOVA, p<0.05). This could be explained by the domination of 
ibuprofen particles. Previous research carried out in our laboratory explained that the 
fragmentation of ibuprofen occurs on the surface followed by elastic/plastic 
deformation (Al-Khattawi et al., 2014a). Furthermore, increased cohesive bonding 
between ibuprofen-ibuprofen particles and crystal habit might be the reasons for 
increasing hardness of the prepared tablets while increasing ibuprofen concentration 
(Garekani et al., 2001). In accordance, our results are in line with findings from 
Inghelbrecht and Remon (1998) who stated that highest ibuprofen concentrations 
(75% w/w) result in increased hardness of tablets.  
It can be predicted that particle shape affects mechanical properties of plastically 
deforming and none fragmenting materials (Alderborn et al., 1988). Nevertheless, from 
this study we found that particle shape possibly plays a role in densification of 
fragmenting materials. This arises from the fact that mannitol which is categorised as 
a brittle material only undergoes fragmentation as observed from SEM images (Figure 
5.4 a and b). On the other hand, it could be that inclusion of fractured mannitol (milled) 
as well as milled mannitol coated starch (as noticed from SEM image) (Figure 5.5 c) in 
tableting result in an enhancement in the compressibility of the excipient as more of 
the compaction energy would be utilised in the bonding of the compact (Koner et al., 
2015). Surprisingly, the results showed that there was no impact of processing 
technique (i.e. interactive or composite mixing) on the hardness of the tablets (ANOVA, 
p > 0.05). 
 
Chapter 5  
 
 
214 
 
 
Figure 5.10: Comparison of friability of ternary mixture pre-blend containing (12% w/w 
starch1500, 87.5% w/w milled or un-milled mannitol and 0.5% silica) tablets of ibuprofen. 
Tablets were compressed at 20 kN compression force. Data marked with a single asterisk (*) 
indicates results that are silica added at start & composite mixed for 30 min. (**) indicates the 
silica added at the end & composite mixed for 5 min, (***) indicates silica added at the end & 
composite mixed for 15 min and (****) indicates ibuprofen+ pre-blend (silica added at the end 
& composite mixed for 5 min) were composite mixed for 10 min. Results reported as mean ± 
SD (n=3). 
 
Results from friability testing were in line with the results obtained from hardness 
testing (Figure 5.10). The friability obtained for all formulation did not meet the 
Pharmacopeial requirement (1%) (Pharmacopoeia, 2012). However, the results 
obtained from 50% w/w ibuprofen were better than that of 10%w/w (≤ 2%, >2%) 
respectively. Consequently, composite milled-mannitol/ starch1500 will be taken 
forward to the next stage to investigate the influence of increased glidant (silica) 
concentration to improve flowability, hardness and reduce friability of tablets.  
5.3.3.2. Effect of glidant (silica) concentration on tablet properties 
The composite mixed formulation containing milled mannitol was taken forward into 
the next stage as it retained the best balance between hardness and disintegration 
among the formulations tested. The tablets were prepared at 20 kN from the blend 
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containing different concentrations of silica (0.5-2% w/w), the amount of silica was 
added at the end of pre-blend powder and composite mixed for 5 min. The purpose 
was to investigate the effect of glidant concentration on tablet’s hardness, friability, 
disintegration time and porosity. The results showed a gradual increase in hardness 
upon increasing silica concentration irrespective of the concentration of ibuprofen. 
Moreover, the results showed significant difference in hardness (ANOVA/Tukey 
p<0.05) (Figure 5.11). 
 
Figure 5.11: Hardness profile of tablets prepared using hydraulic tablet press at 20 kN from 
pre – blend containing 0.5 - 2% w/w silica, milled- mannitol, starch1500, ibuprofen at different 
concentration  was incorporated to pre-blend  and interactive mixed for 10 min, magnesium 
stearate was added at the end and mixed for 2 min . The results showed gradual increase in 
hardness upon increase in glidant (Silica) concentration. Each point represents mean ± SD 
(n=3). 
 
 
The findings of the experiment are in agreement with previous research carried out by 
(Jonat et al., 2005) who found that hydrophilic silica increased tablet strength for 
formulations containing starch1500. The increased mechanical strength could be 
attributed to the reduced destruction of antiparticle bonding due to a decrease in elastic 
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recovery. Elastic recovery is the enlargement of tablet during decompression stage 
which arises as a result of stored elastic energy in the compacted material (Haware et 
al., 2010).  
Investigation was continued to test the tablets for friability, disintegration, and porosity. 
Friability testing is significant as tablets are continuously exposed to abrasion and 
mechanical stresses during packaging and patient handling (Huynh-Ba, 2008). 
Friability of tablets prepared using different levels of silica (0.5-2% w/w) at a 
compression force (20 kN) was higher than 1% which is beyond the acceptable limit 
according to BP and USP (Figure 5.12).  
 
 
Figure 5.12: Friability profile of tablets prepared using hydraulic tablet press at 20 kN from pre 
– blend containing 0.5 - 2% w/w silica, milled- mannitol, starch1500, ibuprofen at different 
concentration was incorporated to pre-blend and interactive mixed for 10 min, magnesium 
stearate was added at the end and mixed for 2 min .The results showed gradual enhancement 
in friability upon increase in glidant (Silica) concentration.  
 
 
Investigating the trend in (Figure 5.12), it is rational to assume that friability would 
decrease below 1% if the concentration of silica is increased beyond the levels tested, 
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though, this approach may not be practical as it will negatively impact on the mouth 
feel after tablet disintegration in the oral cavity. Inclusion of  1.5% w/w silica showed 
that tablet friability was higher than 1% (except for 50% ibuprofen where it was around 
1%), but this slight increase can be controlled by adjusting the processing parameters 
such as increased compression force or change in the shape of the tablet (concave 
tablets instead of flat face). 
 
 
Figure 5.13: Disintegration time profile of tablets prepared using hydraulic tablet press at 20 
kN from pre – blend containing 0.5 - 2% w/w silica, milled- mannitol, starch1500, ibuprofen at 
different concentration was incorporated to pre-blend and interactive mixed for 10 min, 
magnesium stearate was added at the end and mixed for 2 min . Each point represents mean 
± SD (n=3). 
 
 
Disintegration time was maintained upon increase the concentration of silica (Figure 
5.13). It could be that silica resulted in the development of bi-functional materials 
exhibiting glidant-disintegrant properties (Rowe et al., 2012). Furthermore, an 
optimised ratio of silica 1.5% w/w was required to create the balance that achieves 
suitable tablet hardness while maintaining fast disintegration and acceptable friability. 
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Similarly, results showed that varying silica concentration (0.5–2% w/w) did not have 
an impact on porosity of tablets (Figure 5.14). 
 
 
Figure 5.14: Porosity profile of tablets prepared using hydraulic tablet press at 20 kN from pre 
– blend containing 0.5 - 2% w/w silica, milled- mannitol, starch1500, ibuprofen at different 
concentration was incorporated to pre-blend and interactive mixed for 10 min, magnesium 
stearate was added at the end and mixed for 2 min . Each point represents mean ± SD (n=3). 
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5.3.3.3. Disintegration time and porosity studies 
The assessment of the disintegration time is considered an important study in 
optimising and developing ODTs. The results for disintegration time and porosity of 
tablets made from ternary mixtures pre-blend (87.5 % w/w milled or un-milled mannitol, 
12% w/w starch 1500 and 0.5%w/w silica) with 10-50% w/w ibuprofen and 1% w/w 
magnesium stearate showed that upon increasing concentration of ibuprofen, a 
significant increase (ANOVA, p>0.05) in disintegration time was noticeable (Figure 
5.15) either because of increased cohesive bonding between ibuprofen-ibuprofen or 
due to fragmentation plastic behaviour of ibuprofen particles (Al-Khattawi et al., 
2014a).  
 
Figure 5.15: Comparison of disintegration time of ternary mixture pre-blend containing (12% 
w/w starch1500, 87.5% w/w milled or un-milled mannitol and 0.5% silica) tablets of ibuprofen. 
Tablets were compressed at 20 kN compression force. Data marked with a single asterisk (*) 
indicates results that are silica added at start & composite mixed for 30 min. (**) indicates the 
silica added at the end & composite mixed for 5 min, (***) indicates silica added at the end & 
composite mixed for 15 min and (****) indicates ibuprofen+ pre-blend (silica added at the end 
& composite mixed for 5 min) were composite mixed for 10 min. Results reported as mean ± 
SD (n=3). 
 
Furthermore, disintegration time increased with increasing ibuprofen due to their lower 
porosity (ibuprofen powder porosity was 0.69±0.08) (Figure 5.18) and higher 
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densification, hence, increasing the ibuprofen concentration resulted in a decrease in 
porosity (Figure 5.16). 
The tablets produced from composite un-milled mannitol at 10, 30, 50% w/w ibuprofen 
disintegrated in 22, 58 and 620 seconds respectively, whereas composite milled at 
similar ibuprofen concentration disintegrated at 23,33 and 66 seconds respectively. 
Statistically, milled mannitol provides a significantly faster disintegration time, 
(ANOVA, p<0.05). This was attributed to the tablets containing milled mannitol ( 
fractured) had increased wettability due to the small size particle size which leads to 
increasing surface area of hydrophilic region of the crystal (Ho et al., 2010, Koner et 
al., 2015). 
 
 
Figure 5.16: Comparison of porosity of ternary mixture pre-blend containing (12% w/w 
starch1500, 87.5% w/w milled or un-milled mannitol and 0.5% silica) tablets of ibuprofen. 
Tablets were compressed at 20 kN compression force. Data marked with a single asterisk (*) 
indicates results that are silica added at start & composite mixed for 30 min. (**) indicates the 
silica added at the end & composite mixed for 5 min, (***) indicates silica added at the end & 
composite mixed for 15 min and (****) indicates ibuprofen+ pre-blend (silica added at the end 
& composite mixed for 5 min) were composite mixed for 10 min. Results reported as mean ± 
SD (n=3). 
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Interestingly, investigation of the tablet porosity made from composite milled showed 
that it was higher than that of cube milled (Figure 5.16). This meant that composite 
milled tablets retained a high porosity compared with cube which is important in 
enhancing disintegration time of tablets. In fact, this was confirmed when powder 
porosity were carried out using helium pycnometer. Composite milled pre-blend 
powder showed 6% higher porosity (0.89± 0.09) than cube milled (0.83 ±0.03) (Figure 
5.17). 
 
 
Figure 5.17: Powder porosity measurements of un-milled, milled mannitol, starch, ibuprofen 
and pre-blend cube or composite containing 87.5% w/w mannitol, 12% w/w starch1500 and 
0.5% silica. Data marked with a single asterisk (*) indicates results that are silica added at start 
and composite mixed for 30 min. (**) indicates the silica added at the end and composite mixed 
for 5 min. Results reported as mean ± SD (n=3). 
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Overall, the results suggested that combining milled/ starch1500 using composite 
mixing produced pre-blend of ODTs with superior overall properties (disintegration 
time, hardness and porosity) than using cube mixed or un-milled formulations. 
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5.4. Conclusion 
Pre-blend excipients play an important role in the development of ODTs. Formulation 
problems such as flowability, compressibility, compactability and disintegration time 
can be improved using co-processed excipients. This study was carried out to develop 
co-processing of milled mannitol with pregelatinised starch and silica using composite 
dry powder coating that offers an excellent multifunctional base for ODT formulations. 
The novel pre-blend excipient showed acceptable mechanical properties and fast 
disintegration. In addition, the pre-blend was able to accommodate a high amount (up 
to 50% w/w) of API without affecting its functionality.  
Due to the high friability of mannitol based ODTs, replacement of proportion of powder 
mannitol with milled-mannitol was inevitable to enhance ODT mechanical strength and 
friability due to reduced fragmentation during compression and improved 
compressibility. Furthermore, milled-mannitol led to improve disintegration time due to 
increased wettability of the ODT.  
Optimising silica concentration in ODT was also important to enhance flowability. Silica 
at 1.5% w/w was suitable as it achieved the required flowability without significantly 
prolonging disintegration time of ODTs. In summary, the co-processed excipients using 
composite dry powder coater containing 86.5% w/w of milled-mannitol, 12% w/w 
pregelatinised starch and 1.5% w/w silica can be used as a potential multifunctional 
directly compressible ODT pre-blend. 
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6.1. Introduction 
In recent years, paediatric drug development has come to the forefront of research due 
to the incentives offered by regulatory bodies in the US and within the EU, including 
financial rewards and patent extensions for drug formulations (Turner et al., 2014). In 
the past, big Pharma companies were more focused on developing adult friendly 
dosage forms due to the high profit margins and perceived lower risk of development. 
Children are a unique entity in the fact that they develop at a vast rate, from the day of 
birth to becoming adults, with the first 18 years of their lives sub classified in to several 
groups: Premature new-borns (<38 weeks gestational age); Term new-borns (>38 
weeks gestational age); Neonate (0-30 days); Infant (1month-2 years); Young Child 
(2-6 years); Child (6-12 years) and Adolescents (12-18 years) (Kellie and Howard, 
2008). This presents various formulation challenges, primarily pharmacokinetic and 
pharmacodynamic, as absorption, distribution, metabolism and excretion are highly 
varied throughout these years, and the dose for administration needs to be tailored 
throughout the paediatric age range (Ivanovska et al., 2014). 
  
For paediatric dosage forms to be acceptable there are a number of practical aspects 
that also need to be considered such as, risk of choking for solid dosage forms, 
elegance, palatability and acceptance of the dosage form by the child (Nunn and 
Williams, 2005). Historically oral liquid dosage forms, such as syrups, have been the 
dosage form of choice for many paediatric patients due to their ease of administration 
and dose flexibility. Nonetheless, oral liquid dosage forms have many disadvantages 
such as: poor taste of bitter drugs; drug stability, with many antibiotic formulations 
having 7-14 day expiry after reconstitution; storage conditions, with many being items 
that need to be kept in the fridge and transportability issues, with liquid bottles 
occupying large space. Consequently, the WHO recently stated that young children 
Chapter 6  
 
 
226 
 
may be treated with oral solid dosage forms, such as orally disintegrating tablets 
(ODTs) and as such there is a concerted effort in understanding and developing 
technologies to formulate these dosage forms (van Riet-Nales et al., 2013). 
ODTs are a dosage form designed to disperse on the tongue when it comes in to 
contact with saliva, thereby reducing the need for tablets to be swallowed whole 
without water, making them ideal dosage forms for paediatric populations. The 
standards for a dosage form to be classed as an ODT is that ‘it must disintegrate rapidly 
in the oral cavity, with an in vitro disintegration time of approximately 30 seconds or 
less, and in general have a weight of no more than 500mg (Siddiqui et al., 2011). ODTs 
combine the advantages of solid and liquid dosage forms with some novel ODT 
technologies allowing high drug loading whilst offering pleasant mouth feel with an 
acceptable taste.  
 
Although ODTs present many advantages over other paediatric formulations, there are 
several challenges associated with these types of tablets. There are two common 
methods of manufacture; freeze drying, that produces rapidly disintegrating tablets 
which are often mechanically weak and require specialised packaging and equipment, 
and direct compression (Parkash et al., 2011). Direct compression utilises traditional 
tableting equipment and requires no specialised processing techniques to form robust 
and fast disintegrating ODTs. Due to the simplicity of the method, excipient and bulk 
powder characteristics need to be considered. Flowability of the bulk powder is of 
particular importance as the powder needs to be able to flow in to the dies at a 
consistent rate to form uniform tablets that have a consistent weight and drug content. 
As the tablets disintegrate within the oral cavity, taste is a key factor that needs to be 
evaluated, as poor palatability of the dosage form would lead to poor medication 
adherence. This can often be solved using flavourings and sweeteners, with more 
complex systems such as film coating of granules and microencapsulation also used, 
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which can often increase development costs and also expose active pharmaceutical 
ingredients (APIs) to unfavourable conditions. One of the simplest ways to address this 
issue is the use of mannitol, a polyol isomer of sorbitol, which has a very sweet taste 
and cooling effect in the mouth and can often provide a palatable dosage form 
(Yoshinari et al., 2002). It has dual functionality in that it is also a popular binder/filler 
used in ODTs due to its advantages in producing acceptable dosage forms. Other 
considerations specifically for ODTs include disintegration time, as this needs to be 
optimised to allow the dosage form to disintegrate within specified timeframes. This 
can often involve the use of superdisintegrants in the powder blend, such as 
crospovidone, which uses capillary action to induce water uptake in to the tablet 
through wicking mechanisms, resulting in a rapid volume expansion of the tablet and 
subsequent break-up of the tablet structure (Pabari and Ramtoola, 2012).  Inclusion of 
superdisintegrants in to ODTs can increase moisture sensitivity in ODTs. High levels 
of moisture in the final dosage form can present difficulties particularly in ODTs, due 
to their ability to uptake moisture from the surroundings as well as their fast 
disintegrating properties (Hirani et al., 2009) Including mannitol can often aid in 
reducing the hygroscopic nature of the ODT, due to mannitols non-hygroscopic nature 
(Yoshinari et al., 2002). Alongside this, powder deformation processes need to be 
evaluated to minimise the elastic deformation properties of the powder, which could 
lead to capping and lamination of the tablet (Prescott and Barnum, 2000). MCC is a 
common excipient employed in ODTs as it has very high compactability due to its 
plastic behaviour, leading to robust dosage form manufacture (Vromans and Lerk, 
1988). 
 
The objective of this study was to study the effects of moisture content on MCC, which 
is a model filler/binder for ODTs, in order to optimise the moisture levels to produce 
the most beneficial powder/tablets. A novel composite coater developed in our 
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laboratory was used to investigate the effect of process parameters on the moisture 
content, as well as studying the effect of excipient addition on the resultant moisture. 
It was hypothesised that the powder coater could be used as a novel tool to optimise 
moisture levels within MCC to a desirable quantity, producing not only a favourable 
pre-processed material with good flowability and compaction properties, but also a 
suitable tableting excipient to formulate robust ODTs without a resultant compromise 
in disintegration time. The work involves developing a fast and robust technique in 
order to optimise varying moisture content ranges levels of MCC. 
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6.2. Materials and Methods 
6.2.1. Materials  
D-mannitol, magnesium stearate and sodium chloride salt (NaCl) were purchased from 
Sigma-Aldrich (Pool, UK), while microcrystalline cellulose (MCC) (Avicel PH-200) was 
obtained from FMC BioPolymer Europe (Brussels, Belgium). Crospovidone (CrosPVP, 
Polyplasdone® XL-10) was obtained from Ashland (Wilmington, USA). All the 
ingredients were of pharmaceutical grade. 
6.2.2. Methods 
6.2.2.1. Optimisation of Moisture Content  
The first step of the moisture process began with weighing a precise amount of the 
original MCC powder (20g) (MCC1) which was spread evenly on a tray. In the next 
step, increments of distilled water were added at approximately 30 second intervals 
without any shaking. The moisture content was tested at intermittent durations until the 
desired moisture contents 11.2% (MCC 2) and 40% (MCC 3) were obtained. The 
amount of added water was approximately 5-10 ml providing moisture content between 
10% and 40% for the MCC powder. The moist powders were transferred into a small 
airtight container and sealed using para film.  
6.2.2.2. Sieving process, interactive and composite powder coating technique  
The two key excipients studied included microcrystalline cellulose (MCC) and mannitol.  
Selected particle sizes of both D-mannitol and MCC were obtained by sieving. MCC 
was passed through sieve with mesh size of 355μm and the sample retained at sieves 
with pores size of 250μm was used. D-mannitol was sieved using 38μm sieve and 
particles retained on the 20μm sieve were used. The composite mixing process was 
carried out considering several critical operating parameters; speed of the mixer, 
mixing time and the use of air flow. As for the materials used, the parameters 
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considered were pertinent to the guest loading percentage, measured in weight per 
weight, and the type of carrier material in terms of particle size and shape. Samples 
were tested alongside interactive mixtures with the same content, but mixed at low 
speeds (300rpm) and a shorter time (10 minutes). The formulation and the processing 
parameters are listed in (Table 6.1) below. 
Table 6.1: Formulation content and processing parameters of MCC (carrier) and D-mannitol 
(guest) (mannitol particle size <38 μm) used for composite and interactive mix. 
No Mannitol 
%,w/w 
MCC 
%, 
w/w 
Crosp 
%,w/w 
Mg.st 
%,w/w 
Mixing 
Tech 
Duration 
min 
Speed 
(rpm) 
Air 
Pressure 
(PSI) 
Batch 
size 
gm 
F1 64.5 30 5 0.5 Interactive 10 300 NO 10 
F2 64.5 30 5 0.5 Composite 60 1500 NO 10 
F3 64.5 30 5 0.5 Composite 60 1500 YES 10 
6.2.2.3. Characterising interactive and powder coating 
6.2.2.3.1. Measurement of powder moisture content using TGA 
A thermogravimetric analyzer, Pyris 1 TGA from Perkin Elmer (Massachusetts, USA) 
was used to measure the moisture content of all powders. 2-5 mg of each sample was 
loaded onto the TGA pan and heated between 30-300°C at a scanning rate of 
30°C/min and held for 5 minutes at 100°C under a nitrogen stream. Pyris Manager 
Software (version 5.00.02) was used for analysing the obtained thermograms. 
Moisture content was obtained by calculating Δy for each run between 70°C and 
130°C. All samples were analyzed in triplicate. 
6.2.2.3.2. Assessment of powder flow properties by measurement of angle of 
repose 
The angle of repose measurement was performed using the recommended British 
Pharmacopeia procedure (Pharmacopoeia, 2012).  Approximately 10 g of powder was 
poured through a funnel into a base free from vibration to form a pile. The funnel was 
positioned 2 - 5 cm from the top of the powder pile as it was forming. Angle of repose 
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was determined by measuring the height of the pile (h) and diameter of the base (d); 
then angle of repose (α) was calculated from the equation: 
tanα = h ÷ (0.5 × d) 
6.2.2.3.3. Scanning electron microscopy (SEM) 
The morphology of MCC at different moisture contents, D-mannitol, the mixture and 
the coated powder particles were examined using a Stereoscan 90 from Cambridge 
Instruments (Crawley, UK) scanning electron microscope (SEM). Approximately 1-2 
mg of each material was placed onto a double-sided adhesive strip on an aluminium 
stub. The specimen stub was coated with a thin layer of gold using a Polaron SC500 
sputter coater from Polaron Equipment ltd. (Watford, UK) at 20 mA for 3 min followed 
by sample examination using SEM. The acceleration voltage (kV) and the 
magnification can be seen on each micrograph. Various magnifications were applied 
to identify characteristics of the powders. 
6.2.2.3.4. Particle size analysis 
Particle size of the powders was measured by the laser diffraction technique using 
HELOS/BR particles size analyzer equipped with a RODOS dry disperser with VIBRI/L 
vibrating feeder, from Sympatec (Clausthal-Zellerfeld, Germany). The measuring 
range of the lens was 0 - 175µm. About 1 g of each powder was placed in the feeder 
tray and the run started at trigger condition of 2% Copt (optical concentration) for 10 
sec with a powder dispensing pressure of 2bar. Volume mean diameter (VMD) was 
recorded for the powders and all the measurements were examined in triplicate. 
6.2.2.3.5. Atomic Force Microscopy (AFM) 
Acquisition of topographical data was performed using a NanoWizard II AFM (JPK, 
UK) operating in force scan mapping mode under ambient conditions (18oC, 50% 
relative humidity). This involved the use of a scanner with a maximum lateral range of 
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100 × 100μm and a maximum vertical range of 15μm. Data acquisition was performed 
using rectangular Si cantilevers (HQ:CSC17/noAl, MikroMasch, Estonia) having 
pyramidal tips with 10nm nominal radii of curvature. Cantilever spring constants were 
on the order 0.3N/m, calibrated according to the method reported by (Bowen et al., 
2010). Topography was assessed over a 2μm x 2μm area using a grid of 128 x 128 
pixels. Data was acquired by driving the fixed end of the cantilever at a velocity of 
50μm/s towards the sample surface, whilst monitoring the deflection of the free end of 
the cantilever using a laser beam. Upon making contact with a surface feature, the 
height of the contact point was recorded, representing one pixel in the image, which 
was converted into a map of surface topography. A maximum compressive load of 
10nN was applied to the surface during data acquisition. 
6.2.2.3.6. Nano-indentation 
The hardness and Young’s modulus of the powder wafer samples was measured using 
a Nanoindenter XP (MTS, USA) employing a diamond-coated Berkovich indenter. 36 
indentations were performed perpendicular to the wafer surface, each in a different 
unperturbed area. Samples were indented at a strain rate of 0.05s-1 to a maximum 
depth of 500nm. The hardness and Young’s modulus were calculated from analysis of 
the load-displacement data, fitting a second order polynomial to the unloading curve 
(Figure 6.1) (Zhu et al., 2004). The Poisson’s ratio of the powder was assumed to be 
0.3. In this approach the total penetration depth is assumed by the sum of the plastic 
depth (contact depth), δc, and the elastic depth, δe, which represents the elastic flexure 
of the surface during loading. Thus the total penetration depth, δ, is given by 
 
𝛿 =  𝛿𝑐 +  𝛿𝑒 
and 
𝛿𝑒  = 𝜀 (𝑃 ÷ 𝑆𝑢) 
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 Where Su is the slope of the unloading curve at maximum load (see figure 6.1), P is 
the indenter load and ε is a constant which depends on indenter geometry. So the 
hardness, H, is then given by equation 
𝐻 = 𝑃 ÷  𝐴𝑐 
 Where Ac is an ideal Berkovich indenter constant .Young’s modulus can be determined 
from the slope of the unloading curve using a modified form of Sneddon’s flat punch 
equation where 
𝑆u = 𝛾𝛽 
2
√𝜋
  𝐸𝑟√Ac 
 Where γ is the correction factor, β is the cone to pyramid indenter conversion factor 
and Er is the contact modulus which can be derived from Young’s modulus E and 
Poisson’s ratio (v) of the indenter and the test material via 
 
Figure 6. 1: The illustration graph represents load–displacement curve showing the unloading 
(Su) and loading (SI) slopes used in the calculation of hardness and Young’s modulus. Besides 
indicated is the plastic work of indentation Wp which is the area bounded by the loading and 
unloading curves and the displacement on x-axis. 
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1
𝐸𝑟
=
1 − 𝑣𝑚2
𝐸𝑚
+
1 − 𝑣𝑖2
𝐸𝑖
 
 
Where the m and i refer to the test material and indenter, respectively 
6.2.2.3.7. Calculation of surface coverage 
Surface coverage was calculated using the equation and method described in(Yang et 
al., 2005). The amount of guest material in weight percentage (Gwt %) required to 
achieve 100% coverage within the given parameters was as follows: 
                              
                                   
𝐺𝑤𝑡% =
𝑁𝑑3 𝑝𝑑
(𝐷3 𝑝𝐷) + (𝑁𝑑3 𝑝𝑑) 
× 100 
                     
Where N is: 
                            
𝑁 =
4(𝐷 + 𝑑)2
𝑑2
 
Where d is the diameter of guest particle, D is the diameter of the host particle, pd is 
the density of the guest particle and pD is the density of the host particle. 
6.2.2.4. Tablet Preparation and Characterization 
Ternary mixture tablets were prepared comprising of the excipients at fixed quantities: 
30% w/w of MCC, 5% w/w crospovidone, and 64.5% w/w mannitol and 0.5 % w/w 
magnesium stearate (lubricant). Powders were processed as interactive/composite 
mixes and compacted into 500 mg tablets under compression force of 10 KN, with a 
dwell time of 6s before compression force was released. The tablet press utilized for 
preparing the tablets was a bench-top semi-automatic hydraulic press from Specac 
Ltd. (Slough, UK) equipped with flat faced dies of 13 mm diameter. Tablets were 
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characterized for porosity, hardness, disintegration time and friability. All tests were 
carried out in triplicate (n=3). 
6.2.2.4.1. Tablet hardness 
A tablet hardness tester from Schleuniger (Thun, Switzerland) was used to examine 
the hardness of three tablets of each formulation. Hardness is the force required to 
break up the tablet from its original structure and was measured in Newtons (N) for this 
study. All measurements were carried out in triplicate and the values reported as mean 
± standard deviation. 
6.2.2.4.2. Tablet disintegration 
The disintegration time was obtained using the standard USP moving basket 
apparatus (USP Convention, 2005). A  ZT3 disintegration tester from Erweka 
(Heusenstamm, Germany) was used. A tablet was placed in the disintegration basket 
(without using a disk) which was raised and lowered at a constant frequency of 30 
cycles/min in the disintegration medium. Distilled water (800 mL) maintained at 37°C 
was used as the disintegration medium while disintegration time was recorded for one 
tablet at a time to improve accuracy of recording. Time of disintegration was recorded 
when all the disintegrated fractions of tablet passed through the mesh at the base of 
the disintegration basket. 
6.2.2.4.3. Tablet friability 
The ability of the tablets to withstand mechanical stress, known as friability was 
measured using a Roche friabilator from J. Engelsmann AG (Ludwigshafen, Germany). 
10 tablets were rotated at 25 rpm for 100 revolutions. Tablets were de-dusted before 
and after the test, and friability expressed as the percentage loss in weight. The 
percentages loss in weight (% Friability) was calculated using the following equation. 
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% 𝐹𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑊𝑒𝑖𝑔ℎ𝑡 − 𝐹𝑖𝑛𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡
 × 100 
6.2.2.4.4. Tablet porosity 
Tablet porosity was measured using a helium multipycnometer from Quantachrome 
Instruments (Syosset, USA). One tablet was placed in a micro sample cell of the 
instrument and the true volume Vt was obtained using the equation: 
                                            
𝑉𝑡 =  𝑉𝐶 −  𝑉𝑅  (
𝑃1
𝑃2 − 1
) 
        
Where Vt is true volume of the sample, VC is volume of the sample cell, VR is the known 
reference volume, P1 is atmospheric pressure and P2 is pressure change during 
determination. Vt  was used to calculate the true density of the tablet by weighing the 
tablet and substituting the values into: 
𝑇𝑟𝑢𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝑇𝑎𝑏𝑙𝑒𝑡 𝑊𝑒𝑖𝑔ℎ𝑡
𝑇𝑟𝑢𝑒 𝑉𝑜𝑙𝑢𝑚𝑒
 
Porosity (ε) was calculated using the equation: 
𝜀 = 1 −  (
𝐵𝑢𝑙𝑘 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
𝑇𝑟𝑢𝑒 𝐷𝑒𝑛𝑠𝑖𝑡𝑦
) 
Bulk density was calculated from: 
𝐵𝑢𝑙𝑘 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝑇𝑎𝑏𝑙𝑒𝑡 𝑊𝑒𝑖𝑔ℎ𝑡
𝐵𝑢𝑙𝑘 𝑉𝑜𝑙𝑢𝑚𝑒
 
 
Bulk volume was acquired by measuring the radius (r) and thickness (h) of the tablet 
using a digital calliper and substituting in the equation for volume of a flat-faced tablet: 
                                                
𝑉 =  𝜋 ×  𝑟2 × ℎ 
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6.2.2.5. Statistical analysis 
 One way ANOVA followed by Tukey post-hoc test or student t-test were performed 
according to the obtained results, using GraphPad Prism 6.02 software (California, 
USA). Statistical significance was considered at a p value <0.05. Where applicable, all 
results are presented as mean ± SD for triplicate measurements to account for the 
noise encountered within the experiments.  
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6.3. Results and Discussion 
The work presented in this study provides a systematic investigation on the impact of 
moisture content of MCC on powder and tablet performance. Moisture content of the 
pre and post processed materials; MCC, D-mannitol, crospovidone, magnesium 
stearate and the ternary mixtures were analysed using TGA for loss on drying. These 
excipients were selected based on their role as binders, fillers, disintegrants or dual 
functional binder/disintegrant systems within ODTs. The majority of the work on 
moisture content was conducted with MCC as it is a hygroscopic excipient that is 
commonly employed within ODTs as a binder/filler (Rowe et al., 2012).   
6.3.1. Moisture content of the investigated excipients 
Figure 6.2 shows the levels of moisture obtained from each of the studied excipients 
through TGA analysis. It was seen that D-mannitol had the lowest moisture content, at 
about 0.5% w/w compared to MCC, which had a moisture content of 3.8% w/w. This 
was in line with the literature findings where the moisture content of MCC was reported 
to be around 3-4% w/w (Khan et al., 1981), with D-mannitol expected to have low 
moisture content due to its non-hygroscopic nature (Yoshinari et al., 2002). 
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Figure 6. 2: Moisture content of the individual excipient, before blending, using TGA analysis. 
Results are presented as (mean ± SD, n=3). 
 
 
In this study it was hypothesised that the levels of moisture within MCC influenced the 
physio-mechanical properties of the particles, including their hardness/tensile strength, 
flow and their compaction behaviour. In order to achieve different levels of moisture 
within MCC, the micro-spray method was used to increase levels of adsorbed water in 
the MCC to two different levels compared to the control MCC 4% (MCC 1), which had 
not been subjected to moisture addition. The moisture contents investigated were 11% 
w/w (MCC 2) and 40% w/w (MCC 3). The three MCC powders were then subjected to 
a range of investigations to ascertain the effect that the moisture had during 
processing, addition of further excipients and on the tablet properties of the ODTs. 
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6.3.2. Effect of moisture content on morphology and flow of MCC 
Good flow properties are a requirement for the successful manufacture of tablets as it 
affects mixing, content uniformity, tablet compression and scale-up operations 
(Sarraguça et al., 2010). Flow properties of the materials tested were primarily affected 
by the size and shape of the particles within the powder, which in turn affected the 
cohesivity and the mechanical interlocking between the particles (Al-Khattawi et al., 
2014a). Flow properties were evaluated before mixing/tableting was carried out for the 
different MCC powders. Powder flow properties of the different MCC powders were 
assessed by measuring the angle of repose. The results showed significant differences 
(ANOVA, p<0.05) between the angle of repose of the powders, with MCC 2, at 11%w/w 
moisture content, demonstrating the best flowability with a low angle of repose at 
29.60±0.86°, as shown in (Figure 6.3) when compared to the control MCC, which had 
a fair flow, with the angle of repose of 38.52±0.67°. However at high moisture content 
of 40%w/w (MCC 3), poor flow was observed, with the angle of repose at 52±0.61°, 
indicating that high levels of moisture significantly worsened the flow properties of the 
powder (Al-Khattawi et al., 2014b). 
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Figure 6. 3: Flow properties for MCC powders with different moisture content, test used was 
angle of repose. Results are presented as (mean ± SD, n=3). 
 
 
 
At low moisture levels, water on the particle surface acted as a lubricant by decreasing 
friction and increasing the flowability of the powder thereby allowing the particles to 
move more easily over each other. For MCC2 it can be hypothesised that the moisture 
was able to act as a lubricant and increased the distance between the particles which 
also had the dual effect of reducing the effect of the van der Waals forces and reducing 
the cohesive forces. Once monolayer coverage was achieved, additional water did not 
significantly contribute to the lubricating and spacing effect and therefore further 
enhancements in flowability were minimal (Crouter and Briens, 2014). 
On the other hand, MCC showed a sharp decrease in flowability with increasing 
moisture content up to 40% W/W. This was attributed to the increased cohesion from 
the stronger liquid bridges formed from the condensed water on the surface of the 
particles. At higher moisture levels, the water possibly increased cohesion through 
stronger liquid bridges thereby reducing flowability. Furthermore, water could primarily 
affect cohesion by increasing capillary forces through strengthening liquid bridges 
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between the particles (Dawoodbhai and Rhodes, 1989, Shi et al., 2011). When the 
angle of repose test was carried out, it was also observed that MCC  adhered to the 
funnel, (Figure 6.4 c), demonstrating that not only did the powder become more 
cohesive in nature, it also became more adhesive to external surfaces, indicating a 
worsening flow. 
 
Analysis of SEM images after curing of MCC powder showed a slight enlargement in 
size with MCC 2 (at 11% moisture content), as shown in (Figure 6.4 e) which possibly 
was an additional factor for improved flowbaility, as the larger particle size results in a 
reduction in cohesivity of the particles due to lower electrostatic forces, thereby 
enhancing the flow of particles (Karner and Urbanetz, 2011).  It could also be said that 
the fine particles contained within the powder were also able to agglomerate/coat the 
larger particles, resulting in an increased particle size, due to the increased cohesivity, 
which reduced the overall cohesiveness of the blend and synergistically worked with 
the lubricating effect of the surface adsorbed water to improve the flow of MCC. 
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Figure 6. 4: (a-c) Visual structure features of different MCC moisture contents show images of 
MCC 1, MCC 2 and MCC 3 respectively. Arrows in (e) point to aggregated particles of MCC 3, 
(d-f) SEM showing morphology of MCC particles, (d) MCC 1(pure MCC powder, moisture 
content 4%w/w), (e) MCC 2( optimised MCC moisture content 11% w/w) and (f) MCC 3 
(optimised MCC moisture content 40% w/w). 
 
6.3.3. The effect of process parameters on MCC moisture content 
To assess the effects of processing parameters on the moisture content of the MCC 
powders, three different parameters were used with each of the powders of MCC to 
analyse the effect on the resultant moisture content.  
In this study a novel composite coater designed and built in our laboratory was used 
as the mixer of choice, and the effect of processing parameters within this device were 
assessed (Table 6.2). The first parameter was to mix the powder at a low speed of 
300rpm for 10 minutes to achieve interactive mixture (10 minutes was chosen as 
previous work in the group had shown that this duration produced a homogenous 
interactive mix). The second processing parameter included the composite coater at a 
speed of 1500rpm for 60 minutes, which would be used to form composite dry coated 
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particles due to the high shear forces generated by the device. The third parameter 
had the device at the same speed and time as the second parameter (1500rpm for 60 
minutes) but with the inclusion of air to increase the deagglomerating and shear forces 
during mixing and to aid and increase the dry coating capabilities of the excipients 
used in the mix. The resultant moisture content of the three MCC powders after 
undergoing the different processing parameters are displayed in (Table 6.2). 
 
Table 6.2: Initial and final moisture contents for MCC at different processing parameters using 
powder coater (rpm: revolutions per minute).  
Initial MCC Powder 
moisture content % 
Process Parameter Final Moisture Content % 
Mean ± SD (n=3) 
MCC1 (4%)  
300rpm 
3.7 ± 0.53 
MCC 2 (11%) 9.16 ± 0.84 
MCC 3 (40%) 37.7 ± 3.74 
MCC1 (4%)  
1500rpm 
3.41 ± 0.02 
MCC 2 (11%) 7.33 ± 0.93 
MCC 3 (40%) 35.31 ± 0.93 
MCC1 (4%)  
1500rpm + air flow 
1.28 ± 0.14 
MCC 2 (11%) 2.96 ± 0.22 
MCC 3 (40%) 8.38 ± 0.622 
 
 
The interactively mixed powders at 300rpm are shown in (Figure 6.5 a). The results 
showed no significant difference (ANOVA p>0.05) between the moisture content over 
time, indicating the mixing method had little effect on the moisture. Similarly, (Figure 
6.5 b) shows that no significant difference in moisture content was observed using 
composite mixing without including air pressure (ANOVA p>0.05) in all three powders.  
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Figure 6. 5: (a) Moisture content profiles of different MCC batches using interactive mixing 
(ordered mixing) at 300 rpm. (b) Moisture content profiles of different MCC batches using 
composite mixing at 1500 rpm. (c) Moisture content profiles of different MCC batches using 
composite mixing at 1500 rpm with air. Results are presented as (mean ±SD, n=3).  
 
 
Results of the moisture content over time using air in the mixing process are shown in 
(Figure 6.5 c) and demonstrated that the use of air at a mixing speed of 1500 rpm 
resulted in a significant decrease in the moisture content of MCC (p<0.05). This could 
possibly be attributed to the formation of vortexes/whirlpools within the system upon 
fluidisation of powder bed, which was demonstrated by computational fluid dynamics 
(CFD) (data not shown). This vortex was responsible for the fluid environment in the 
chamber resulting in the enhancement of the drying of the powder; hence there was a 
large reduction in moisture content of the powders when air was introduced during 
mixing. This led to the hypothesis that use of air in the processing of high moisture 
excipients could therefore be used to optimise levels of moisture within the excipient 
to the user’s desired levels, with processing times altered according to the required 
final moisture content. 
Chapter 6  
 
 
246 
 
6.3.4. Mechanistic investigation of adding excipients and its effect 
on the moisture content of MCC 
To assess the effects of excipient addition on moisture content, mannitol and 
crospovidone were added to the different MCC powders. For interactive mixing, all 
three materials were added together and mixed for 10 minutes (F1). For composite 
coating, excipients were added in a two-step process. Firstly to optimise the amount 
of mannitol added to form a full surface coverage around the MCC particles, surface 
coverage was calculated using equations by Yang et al (2005) with the following 
parameters; true density of MCC being 1.94g/cm3 and D-mannitol 1.67 g/cm3; particle 
size of MCC being 250μm and D-mannitol 25.9μm, resulting in the percentage per 
weight of mannitol to achieve complete coverage calculated at 30.28%. This amount 
of guest particle (mannitol) was in agreement with the results stated in (Yang et al., 
2005) as with a volume ratio of 5 the average coverage was around 56%. The value 
for surface coverage would be significantly reduced upon the reduction in particle size 
of mannitol or increase in particle size of MCC. The second step involved the addition 
of the remaining portion of the mannitol, alongside the addition of the crospovidone 
which was mixed for a further 30 minutes to form the final mixture (F2 and F3). 
 
 (Figure 6.6 a-c) shows the moisture content profiles of the interactive against 
compositely mixed powders. All graphs indicated a reduction in the moisture content 
when the materials, in particular mannitol, were added to MCC, compared to MCC 
alone (ANOVA, p<0.05). With the interactive mix there was a large drop in the MCC 
moisture content for all three of the powders tested when the excipients were added 
to the powder blend and mixed over the 10 minute time period. 
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Figure 6. 6: (a) Moisture content profile of different physical mixtures using interactive mixing 
(ordered mixing) at 300 rpm, (b) Moisture content profile of different batches using composite 
mixing at 1500 rpm and (c) Moisture content profile of different batches using composite mixing 
at 1500 rpm with air. Results are presented as (mean ±SD, n=3). 
 
 
In terms of the composite blends, SEM images, in (Figure 6.7b and c), showed that the 
mannitol was attached to the surface of MCC 2 particles and formed a coat around the 
MCC. (Figure 6.6 b and c) showed the moisture loss of the two composite coating 
processes, without air and with air respectively, and both indicated very large drops in 
moisture content after 60 minutes, due to the addition of the excipients. With the mixing 
that included air, as shown in (Figure 6.6 c), the moisture content was expected to 
reduce more dramatically as the air within the chamber aided in the drying of the MCC 
powder. Alongside the use of air, the addition of excipient resulted in around 35% of 
moisture being lost in the first 10 minutes for MCC 3. In comparison to the use of air 
alone (Figure 6.5 c) where the moisture loss after 10 minutes was around 25%, it 
showed that the addition of excipients was a key factor in the loss of moisture from the 
MCC particles. Comparing air and excipients, it was seen that the moisture loss of the 
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MCC at 1500 rpm with air was very similar to when the mannitol was added to the 
MCC without air at a 1500 rpm mixing speed, with the moisture content of MCC 3 
dropping to around 15% in both cases. 
 
 
Figure 6. 7: (a) schematic illustrating microcrystalline cellulose (MCC) particles being partially 
coated by mannitol (guest), (b and c) scanning electron microscopy of MCC 2- composite 
particles (b) showing MCC 2 particles coated with mannitol 200x magnification & (c) Zoomed 
area showing small particles of mannitol coating the surface of MCC 2 1500x magnification. 
 
 
 
 
It was hypothesised that the water particles acted as a guest molecule and surrounded 
MCC during the introduction of external moisture. However, once the mannitol was 
added to the mix, it attaches itself to the surface of the MCC during the coating process, 
to replace water molecules, as there was a difference in the densities between 
mannitol and water, with water having a relative density of 1g/cm3 and mannitol density 
being 1.67g/cm3. Therefore, it was assumed that water droplets were knocked out from 
the surface of MCC by mannitol, which resulted in the reduction in the moisture content 
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observed in (Figure 6.7 a). Of particular interest was the composite mix without air, 
shown in (Figure 6.6 b), where there was a large loss of moisture observed upon the 
addition of the first portion of mannitol, with around 25% moisture loss within 10 
minutes of mixing followed by a plateau of moisture loss up until 30 minutes. However 
upon the second stage of excipient addition at 30 minutes, there was a further large 
drop in moisture content between 30-40 minutes by around 10%, which again 
plateaued. This indicated that the addition of other solid materials in to the powder 
blend clearly resulted in a loss in moisture as increased amounts of water were 
displaced from the surface of the MCC particles during the addition of further solid 
material. This supported the theory that water was substituted on the surface of MCC 
particles, as shown in (Figure 6.7 a), as the addition of the excipients in two stages 
resulted in further loss of water at each stage of excipient addition. To further 
understand these differences and to substantiate the above hypothesis, micro and 
macro properties of the materials were studied using a range of different techniques. 
 
6.3.5. Investigation of the Micro and Macro properties of Ternary 
mixed powder blends  
6.3.5.1. Micro Property assessment using AFM, Nano indentation and SEM 
Nanoindentation was used to assess the micro-mechanical properties of the different 
MCC particles, with penetration resistance and hardness being two key features 
assessed. Wafers were prepared to give a uniform flat surface, as nanoindentation 
only tested local to the sample surface on to which the indents were performed. Wafers 
with the three different moisture contents of MCC and the interactive/compositely 
mixed powders were prepared and were subjected to the nanoindentation test, to 
examine viscoelastic behaviour and their elastic modulus and hardness.  Modulus and 
hardness of the wafers prepared from the three MCC moisture contents and powders 
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compositely mixed at 1500 rpm with and without air were obtained and displayed in  
(Figure 6.8 a, b and c) respectively. With regards to the pre-processing materials, MCC 
1, MCC 2 and MCC 3 pellets were subjected to the nanoindentaion test and the load 
penetration graph is shown in (Figure 6.8 d). The penetration of the nanoindenter on 
the surface of the pellet was governed by many features, for example the degree of 
compaction of the particles in the pellet  and the structure and porosity of the particles 
(Das et al., 2009). MCC 1 and MCC 2 showed similar profiles, indicating approximately 
the same absorption of energy during the loading/unloading cycle. In MCC 3 
penetration was much less and the deformation predominantly showed an elastic 
profile. MCC 3 was found to have the lowest modulus at around 3.34 GPa and 
hardness around 17 Vickers, which could have been due to high moisture content and 
wide particle size distribution, giving rise to porous aggregates, which were 
subsequently confirmed by visual and SEM analysis in (shown in section 6.3.2). The 
results of the modulus and hardness of the different MCC powders showed a 
significant difference (ANOVA,p<0.05).  
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Figure 6.8: (a) The modulus and hardness of MCC1, cured MCC2 &MCC3 wafers as measured 
from nanoindentation test, (b) Effect of MCC composite moisture content (1.8 - 4.3% w/w) on 
modulus and hardness as measured from the nanoindentation test of ternary mixture wafers, 
(coating method, composite mixed at 1500rpm for 60 minutes without air), (c) Effect of MCC 
composite moisture content (0.5 – 1% w/w) on modulus and hardness as measured from 
nanoindentation test of ternary mixture wafers, (coating method, composite mixed at 1500rpm 
for 60 minutes with air), (d) Nanoindentation load–displacement curves for pre-processed 
materials (MCC1, MCC2and MCC3. The poor overlap of the loading curves shows the non-
uniformity of properties and rough surface of the materials. Where applicable results reported 
as mean ± SD (n=3).  
 
 
Data from AFM also showed that MCC 3 was composed primarily of smooth surface 
topography particles with the lowest average roughness Ra of approximately 35nm, as 
shown in (Figure 6.9 a). This was possibly due to the high levels of adsorbed moisture 
on the surface on the particles, which resulted in a smoother surface (Mujumdar et al., 
2004). The highest modulus and hardness was observed with MCC 2, and these 
values correlate to the AFM readings whereby particle roughness was highest. 
 
A major change in hardness and modulus was observed in compositely mixed blends 
shown in (Figure 6.8 b and c) compared to pre-processing materials. This experiment 
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provided evidence that MCC was coated by mannitol as a sharp decrease in hardness 
and modulus of the particles was observed. The decrease in mechanical properties 
indicated that the surface of MCC was coated with mannitol.  Mannitol has lower 
compactability when used in tablet formulation, giving tablets of a lower mechanical 
strength; hence, mannitol had undergone fragmentation under pressure, resulting in 
the formation of weak wafers (Koner et al., 2015).   
 
In addition, previous research from our group has stated that the needle shape of the 
particles of mannitol results in its low compactability (Al-Khattawi et al., 2014a). To 
further support the fragmentation pattern, AFM topographical analysis was performed 
which showed a considerable number of asperities that were liable to damage when 
slight force was applied using the AFM cantilever. Additionally, morphological studies 
using SEM showed columnar/longitudinal particles for pure mannitol in comparison to 
MCC which was primarily composed of irregularly shaped particles with microfibrilar 
structure (Al-Khattawi et al., 2014a). Using one way ANOVA, results of modulus and 
hardness demonstrated no significance difference between composite mix with/without 
air flow (p>0.05).  
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Figure 6.9: Nano structural features of MCC and MCC composite obtained from AFM. (a) AFM 
average surface roughness of MCC particles and MCC composite at different moisture 
contents. (b-f) show AFM topographical images of MCC1, MCC2, MCC3, MCC2-composite (at 
1500rpm, no air) and MCC2-composite* (at 1500rpm and air).  
 
 
Furthermore, AFM confirmed the smooth surface of particles when no air was included 
(Figure 6.9 e), whereas, the composite mixing with air presented a very high roughness 
(Ra was 534 approaching approximately five times that of composite mixing without 
air) (Figure 6.9 a).  
6.3.5.2. Macro properties of ternary mixed powder blends   
In this section tablet properties of the different ternary mixtures of powders containing 
the different MCC moisture content powders were investigated. Disintegration time, 
hardness and porosity were both affected by the increase in moisture content possibly 
as a result of the different densification mechanisms of the powder bed and particulate 
deformation due to the fragmentation of mannitol and plastic deformation of MCC 
(Tatavarti et al., 2008).  
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6.3.5.2.1. Investigation of the effect of moisture content on mechanical 
properties of ODTs  
The results of tablets made from ternary mixtures comprising of 64.5% w/w mannitol, 
30% w/w MCC (different moisture contents), 5% w/w crospovidone and 0.5% w/w 
magnesium stearate showing the relationship between moisture content and 
hardness/friability, are depicted in (Figure 6.10 a-c). With regards to the interactive 
mixture, using MCC 2 where the final moisture content of the powder came to 
approximately 2.7% w/w,  provided tablets with increased compact strength whereas 
at higher moisture contents, using MCC 3 (>4% w/w final moisture content) a dramatic 
reduction in tablets hardness was obtained as shown in (Figure 6.10 a and b). The 
initial increase in crushing strength of tablet compacts with increasing moisture content 
up to 2.7% w/w was possibly due to the hydrodynamic lubrication effect of moisture, 
which allowed a greater fraction of the applied force to be diffused through the compact 
on to the lower punch. Meanwhile, an initial increase in moisture content resulted in a 
higher crushing strength, due to increased particle-particle interaction. Consequently 
the increased moisture possibly improved plastic deformation (Nokhodchi et al., 1995). 
 
With regards to the composite blend without the inclusion of air, it was clear that 
increased moisture content up to 2% w/w resulted in an improvement of the tablet 
hardness. For example, the MCC 2 formulation (2.1% w/w moisture content) had a 
hardness of 52N, whereas the hardness of tablets with MCC 1 (1.8% w/w moisture 
content) was 29N. It is possible that the increased amount of moisture contributed to 
an increase in the initial consolidation rate as well as the final granule consolidation 
during compaction as the moisture acted as a low viscous binder (Iveson et al., 2001). 
 
The use of the composite dry powder coating process without air to form a final 2.1% 
w/w moisture content (MCC 2) resulted in enhancement of the hardness profile of the 
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tablets, up to 80%, when compared to 1.8% w/w moisture content powder (using MCC 
1), as shown in (Figure 6.10 b). This was attributed to the strong adherence of the fine 
mannitol particles to the surface of MCC. Furthermore, the increase in hardness due 
to the moisture content and coating may have been due to the formation of a mono 
molecular layer of moisture around the powder particles. This film of moisture could 
enable the formation of interparticle hydrogen bonding and/or increased the van der 
Waals' forces, therefore smoothing out the surface micro irregularities and dropping 
interparticle separation (Malamataris and Pilpel, 1983). 
 
The presence of excessive moisture decreased the compact strength, by reducing the 
hydrodynamic resistance and therefore increasing elastic recovery after ejection (Li 
and Peck, 1990). A high compaction force and high moisture content may have also 
led to a significant moisture squeeze out onto the particle surface, thus reducing 
interparticle bonding and thereby increasing elastic recovery resulting in a reduction of 
the crushing strength (Nokhodchi et al., 1995). A previous study found that sodium 
chloride compacts containing higher moisture content had lower strength (Khan et al., 
1981). Another possible explanation for a decrease in hardness at high moisture 
content was the formation of multilayers of water at the particle surface. These layers 
may have disturbed or decreased inter molecular attraction forces and thus reduced 
tablet strength (Kristensen et al., 1985). 
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Figure 6.10: (a) Effect of MCC mixture moisture content (1.2 - 7.7% w/w) on hardness and 
friability of ternary mixture tablets (interactive method, mixed at 300 rpm for 10 minutes), (b) 
Effect of MCC composite moisture content (1.8 - 4.3% w/w) on hardness and friability of ternary 
mixture tablets (composite mixed at 1500rpm for 60 minutes without air),  (c) Effect of MCC 
composite moisture content (0.51– 1% w/w) on hardness and friability of ternary mixture tablets 
(composite mixed at 1500rpm for 60 minutes with air), (d) Effect of MCC mixture/composite 
moisture content (0.51 - 7.7% w/w) on tablets hardness irrespective of process parameters and 
.Tablets were compressed at 10 kN compression force. Results reported as mean ±SD (n=3). 
(e-g) Moisture based tablet after friability test for compositely mixed powders at 1500rpm for 60 
minutes without air, (e) Weight loss of 4.79% at 1.8% w/w moisture content, (f) weight loss of 
2.38% at 2.1% w/w moisture content and (g) weight loss of 5.14% at 4.3% w/w moisture 
content. 
 
 
Overall, a proportional relationship between the tablet hardness and friability was seen; 
as hardness increased the friability was improved in all approaches. For example, 
hardness in (Figure 6.10 a) showed that at 7.7% w/w moisture content, the tablets had 
the lowest hardness value at 13.57±3.32N and the highest friability percentage at 
7.6%. While, the highest hardness of 51.9±2.35N with lowest friability of 2.38%, was 
found with 2.1% w/w moisture content as shown in (Figure 6.10 b).  
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It was also observed that post friability test, capping of prepared tablets increased with 
the increased moisture content (>4% using MCC 3) as shown in (Figure 6.10 g). The 
tendency to cap may have increased due to the weakening of the interparticle bonds 
as a result of the disruption of molecular forces and greater separation of the MCC 
particles by excess moisture (Nokhodchi et al., 1995).  
6.3.5.2.2. Effect of moisture content on disintegration time and tablet porosity  
Figure 6.11 shows the effect of moisture content on tablet disintegration time and 
porosity. For example, at 7.7% w/w moisture content (with MCC 3) using interactive 
mixing at low speed (300 rpm), the tablets had a disintegration time of 7±1s whereas 
those prepared from 1.2% moisture powders (using MCC 1) had a longer disintegration 
time of 39±2s (P<0.05),(Figure 6.11 a).  
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Figure 6.11: (a) Effect of MCC mixture moisture content (1.2 - 7.7% w/w) on disintegration time 
and porosity of ternary mixture tablets using interactive mixing at 300 rpm for 10 minutes, (b) 
Effect of MCC composite moisture content (1.8 - 4.3% w/w) on disintegration time and porosity 
of ternary mixture tablets compositely mixed at 1500rpm for 60 minutes without air , (c) Effect 
of MCC composite moisture content (0.51– 1% w/w) on disintegration time and porosity of 
ternary mixture tablets , compositely mixed at 1500rpm for 60 minutes with air &(d) Effect of 
MCC mixture/composite moisture content (0.51 - 7.7% w/w) on disintegration time irrespective 
of process parameters .Tablets were compressed at 10 kN compression force. Results reported 
as mean ±SD (n=3). 
 
 
The porosity results during interactive mixing, shown in (Figure 6.11 a), were 
consistent with disintegration results as the increase in moisture content caused a 
significant increase in porosity and a sharp decrease in disintegration time (ANOVA, 
p<0.05). This suggested that the high amount of moisture content may have led to 
creating a freely moving environment of the particle that contributed to finding the most 
suitable compact configuration; while disintegration time was prolonged at low 
moisture content as the reduction of pores reduced the ability for water to penetrate 
and break up the tablet. Although tablets retained high porosity, which is important to 
enhance water penetration and disintegration of tablets, their hardness was insufficient 
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at 14±3.3 N (Figure 6.10 a). Additionally, increasing particle size range may have led 
to larger void spaces, which yielded a growth in porosity. Interestingly, when scanning 
electron microscopy (SEM) tests were carried out, it was recognized that a small 
increase in particle size of the MCC 2 moisture content particles was observed 
compared to MCC 1.  
These increases in average particle size of the MCC 2 powders could be referred to 
as the coalescence process, at which the particles combined to form big clusters. 
Therefore, it is possible that the increased non-viscous binder (water) led to improved 
hardness, friability, disintegration time and porosity of tablets as the increased moisture 
created free movement for particles, increasing the consolidation process and 
decreasing the coalescence processes (Iveson et al., 2001).  
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6.4. Conclusion 
Manufacturing powders with differing levels of moisture content resulted in an 
alteration in the powder morphology as observed from SEM and AFM studies. This 
study showed that the amount of moisture content within MCC affected the mechanical 
properties of the subsequent powders and it was concluded that inclusion of 11% MCC 
moisture content resulted in the most flowable powder with favourable ODT 
characteristics, as tablets displayed increased hardness when formed using direct 
compression. Extreme moisture contents in pre-processing materials could be reduced 
using varying process parameters using composite dry coating, as well as mixing of 
the powders with excipients designed to dry coat the surface of the high moisture 
content carrier particles. The understanding of tableting performance of excipients at 
the particle level (nanoindentaion study) would facilitate the rational design of ODT 
formulations through consideration of the main factors that contribute to high hardness 
and fast disintegration which in turn would considerably accelerate product 
development.
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7.1. General Discussion and Conclusions 
The extensive use, in paediatrics, of off-label and unlicensed medicines formulated 
specifically for adults, caused the European Union to pass regulations that necessitate 
the formulation of medicines specifically targeted at the paediatric population. Reasons 
behind this move include, but are not limited to, the marked differences in organ 
development, metabolic competence and skin maturation in children; which produces 
vastly different pharmacokinetic and pharmacodynamics responses within this 
heterogeneous population; and when compared to adults. Therefore research into 
paediatric formulation has become a topical theme in the last few years. However, the 
stability issues associated with liquid dosage forms, which are commonly used in 
paediatric therapy, has caused the World Health Organisation (WHO) to advocate a 
paradigm shift from liquid dosage forms to solid dosage forms for paediatrics. This has 
become a great opportunity to explore the successful use of Orally Disintegrating 
Tablets (ODTs) in paediatric formulations, since these dosage forms which are seen 
as an intermediate between solid and liquid dosage forms can solve stability issues 
related to liquids, and reduce the risk involved in children swallowing conventional 
tablets, in cases of dysphagia. However, formulating paediatric doses as solid dosage 
form would require the consistent and uniform mixing of much smaller does into 
dosage forms. Blending requirements become more stringent for these low dose 
formulations. Because the final outcome of therapy in paediatric patients depends on 
the patients themselves, their careers and the prescribers, it became necessary to 
investigate the perceptions and motivations of these critical stakeholders, with regards 
the use of ODTs for children. Thus the aim of this work was to firstly, extract and 
understand the stakeholder (children/ carer and prescriber/ dispenser) preferences for 
ODT tablet characteristics that could ensure maximum patient compliance; and 
secondly to explore various mixing techniques that would deliver the highest quality of 
Chapter 7 
 
 
263 
 
pre-blended multifunctional excipients to facilitate the effective production of paediatric 
ODT formulations.  
Acceptability studies were carried out across three international centres, to assess the 
ODT preference and acceptability amongst children of different age groups. The 
general outcome was that solid dosage forms are the preferred dosage forms with 
ODTs being the preferred dosage form for children and young adults.  The preferences 
highlighted from this study included: pink or white colours, small size, round shape and 
strawberry flavour. Necessary physical attributes in terms of ODT acceptability 
revealed disintegration time and taste as having the highest priority, and importance 
reducing in the order of, size, flavour and shape. This study has identified the favoured 
medication characteristics as expressed by the participants. However it has not been 
tested whether these desirable characteristics are deliverable due to the physical 
properties of individual active pharmaceutical ingredients. Similarly the potential 
benefits in terms of patient adherence are implied only, and have not been tested in 
this present study. This leaves room for further onward research in this area. 
 
Awareness of the critical role the prescriber plays in ensuring the appropriate choice 
and use of dosage forms for paediatric patients, coupled with the unavailability of data 
outlining the opinion and professional use of ODTs by prescribers, necessitated the 
conduction of a multifactorial study design across two hospital sites, to assess the 
opinions of different healthcare professionals in relation to ODTs. Results reaffirmed 
the popularity of liquids for prescribing in paediatrics, ODTs emerged as the second 
most popular dosage form, with healthcare practitioners indicating an increasing 
popularity in the use of this dosage form amongst patients in the hospital setting, and 
a clear indication that many liquid formulations could be substituted with a suitable 
ODT. The desired properties of an ideal ODT were also identified with healthcare 
practitioners preferring a small fast disintegrating tablet, with taste, flavour and 
disintegration time being the key attributes identified. This study provided a pragmatic 
Chapter 7 
 
 
264 
 
approach in assessing healthcare professional’s opinions on ODTs, filling a clear gap 
in knowledge regarding the ideas and thoughts of practitioners who are on the frontline 
of paediatric prescribing and treatment. 
 
To facilitate the formulation of ODTs containing very low doses of API, it was necessary 
to develop an understanding of API and excipients properties, under the processing 
conditions of various available blending techniques. Vitamin D was used as a potent 
low dose drug while MCC, starch and pregelatinised starch were investigated as model 
excipients.  It was found that flow properties improved as particle size increased, with 
the non-sieved, non-cohesive MCC and non-cohesive pregelatinised starch having 
excellent flow whereas the cohesive pregelatinised starch and starch had an angle of 
repose just outside the threshold of being considered to have poor flow properties. In 
case of geometric mixing technique for 1 minute all formulations failed to meet the 
required pharmacopeial standards for drug content uniformity. Therefore, an increase 
in mixing time to 5 minutes with geometric addition showed considerable uniformity 
improvements for all carrier types. Ordered mixing with the dry powder coater allowed 
for uniformity to be reached faster than hand order mixing, and was able to keep the 
blend containing cohesive powder within the acceptable uniformity range throughout 
the mixing period. The powder coater was also useful in obtaining good uniformities at 
0.5% and 1% API using non-sieved carrier. All blends showed acceptable uniformity 
after the 32 minute mixing period, with the 1% API also achieving this only for MCC 
after 8 minutes of mixing, whereas the 0.5% API with MCC blend reached ideal 
uniformity at the end of the 16 minutes mixing period. This study also highlighted the 
importance of excipient mixing order for (mannitol, MCC, crospovidone and 
magnesium stearate) on tablet and powder properties. Although all formulations (F1-
F3) demonstrated similar results for powder and tablets characterisations (no 
significant difference), powder flow was fair to passable for all batches whilst MCC 
alone showed excellent flow property. The inclusion of excipients with high plastic 
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deformation proficiency (MCC) improved tablet hardness and reduced friability. The 
resultant mixture tablets exhibited good hardness and friability profile. Overall, it is 
critical to realize that mixing order has significant impact on blending and tablet 
properties.  
 
Pre-blend excipients play an important role in the development of ODTs. Formulation 
problems such as flowability, compressibility, compactability and disintegration time 
can be improved using co-processed excipients. The next study was carried out to 
develop co-processedmilled mannitol with pregelatinised starch and silica using the 
composite dry powder coating that would offer an excellent multifunctional base for 
ODT formulations. The novel pre-blend excipient showed very good mechanical 
properties and fast disintegration. In addition, the pre-blend was able to accommodate 
a high amount (up to 50% w/w) of API without affecting its functionality. Replacement 
of proportions of mannitol powder (responsible for the production of highly friable 
ODTs) with milled-mannitol was found to enhance ODT mechanical strength and 
friability due to reduced fragmentation during compression and improved 
compressibility. Furthermore, milled-mannitol led to improve disintegration time due to 
increased wettability of the ODT. Optimising silica concentration in the ODT was also 
important to enhance flowability. Silica at 1.5% w/w was suitable as it achieved the 
required flowability without significantly prolonging disintegration time of ODTs. In 
summary, the co-processed excipients using composite dry powder coater containing 
86.5% w/w of milled-mannitol, 12% w/w pregelatinised starch and 1.5% w/w silica can 
be used as a potential multifunctional directly compressible ODT pre-blend. 
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Finally, we found that manufacturing powders with differing levels of moisture content 
resulted in an alteration in the powder morphology as observed from SEM and AFM 
studies. This study showed that the amount of moisture content within MCC affected 
the mechanical properties of the subsequent powders and it was concluded that 
inclusion of 11% MCC moisture content resulted in the most flowable powder with 
favourable ODT characteristics, as tablets displayed increased hardness when formed 
using direct compression. Extreme moisture contents in pre-processed materials could 
be reduced using varying process parameters such as composite dry coating, as well 
as mixing of the powders with excipients designed to dry coat the surface of the high 
moisture content carrier particles. The understanding of tableting performance of 
excipients at the particle level (nanoindentation studies) would facilitate the rational 
design of ODT formulations through consideration of the main factors that contribute 
to high hardness and fast disintegration which in turn would considerably accelerate 
product development. 
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7.2. Future Work  
The acceptability study of paediatric populations may bring to the attention of medical 
practitioners and other stakeholders, the need to accord more time and resources to 
ODTs as a form of paediatric drug administration. As the study was conducted in three 
countries, such future developments and expectations are required. This calls for 
putting in place measures that will streamline and present new avenues for making 
ODTs a success.  Future work in this area would involve:   
- Investigation and development of palatability studies for paediatrics since findings 
from healthcare professionals suggest that age-appropriate formulations should be 
developed to provide both suitable dose units and acceptable palatability for paediatric 
patients.  
- The main issue raised after consultations with paediatric patients and healthcare 
professionals was related to the taste of specific medicines. Therefore, the 
development of a suitable taste masking technology for bitter tasting compounds, with 
significant potential for commercialisation in the near future, would be necessary. 
- Development of a novel oral disintegrating granules formulation which convert small 
particles into physically stronger and larger aggregates. Aston Particle Technologies 
(APT) will be developed as a single and reproducible process, including high shear 
mixing granulation.
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Appendix 1- Acceptability study survey (Chapter 2) 
 Evaluation the acceptability and palatability of solid 
oral dosage forms for paediatric
Section One: About You 
1. Your Age
How old are you?
- 
2. Your Gender
What is your gender? (Place a √ only one)
 
3. Your Education
What is your education level? (Place a √ only one)
 Are you at School  
 Are you at higher education 
 Are you working 
  Others 
Section two: About medicines 
4. What experience do you have for taking medicine?
5. Which of the following dosage forms you prefer? (Place a √ only one)
Pages 281-282 removed for copyright restrictions.
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Big size 
10. How thickness of tablets would you prefer?  (Place a √ only one)
 Thick 
Thin 
11. Which taste of tablets would you prefer? (Place a √ only one)
 Without taste          Sweet taste  
 Bitter taste      
12. Which flavour of tablets would you like? (Place a √ only one)
 Strawberry
 Orange
 Cherry
 Vanilla
 Mint
 Lemon
 Chocolate
Other (specify) 
13. Which length of time for the tablets to dissolve would you prefer? (Place a √ only
one) 
 Very rapidly < 30 seconds 
 Rapidly 30 - 1.30 minutes 
 From 1.30 - 3 minutes  
14. Which three are the most important characteristics of orally disintegrating tablets
(ODTs)? (Place a √ only three) 
 Colour 
 Shape 
 Size 
Thickness 
Taste
Flavor
The length to dissolve in mouth 
15. Any feedback on the questionnaire, suggestions for any improvements?
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Appendix2-The plan for agenda design (Chapter 2) 
Number of event Name of event Duration (Minutes) 
1 Welcome and discuss the 
aim of the event 
2-5
2 Slide show for dosage 
forms and questions 
10-15
3 Visual demonstrations 
comparing ODT and 
immediate release 
paracetamol tablet 
10 
4 Distribute Questionnaire 10 
5 Feedback on questionnaire 5 
6 Suggestions for any 
improvements 
10 
7 Distribution of ‘Thank You’ 
letter 
5 
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Appendix 6- A question guide-Phase 1 (Chapter 3) 
Current Opinions and Recommendations of Healthcare 
Professionals Regarding the Importance and their 
Preferences Concerning Paediatric Dosage Forms- Focus group 
question guide  
Method/Question guide 
Introduction 
Hi everyone. Thank you for attending the focus group session. During this focus 
group session we will be discussing and finding out your opinions and views on 
the paediatric (age 6-18 yrs.) dosage forms. 
Focus group ground rules  
Before we start the focus group just some information and ground rules  
Distribute PIS  
I will be recording the focus group, however, in any transcripts and reports, all 
your details will be kept anonymous.  
The session will be 40 minutes.  
During this session we will be focusing on ODTs 
Sign consent form  
Opening questions (10 minutes)  
Before we start on the key questions, I would like to ask you all to discuss 
1) What dosage form of prescribed medication (e.g. liquids, tablets, capsules)
would you prefer to prescribe for (doctors) / recommend (pharmacists) / give to
(nurse) children and how does it affect your practice?
2) What are your views concerning the safety and dose accuracy of formulation
types? What do you think about utility of dosage forms for children?
3) If ODTs were available for a medication, what would motivate you to
prescribe this over unlicensed liquid for a child?
4) How do you feel cost would be affected as a result of a switch from
unlicensed liquid to ODTs?
5) Do you receive any feedback from patients and their parents about the
acceptability of the formulation? What are the views and comments that are fed
back to them from patients who are prescribed and given ODTs?
Ok now that we have gathered the group member’s views in terms of the definition 
and concerning paediatric dosage forms lets discuss the most preferred dosage 
forms and your views concerning physical characteristics of ODTs. 
Key Question 1 (15 minutes) Discussion on the paediatric dosage forms 
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Now I would like to discuss your views and experience about 
prescribing/dispensing or administering medicine to children. What is the most 
common dosage forms that are given to patients?   
What do you think the most preferred dosage forms to be given to children and why?  
In particular, oral dosage forms including (Tablets, capsules, liquids and ODTs). 
What do you think about dose frequency?  
 
Key Question 2 (10 minutes) Discussion on the development of ODTS 
(physical characteristics) 
Now that we have discussed the paediatric dosage forms (mainly ODTs), for the 
next session, let’s discuss your views concerning the design and development of 
ODTs?  
What do you think about taste, flavours, size and colour (in your opinion what 
most preferred)?  
 
 
Ending questions (5 minutes)  
 
That is very useful; we now need to draw the focus group to a close. Before we 
finish I would like to ask you to raise any other issues, suggestions, comments in 
general regarding the paediatric dosage forms, which we may not have 
discussed? We have 10 minutes left.  
Once again I would like to thank you for attending the focus group, this has been 
very helpful. 
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Appendix 9- Online Survey-Phase 3 (Chapter 3) 
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Appendix 10- UV spectrum scan (Chapter 4) 
 
 
UV spectrum scan (a) absorption spectrum of ergocalciferol showing maximum absorbance at 
261nm, (b) ,(c) and (d) UV spectrum scan performed for MCC, starch and pre gelatinised starch 
respectively between 250nm and 270nm showed no interference. 
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Appendix 11- Calibration curve (Chapter 4) 
 
 
Calibration curve of ergocalciferol at 265 nm using UV spectrophotometer (Mean ±SD, n=3). 
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Appendix 12- Snap shot of ImageJ (Chapter 5) 
 
Snapshot of ImageJ user guide showing selected region of interest (i) drawn on an image and 
set measurement feature (ii). 
 
 
 
 
 
 
 
 
 
